Document:

<PAGE>   1
                                                                    EXHIBIT 10.2

                   SALES, MARKETING AND DISTRIBUTION AGREEMENT

     THIS SALES, MARKETING AND DISTRIBUTION AGREEMENT (the "Agreement") is made
and entered into as of December 14, 1999 (the "Effective Date"), by and between
Genomic Solutions, Inc., a Delaware corporation, and PerkinElmer, Inc., a
Massachusetts corporation.

                                    RECITALS:

     Genomic Solutions, Inc. manufactures and distributes biochip systems,
protemic systems, gel analysis products and other products, software and systems
in the United States and throughout the world.

     Genomic Solutions, Inc. desires to hire PerkinElmer, Inc. to promote,
market and distribute its products and services and perform certain field
service responsibilities, subject to the terms and conditions of this Agreement.

     NOW THEREFORE, for and in consideration of the foregoing Recitals, the
mutual covenants and undertakings set forth below and other good and valuable
consideration, the receipt and adequacy of which are acknowledged, the
undersigned agree as follows:

1.   Definitions. The following terms shall have the meaning set forth in this
     section. All other capitalized terms shall have the meaning set forth in
     the section defining such terms.

     (a)  "Active Date" means January 1, 2000 or such other date as the parties
          shall mutually agree in writing.

     (b)  "Affiliates" of a party shall mean any person, corporation or other
          business entity controlled, controlled by or under common control with
          such party, with "control" meaning a fifty percent (50%) or greater
          ownership interest.

     (c)  "Core Markets" means the United States of America, the United Kingdom
          and Japan.

     (d)  "GSI" means Genomic Solutions, Inc. and its Affiliates.

     (e)  "GSI Products" means the products identified on Exhibit A hereto. In
          the event that during the Term, GSI offers any other products not
          described on Exhibit A, such products shall automatically be deemed
          "GSI Products" for purposes of this Agreement. GSI shall provide PKI
          with thirty (30) days advance written notice of the discontinuation of
          the manufacture of any GSI Product and the material modification or
          improvement of any GSI Product.

     (f)  "PKI" means PerkinElmer, Inc. and its Affiliates

     (g)  "Term" means the two (2) year period commencing on the Active Date,
          provided, that upon expiration of the initial Term, this Agreement
          shall automatically review for successive two (2)

<PAGE>   2

          year periods unless either party notifies the other in writing at
          least ninety (90) days prior to the expiration of the then current
          term of its intention not to renew.

2.   Preparation Activities.

     (a)  Preparation Sales. Commencing on the Effective Date, PKI may begin
          promoting the sale of the GSI Products and will work with GSI to
          prepare for the assumption of certain sales, marketing, distribution
          and field service activities on the Active Date. GSI shall be
          responsible for all sales and distribution activities world-wide prior
          to the Active Date (including all sales, marketing, distribution and
          service costs) and shall be entitled to receive all revenue from such
          activities. GSI shall also be entitled to all world-wide revenue from
          orders for GSI Products placed prior to the Active Date, so long as
          such GSI Products are actually shipped within one hundred eighty (180)
          days after the Active Date.

     (b)  Preparation Activities. Commencing on the Effective Date, GSI and PKI
          shall jointly and cooperatively prepare for PKI's distribution of GSI
          Products outside of Core Markets and promotion of GSI Products in the
          Core Markets as contemplated in Sections 3 and 4, respectively. GSI
          and PKI shall provide sufficient resources commencing on the Effective
          Date to allow PKI to undertake sales and distribution of GSI Products
          on the Active Date. Such preparation activities shall include, but not
          be limited to, the following:

          (i)   Training and preparation of PKI sales and field service forces,
                including account planning, quota setting, role definition and
                other sales preparation activities.

          (ii)  Incorporation of sales and service activities into PKI
                infrastructure, including logistics preparation and planning.

          (iii) Development of coordinated marketing launch and plan, including
                development of integrated message to customers, branding
                preparation and other launch related activities.

3.   Exclusive Distributor Appointment.

     (a)  Exclusive Rights and Responsibilities of PKI. Effective as of the
          Active Date and subject to the terms of this Agreement, PKI shall have
          the exclusive right and responsibility to engage in sales, marketing,
          distribution and field service activities with respect to GSI Products
          in any market or geographical area other than the Core Markets
          provided, however, that: (i) GSI has distributor contracts for
          non-Core Markets with those third parties listed in Exhibit B hereto,
          with territories and termination notice periods as set out in such
          Exhibit B for each such contract; and (ii) GSI shall send all of its
          distributors in the non-Core Markets as listed on Exhibit B notices of
          termination as soon as possible, but no later than four (4) days after
          the first date on which it may send such termination notices, through
          whatever means necessary to ensure that such third parties receive
          those notices as soon as possible (except the parties will work
          together in good faith to allow PKI to utilize Science & Technology,
          Ltd., the current distributor for GSI in New Zealand, from and after
          the Active Date).

<PAGE>   3

     (b)  Sales Goals and Quotas. GSI shall make GSI Products available to PKI
          in accordance with the terms and pricing in Section 7 below. Exhibit C
          attached is a schedule of PKI sales targets for the first four (4)
          quarters after the Active Date. Purchases of GSI Products in excess of
          the minimum sales target set forth in Exhibit C for any calendar
          quarter shall be credited towards the minimum sales target set forth
          therein for subsequent calendar quarters. These minimum sales targets
          are U.S. Dollar volumes based on GSI Product orders received by GSI
          from PKI on or before the last day of such calendar quarter, and are
          based on GSI's transfer price to PKI for such GSI Products. Exhibit C
          shall be reviewed and updated annually by the parties to set new
          quarterly minimum sales targets. In the event that parties are unable
          to agree on sales targets, the matter will be submitted for
          arbitration before a single arbitrator approved by the parties. All
          arbitration shall take place in accordance with the rules of the
          American Arbitration Association at such organization's Wilmington,
          Delaware offices. Such arbitrator shall make such adjustments based on
          then-current market conditions.

     (c)  Failure to Meet Minimum Sales. In the event that PKI fails to meet the
          quarterly minimum sales for GSI Products for three (3) consecutive
          calendar quarters, GSI, in its sole discretion and upon notice to PKI,
          may convert PKI's right to sell, market, distribute and provide field
          services for GSI Products outside of the Core Markets from exclusive
          to non-exclusive.

     (d)  Consideration. The consideration for the grant of exclusivity of
          distribution to PKI in the non-Core Markets shall consist of PKI's
          obligations under this Agreement to sell, market, distribute and
          service the GSI Products and other good and valuable consideration,
          the receipt and adequacy of which are acknowledged.

4.   Non-Exclusive Sales Representative Activities of PKI; PKI Providing
     Technical Assistance Services.

     (a)  Appointment of PKI as Sales Representative. PKI shall promote the
          products within the Core Markets, providing sales leads and opening
          access to PKI's broad network of customer relationships within the
          Core Markets. PKI shall therefore, from time to time after the Active
          Date, identify Leads in the Core Markets and communicate the identity
          of those Leads to GSI. GSI hereby appoints PKI, effective as of the
          Active Date, as a non-exclusive sales representative for the GSI
          Products in Core Markets. GSI further agrees that it will not, without
          first obtaining PKI's written consent (with such consent not to be
          unreasonably withheld) appoint any additional sales representatives,
          dealers, distributors or other agents in connection with the marketing
          and distribution of the GSI Products in the Core Markets after the
          Effective Date; except, however, that GSI may make customary changes
          in the ordinary course of business to its dealer/distributor network
          in Japan without first obtaining PKI's written consent.

     (b)  Sales Commissions. GSI shall pay sales commissions to PKI for sales
          procured as a result of assistance or efforts of PKI as follows:

          (i)   For all sales directly attributable to Leads or assistance
                provided by PKI to GSI, GSI shall pay to PKI a commission based
                on a percentage of the Net Revenue (as defined below) actually
                received by GSI with respect to such sales. [*] The commission
                for any particular sale shall be determined based on the mutual
                agreement of the parties taking into consideration the foregoing
                and the relative contributions to the sale by the parties. For
                purposes of this section, "Lead" means a qualified lead or
                prospect, including name of company, key contact, defined need,
                reasonable indication of finances, and other information to
                indicate that a relationship has been established for a bona
                fide prospective purchaser of GSI Products.

          (ii)  Timing of Payments. All commissions due and payable to PKI shall
                be paid by GSI to PKI within thirty (30) days after the end of
                the calendar quarter in which payment is actually received by
                GSI. Such commissions shall be paid in three separate checks,
                corresponding to the amounts earned in each of the three Core
                Markets.

          (iii) Definition of Net Revenue. For purposes of this Agreement, Net
                Revenue means the invoice amount of sales of GSI Products to end
                users attributable to Leads or assistance provided by PKI,
                excluding fees for personal or field services, software upgrade
                or maintenance services, freight charges, tariffs, taxes or
                similar charges and net of all discounts, returns and
                allowances, for (A) an initial purchase and subsequent purchases
                by an account during the six-month period immediately following
                such initial purchase; and thereafter (B) any subsequent
                purchases by such account, for which PKI sales personnel were
                directly involved in obtaining such purchases.

          (iv)  GSI shall deliver to PKI within forty-five (45) days after the
                end of each calendar quarter, beginning with March 31, 2000, a
                written report describing, for the applicable quarter: (A) GSI's
                Net Revenues subject to the commissions described in this
                Section 4(b); and (B) the Leads who have paid such amounts to
                GSI. Each such report shall be accompanied by full payment to
                PKI of the total commissions due to PKI for such Net Revenues.

          (v)   All commissions payable to PKI hereunder shall be paid in U.S.
                Dollars and there shall be no chargebacks against such
                commissions. To the extent that the Net Revenues upon which such
                commissions are computed are received by GSI in a currency other
                than U.S. Dollars, GSI shall convert such fees into U.S. Dollars
                in accordance with its normal accounting procedures.

          (vi)  In order for PKI to confirm full payment of the commissions due
                to PKI from GSI in accordance with this Section 4(b), GSI agrees
                to make and keep full and accurate books and records in
                sufficient detail to enable commissions payable hereunder to be
                determined. On thirty (30) days' prior written notice to GSI
                (but no more than twice during any calendar year), PKI's
                independent certified public accountants shall have full access
                to the books and records of GSI necessary to confirm the
                commissions which are due to PKI hereunder, and for no other
                purposes, and such accountants shall have the

          [*]   Certain information on this page has been omitted and filed
                separately with the Commission. Confidential treatment has been
                requested with respect to the omitted portion.

<PAGE>   4
                right to make copies therefrom at PKI's expense. PKI's
                independent certified public accountants shall have such access
                during normal business hours. Prompt adjustment shall be made by
                the proper party to compensate for any errors or omissions. PKI
                shall pay all costs of conducting audits pursuant to this
                Section 4(b)(vi); provided, however, that GSI shall reimburse
                PKI in full for PKI's reasonable out-of-pocket costs whenever an
                audit reveals that, with respect to any audited period, the
                underpayment of commissions due was greater than ten percent
                (10%) of the commissions actually paid to PKI for such period.
                PKI agrees to hold confidential all information learned in the
                course of any audit of GSI's books and records hereunder, except
                when it is necessary for PKI to reveal such information in order
                to enforce its rights under this Agreement, or except when
                compelled by law.

     (c)  All commissions due and owing to PKI hereunder but not paid by GSI on
          the due date thereof shall bear interest (in U.S. Dollars) at the rate
          of the lesser of: (i) twelve per cent (12%) per annum; and (ii) the
          maximum lawful interest rate permitted under applicable law. Such
          interest shall accrue on the balance of unpaid amounts from time to
          time outstanding from the date on which portions of such amounts
          become due and owing until payment thereof in full.

5.   PKI Obligations Generally.

     (a)  Product Labeling. All GSI Products shall be sold under the GSI name
          and logo which will be the predominant branding element. Both parties
          acknowledge and agree that the presence of PKI's "PerkinElmer" brand
          will facilitate market recognition, credibility and customer
          communications. Accordingly, PKI shall cooperate with GSI to design
          and produce a subordinated brand label for GSI Products distributed
          outside Core Markets (eg. "in partnership with PerkinElmer) and a
          miniature brand label (eg. "Perkin Elmer global alliance partner) for
          use in Core Markets. PE shall bear all of its own costs and expenses
          incurred in connection with such design activity and GSI shall bear
          its own cost in connection with production activities.

     (b)  Inventory and Production Forecasts. PKI shall provide GSI with a six
          month non-binding rolling production forecast of anticipated sales and
          GSI Products requirements. Such forecast shall be updated and
          delivered to GSI on a monthly basis for each of the particular
          countries where PKI will be undertaking sales activities. PKI shall
          also keep GSI reasonably informed of potential problems concerning the
          GSI Products. All shipments shall be made by GSI to PKI facilities or
          warehouses, with PKI (or its distributors) then responsible for
          further distribution to end-users.

     (c)  Marketing, Promotion and Sales Efforts. PKI shall use commercially
          reasonable efforts to market, promote the sale of, maintain and
          service the GSI Products in markets other than Core Markets and to
          market and promote the sale of GSI Products in Core Markets, subject
          to the other provisions of this Agreement. PKI shall provide and
          maintain, at its own expense, suitable facilities with adequate and
          efficient sales personnel and field engineers. PKI shall provide all
          ordinary service to its customers in markets outside the Core Markets
          as the nature of the business makes necessary or desirable in
          connection with the sale and distribution of GSI Products.

<PAGE>   5

     (d)  Promotional Materials. PKI will develop marketing and promotional
          material for generating leads and sales of the GSI Products at its
          sole cost and expense. Such materials shall conform with the labeling
          standards set forth in subsection (a) above and shall be subject to
          the approval of GSI.

     (e)  License to GSI Marks. GSI hereby grants to PKI a nonexclusive,
          royalty-free license during the Term to use GSI's name and any other
          trademarks or service marks associated with the GSI Products
          (collectively, the "GSI Marks") in connection with PKI's performance
          of its rights and obligations under this Agreement and to market and
          sell the GSI Products under such GSI Marks. Such license shall be
          non-transferable, except that PKI shall be entitled to grant its
          dealers and others to which it sells GSI Products a nonexclusive,
          nontransferable license to use such GSI Marks in connection with the
          marketing, promotion and sale of such GSI Products. PKI acknowledges
          that GSI is the sole and exclusive owner of all right, title and
          interest in and to the GSI Marks. At no time, whether during or after
          the term of this Agreement, shall PKI (i) represent, in any manner,
          that it has any right, title or interest whatsoever in or to the GSI
          Marks; (ii) use the GSI Marks in any way other than that expressly
          contemplated in this Agreement; (iii) register or attempt to register
          the GSI Marks or any mark or name similar to the GSI Marks under the
          laws of any jurisdiction; or (iv) cause or allow to be done any act or
          thing which would tend to impair the distinctiveness of the GSI Marks
          or any part of GSI's right, title and interest in the GSI Marks. In
          order to comply with GSI's quality control standards, PKI shall: (x)
          use the GSI Marks in compliance with all relevant laws and
          regulations; (y) accord GSI the right to inspect during normal
          business hours, without prior advance notice, PKI's facilities used in
          connection with efforts to sell the GSI Products in order to confirm
          that PKI's use of such GSI Marks is in compliance with this Section
          5(e); and (z) not modify any of the GSI Marks in any way and not use
          any of the GSI Marks on or in connection with any goods or services
          other than the GSI Products.

     (f)  License to PKI Marks. PKI hereby grants to GSI a nonexclusive,
          royalty-free license during the Term to use PKI's name and any other
          trademarks or service marks of PKI (collectively, the "PKI Marks") in
          connection with affixing co-branded labels to the GSI Products, in
          accordance with the co-branding arrangements contemplated herein. Such
          license shall be non-transferable, except that GSI shall be entitled
          to grant its sales representatives, dealers, distributors and other
          agents to which it sells GSI Products in the Core Markets a
          nonexclusive, nontransferable license to use such PKI Marks in
          connection with the marketing, promotion and sale of such GSI
          Products, subject to their compliance with GSI's obligations under
          this Section 5(f). GSI acknowledges that PKI is the sole and exclusive
          owner of all right, title and interest in and to the PKI Marks. At no
          time, whether during or after the term of this Agreement, shall GSI
          (i) represent, in any manner, that it has any right, title or interest
          whatsoever in or to the PKI Marks; (ii) use the PKI Marks in any way
          other than that expressly contemplated in this Agreement; (iii)
          register or attempt to register the PKI Marks or any mark or name
          similar to the PKI Marks under the laws of any jurisdiction; or (iv)
          cause or allow to be done any act or thing which would tend to impair
          the distinctiveness of the PKI Marks or any part of PKI's right, title
          and interest in the PKI Marks. In order to comply with PKI's quality
          control standards, GSI shall: (x) use the PKI Marks in compliance with
          all relevant laws and regulations; (y) accord PKI the right to inspect
          during normal business hours, without prior advance notice, GSI's
          facilities used in connection labeling the GSI Products in order to
          confirm that GSI's use of such PKI Marks is in

<PAGE>   6

          compliance with this Section 5(f); and (z) not modify any of the PKI
          Marks in any way and not use any of the PKI Marks on or in connection
          with any goods or services other than the GSI Products.

6.   Non-Competition.

     (a)  Reverse Engineering, etc. PKI shall not reverse engineer, redesign or
          disassemble or dismantle any GSI Products, except to the extent
          required to carry out the terms and conditions of this Agreement, in
          the biochip or proteomic area for the purpose of attempting to create
          products potentially competitive with the GSI Products. All such data
          regarding the GSI Products will be considered "confidential" for
          purposes of the Mutual Confidentiality Agreement between PKI and GSI
          of even date herewith. In the event that PKI engages in any activity
          as described in the first sentence of this subsection, then GSI may
          immediately terminate this Agreement.

     (b)  Sales of Competitive Products. In the event that PKI sells, markets or
          distributes, directly or indirectly, any products (other than GSI
          Products) which are competitive with any GSI biochip products (defined
          as any products which print or spot DNA on a glass slide or similar
          substrate) or competitive with any GSI proteomics products (defined as
          gels and mass spec products), then GSI shall have the right to convert
          the exclusive rights granted to PKI under Section 3 above to
          non-exclusive rights, upon giving PKI written notice of such
          conversion.

7.   Acceptance of Orders: Fulfillment; Pricing. The following terms shall
     apply for PKI ordering and sales outside of the Core Markets:

     (a)  Order Placement. PKI shall submit to GSI, its orders for the GSI
          Products in writing at least sixty (60) days before delivery is
          required for hardware, instruments and equipment and thirty (30) days
          before delivery is required for consumables, reagents and gels. All of
          PKI's orders for GSI Products consisting of consumables, reagents and
          gels (but excluding demonstration products) shall be for complete
          lots, the size of which shall be determined by GSI in its reasonable
          discretion. In this regard, GSI shall use reasonable efforts to
          minimize its lot sizes.

     (b)  Order Acceptance and Fulfillment. GSI shall give careful consideration
          to PKI's orders for GSI's Products, but all such orders shall be
          subject to GSI's approval and acceptance. If GSI does not communicate
          its rejection of an order to PKI within seven (7) days after receiving
          such order, then GSI shall be deemed to have accepted such order. GSI
          shall not be liable for any rejection of an order. All rejected orders
          shall be deemed purchased by PKI for the purposes of determining
          whether PKI has met the quarterly minimum sales targets in Exhibit C
          hereto. In the event of a shortage of GSI Products, GSI shall accept
          orders and allocate GSI Products in a reasonable manner so as to
          support PKI as a distributor of GSI Products, and at a minimum, GSI
          shall allocate its manufacturing capability on a unit basis so that
          PKI receives the same percentage of GSI's total output of GSI Products
          as PKI received on average during the most recent six (6) months prior
          to the shortage.

     (c)  Servicing and Certain Revenue. PKI shall be solely responsible for all
          installation, field servicing, maintenance and warranty repair with
          respect to GSI Products distributed by PKI

<PAGE>   7

          outside of Core Markets, provided, that GSI shall provide reasonable
          application and technical support to PKI marketing and sales
          personnel. PKI shall be entitled to receive all revenue generated from
          field servicing and maintenance outside of the Core Markets. Revenue
          from software upgrades and maintenance or subscription services shall
          be split equally by GSI and PKI.

     (d)  GSI Product Pricing. GSI shall sell the GSI Products to PKI at the
          transfer prices set forth on Exhibit A attached. If GSI develops any
          new products which constitute GSI Products at anytime after the Active
          Date, the parties shall negotiate in good faith toward reaching a
          mutual understanding as to the rate at which GSI shall sell such GSI
          Products to PKI. All orders of GSI Products by PKI shall be
          non-cancelable. The parties agree to annually evaluate the pricing of
          GSI with consideration to be given for adjustment based on market
          dynamics, the cost of products and services, and changing consumer
          conditions. In the event that the parties fail to reach agreement on
          product pricing, any price changes shall be subject to arbitration as
          provided in Section 3(b) above.

     (e)  F.O.B. All prices are and shall be, and all deliveries of GSI Products
          shall be made, F.O.B. GSI's U.S. or U.K. shipping dock. Risk of loss
          and title to the GSI Products passes to PKI at such F.O.B. point.

     (f)  Invoicing. All invoices for GSI Products shipped shall be due and
          payable in U.S. Dollars on or before the thirtieth (30th) day after
          the later of (i) the date the invoice is sent by GSI; and (ii) the
          date of shipment. All payments due and owing to GSI hereunder but not
          paid by PKI on the due date thereof shall bear interest (in U.S.
          Dollars) at the rate of the lesser of: (i) twelve per cent (12%) per
          annum; and (ii) the maximum lawful interest rate permitted under
          applicable law. Such interest shall accrue on the balance of unpaid
          amounts from time to time outstanding from the date on which portions
          of such amounts become due and owing until payment thereof in full

     (g)  Taxes. All prices for GSI Products shall be quoted or listed exclusive
          of any federal, state or local sales, use or excise taxes levied on or
          measured by the sale, sales price or use of GSI Products
          (collectively, "Taxes"). Unless PKI is exempted from such Taxes, all
          such prices shall be increased by the amount of the Taxes, if any, to
          which the GSI is subject in connection with the sale of the GSI
          Products.

     (h)  Resale Prices. PKI may sell the GSI Products at such prices and on
          such terms and conditions as it deems appropriate in its sole
          discretion. PKI shall have no authority to obligate GSI in any way
          through the terms and conditions on which it sells the GSI Products.

     (i)  Limited GSI Products Warranty. GSI will warrant all GSI Products
          (parts only) sold outside of Core Markets against defects in materials
          or workmanship for a period of twelve (12) months from the customer
          installation date under normal service and use; except that GKI will
          warrant consumables, gels and reagents for a period of ninety (90)
          days after shipment to the customer. The GSI Warranties shall not
          apply to any GSI Product which is used for a purpose or in a manner
          for which it was not intended, which is defectively or improperly
          installed, which is altered in any way other than in connection with
          its proper installation, or which is subject to misuse, negligence,
          accident or neglect, so as to affect adversely the condition,
          performance or

<PAGE>   8

          value of such GSI Product. GSI's obligations with respect to this
          warranty are limited to the repair and replacement of defective parts
          after GSI's inspection and verification of such defects. Such
          obligations specifically exclude labor costs.

     (j)  Disclaimer of Express and Implied Warranties. THE GSI WARRANTY ABOVE
          IS THE ONLY WARRANTY MADE WITH RESPECT TO THE GSI PRODUCTS OR ANY
          PARTS OR COMPONENTS THEREOF, EXPRESS OR IMPLIED. GSI MAKE NO IMPLIED
          WARRANTIES AND SPECIFICALLY DISCLAIMS ANY WARRANTY THAT ITS PRODUCTS
          ARE MERCHANTABLE OR FIT FOR ANY PARTICULAR PURPOSE.

     (k)  Remedy; Limitation of Liability. If PKI believes that GSI has breached
          any warranty it shall notify GSI of the way in which the GSI Product
          is defective and, upon request, shall return at GSI's expense the
          defective GSI Product or component part to GSI. If GSI agrees that the
          GSI Product is defective, it shall promptly repair or replace the
          defective GSI Product or issue a credit for the price of the GSI
          Product. EXCEPT WITH RESPECT TO THIRD PARTY PRODUCT LIABILITY CLAIMS
          ARISING FROM GSI PRODUCTS NOT CONFORMING TO THIS WARRANTY AND EXCEPT
          FOR GSI'S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8(b)(vi) BELOW, IN
          NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY
          PURCHASER OF GSI PRODUCTS FOR INDIRECT, SPECIAL, INCIDENTAL,
          EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, FOR LOSS OF ANTICIPATED
          PROFITS OR BUSINESS, OR FOR INTERRUPTIONS IN BUSINESS, WITH RESPECT TO
          ANY CLAIM OF ANY KIND RESULTING FROM THE GSI PRODUCTS OR THEIR USE OR
          MISUSE, ANY ORDER UNDER THIS AGREEMENT OR ANY PERFORMANCE,
          NON-PERFORMANCE OR BREACH OF THIS AGREEMENT, WHETHER THE BASIS OF SUCH
          LIABILITY IS BREACH OF CONTRACT, TORT (INCLUDING, WITHOUT LIMITATION,
          NEGLIGENCE AND STRICT LIABILITY), STATUTORY OR ANY OTHER LEGAL THEORY
          WHATSOEVER. The remedy set forth in this Section shall be PKI's sole
          and exclusive remedy for breach of GSI's warranties.

8.   Indemnity.

     (a)  PKI shall defend and hold harmless GSI, its Affiliates and all
          officers, directors, employees and agents thereof against and from any
          and all claims made against GSI based upon, arising out of or in any
          way related to (i) PKI's acts or omissions in connection with the
          sale, marketing, distribution, installation, maintenance and servicing
          of the GSI Products; (ii) PKI's conduct or operation of its business;
          (iii) any negligent acts or omissions of PKI or any of its agents,
          contractors or employees; (iv) any representations or warranties made
          by PKI with respect to the GSI Products which were not authorized by
          GSI; (v) any breach or violation of this Agreement; and (vi) PKI's
          failure to comply with relevant laws and regulations. Such indemnity
          shall extend to all costs, awards, claims or damages of any kind or
          nature, including attorney fees and related expenses ("Damages").

     (b)  GSI hereby agrees to indemnify, defend and hold harmless PKI, its
          Affiliates and all officers, directors, employees and agents thereof
          from all Damages arising out of (i) GSI's acts or omissions in
          connection with the production, sale, marketing, distribution,
          installation, maintenance and servicing of the GSI Products; (ii)
          GSI's conduct or

<PAGE>   9

          operation of its business; (iii) any negligent acts or omissions of
          GSI or any of its agents, contractors or employees; (iv) GSI's breach
          of this Agreement; (v) GSI's failure to comply with relevant laws and
          regulations; and (vi) PKI's use or reselling of the Products
          infringing on the intellectual property rights of third parties or
          constituting a misappropriation of any third party's trade secrets;
          provided, however, that with respect to part (vi) above:

          (A)  In the event that any GSI Product is held in a suit or proceeding
               to infringe any intellectual property rights of a third party and
               the use or reselling of such GSI Product is enjoined, or GSI
               reasonably believes that it is likely to be found to infringe or
               likely to be enjoined, then GSI shall, at its sole cost and
               expense, either (1) procure for PKI the right to continue
               reselling such GSI Product; or (2) modify such GSI Product so
               that it becomes non-infringing. If neither (1) nor (2) is
               practicable, then GSI may, in its sole discretion, cease
               distributing such GSI Product in the affected countries outside
               the Core Markets, in which case such GSI Product shall be deemed
               removed from this Agreement with respect to such affected
               countries upon repurchasing PKI's inventory of such GSI Product
               which are saleable and in the original packages and unaltered
               from their original form and design, subject to GSI's inspection,
               test, and acceptance. Any such repurchase of PKI's inventory of
               GSI Products shall be at the product prices indicated in Exhibit
               A hereto. Such repurchased inventory shall be shipped by PKI,
               freight and insurance to be paid by GSI, according to GSI's
               instructions. GSI shall pay PKI for such repurchased GSI Products
               within thirty (30) days after GSI receives those GSI Products in
               one of its facilities.

          (B)  GSI shall have no obligation for any claim of infringement
               arising from: (1) any combination of GSI Products with products
               not supplied or approved in writing by GSI, where such
               infringement would not have occurred but for such combination;
               (2) the adaptation or modification of GSI Products not approved
               by GSI, where such infringement would not have occurred but for
               such adaptation or modification; (3) the use of a GSI Product in
               an application for which it was not designed, intended or
               approved by GSI, where such infringement would not have occurred
               but for such use; (4) a claim based on intellectual property
               rights owned by PKI or any of its Affiliates; or (5) improper
               service or installation.

     (c)  The party seeking indemnification (be it GSI under Section 8(a) above
          or PKI under Section 8(b) above) (the "Indemnified Party") hereby
          agrees that: (i) the Indemnified Party shall give the other party (the
          "Indemnifying Party") prompt written notice of each such claim; (ii)
          the Indemnifying Party shall have sole control and authority with
          respect to the defense or settlement of any such claim; and (iii) the
          Indemnified Party shall cooperate fully with the Indemnifying Party,
          at the Indemnifying Party's sole cost and expense, in the defense of
          any such claim. Any settlement of any such claim that imposes any
          liability or limitation on the Indemnified Party shall not be entered
          into without the prior written consent of the Indemnified Party.

<PAGE>   10

     (d)  In the event a claim is based partially on an indemnified claim
          described in Sections 8(a) and/or 8(b) above and partially on a
          non-indemnified claim, or is based partially on a claim described in
          Section 8(a) above and partially on a claim described in Section 8(b)
          above, any payments and reasonable attorney fees incurred in
          connection with such claims are to be apportioned between the parties
          in accordance with the degree of cause attributable to each party.

     (e)  During the term of this Agreement, GSI shall maintain an occurrence
          based comprehensive general liability insurance policy issued by a
          reputable insurance company, naming PKI as an additional insured,
          which policy shall insure against any and all bodily injury and/or
          property damages for which GSI has agreed to indemnify PKI as stated
          above in this Section 8. Such insurance shall be in the amount of at
          least $1,000,000 per claim and $2,000,000 for claims in the aggregate.

9.   Assistance.

     (a)  Promotional Materials. GSI shall make available to PKI, such
          advertising, sales and promotional materials, price lists, sales
          assistance and other information concerning the GSI Products as GSI
          deems appropriate in its reasonable discretion. PKI shall not produce
          or cause to be produced any advertising, sales, promotional or other
          information concerning the GSI's Products without GSI's prior review
          and written consent, which shall not be unreasonably withheld or
          delayed. On termination of this Agreement by either party for any
          reason whatsoever, PKI shall immediately return to GSI any and all
          advertising, sales or promotional materials, price lists, copies of
          invoices and any and all other documents, materials or records
          pertaining to the GSI Products, whether produced by or at the
          direction of PKI or GSI.

     (b)  Technical Support and Assistance. GSI agrees to make reasonable
          efforts to answer any technical support inquiries which GSI receives
          from PKI.

10.  Early Termination.

     (a)  Termination by Either Party. Any provision of this Agreement to the
          contrary notwithstanding, either party shall have the right to
          terminate this Agreement, at any time without prior notice, except as
          required below, on the occurrence of any of the following:

          (i)   The other party fails, neglect or refuses in any material manner
                to satisfactorily perform the duties assigned to or required of
                it under this Agreement, but only after such other party has
                been given sixty (60) days notice of and opportunity to cure
                such failure, neglect or refusal;

          (ii)  The other party becomes insolvent or unable to pay its debts as
                they become due or makes an assignment for the benefit of its
                creditors;

          (iii) A receiver or a trustee is appointed for the other party's
                assets, and such receiver or trustee is not discharged within
                sixty (60) days of such appointment;
<PAGE>   11

          (iv)  A proceeding of any nature under the federal Bankruptcy Code, as
                amended, or any state insolvency statute, is commenced by or
                against the other party, and such proceeding, if involuntary, is
                not set aside within sixty (60) days from the date of its
                institution;

          (v)   Either party shall have the right to terminate this Agreement
                with ninety (90) days written notice given no later than sixty
                (60) days after the occurrence of the following two conditions:
                (A) the consummation of a bona fide initial public offering of
                GSI's capital stock that is firmly underwritten by a nationally
                recognized underwriter, that results in no less than $20,000,000
                of gross proceeds to GSI and that results in GSI's stock being
                listed for trading on the New York Stock Exchange or the
                National Market Tier of the Nasdaq Stock Market (defined herein
                as "IPO"), and (B) a post-IPO "change in control" of GSI,
                defined as the sale of all or substantially all of the business
                and assets of GSI or a sale of more than 50% of the issued and
                outstanding shares of GSI. The parties further agree that the
                foregoing right of termination shall not apply (X) merely
                because an IPO has occurred, or to an event that may be
                considered a change of control in GSI but does not follow an
                IPO, including by way of example, (Y) the sale of all or
                substantially all of the business and assets of GSI prior to an
                IPO or (Z) a sale of more than 50% of the issued and outstanding
                shares of GSI prior to an IPO.

     (b)  Termination by GSI. In addition to the foregoing, GSI may terminate
          this Agreement in the event that PE fails to make any required
          payments on the due date thereof and such failure is not cured within
          fifteen (15) days of notice by GSI to the addresses indicated in
          Section 14 below.

     (c)  Effect of Termination or Expiration. Upon termination or expiration of
          this Agreement, as the case may be, PKI shall have no right to market
          and distribute the GSI Products (except for the six-month period
          immediately following the effective date of termination or expiration,
          as the case may be, during which PKI shall be entitled to sell-off its
          inventory of GSI Products) and all licenses hereunder shall
          immediately terminate. PKI shall not be entitled to any commissions
          for sales closed after termination or expiration, regardless of
          whether PKI participated in the sale. In addition, each party shall
          return to the other party all copies of any promotional material,
          written literature, product samples, and any Confidential Information
          as herein defined. Termination and expiration shall not affect PKI's
          obligations with respect to GSI Products previously sold hereunder or
          with respect to any indebtedness owed by either party to the other.

     11.  RESERVED

12.  Dealer Status. Nothing in this Agreement shall be construed in such a
     manner as to constitute one party the agent or legal representative of the
     other party for any purpose whatsoever. Neither party shall have any
     authority whatsoever, whether express or implied, to assume, create or
     incur any obligation or liability whatsoever on behalf of or in the name of
     the other party, or to bind the other party in any manner whatsoever.
     Neither party shall be liable for any damages, loss, cost or expense
     whatsoever, including incidental or consequential damages, resulting from
     any sale or other activities performed by the other party.

<PAGE>   12

13.  Cooperative Exchange and Licensing. Attached as Exhibit D hereto is a list
     of representative PKI technologies. PKI agrees to license GSI, on a
     non-exclusive basis, the right to use those technologies to make, use and
     sell products for the proteomic market and/or for the biochip market. As
     GSI identifies each such use of those PKI technologies, the license fee
     level for such use will be set by the parties at then-current market rates,
     based upon the specific technology to be licensed and the intended use. GSI
     will receive a 30% discount on the agreed-upon license fees so long as: (i)
     this Agreement remains in effect; and (ii) PKI's rights under Section 3
     above remain exclusive. If either of these conditions (i) or (ii) is not
     met, then GSI will lose the 30% discount, but will maintain the license
     rights at the agreed-upon market rates. At the time the parties set the
     license fee level for each such use, they shall also negotiate in good
     faith to conclude the other terms and conditions of such license agreement.

14.  Notices. Any and all notices, requests, demands and other communications
     permitted under or required pursuant to this Agreement (each, a "notice")
     shall be in writing and shall be (i) personally delivered; (ii) sent by
     facsimile transmission (with a hard copy to follow in one of the other
     manners contemplated in this Section 14); (iii) sent via overnight courier,
     shipping charges prepaid; or (iv) sent via U.S. Mail, postage prepaid,
     certified mail, return receipt requested, to the parties at the addresses
     or fax numbers set forth below, or at such other addresses or fax numbers
     as they may indicate by written notice given as provided in this Section
     14.

         If to PKI:                           With a required copy to:

         PerkinElmer, Inc.
         45 William Street                    Hale and Dorr LLP
         Wellesley, Massachusetts  02481      60 State Street
                                              Boston, Massachusetts  02109
         Fax no: 781-431-4115                 Fax no.:  617-526-5000
         Attn: General Counsel                Attention:  David E. Redlick

         If to GSI:                           With a required copy to:

         Genomic Solutions Inc.               Jaffe, Raitt, Heur & Weiss,
         4355 Varsity Drive                   Professional Corporation
         Ann Arbor, MI  48108                 One Woodward Avenue, Suite 2400
         Fax:  (734) 975-4808                 Detroit, MI  48226
         Attn:  Jeff Williams                 Fax:  (313) 961-8358
                                              Attention:  Peter Sugar

     Any notice sent in the manner contemplated in clause (i) above shall be
     deemed to have been given on the date delivered; in the manner contemplated
     in clause (ii) above, as of the time the sender receives confirmation from
     its fax machine that the facsimile transmission has been successfully
     completed (provided, however, that if such time is after 4:00 p.m.,
     measured in terms of the recipient's local time, the notice shall be deemed
     to have been given as of 8:00 a.m. on the next business day of the
     recipient); in the manner contemplated in clause (iii) above, on the first
     (1st) business day after the notice has been deposited in a regularly-
     maintained receptacle for such a parcel; and in the manner contemplated in

<PAGE>   13
     clause (iv) above, on the third (3rd) business after the notice has been
     deposited in a regularly-maintained receptacle for U.S. Mail.

     Each party agrees that any press releases, publicity or advertising which
     shall be released by it in which the other party is identified shall
     require the prior written approval of such other party, such approval not
     to be unreasonably withheld or delayed.

15.  Non-Assignable. Neither party may assign this Agreement or its rights or
     obligations under this Agreement without the written consent of the other
     party; which consent may be granted or withheld in the other party's sole
     discretion.

16.  Waiver. Any party's waiver of any breach of any provision of this
     Agreement, and any party's failure to exercise any of its rights under or
     in connection with this Agreement, shall not operate or be construed as a
     waiver by such party of any subsequent or similar breach or of any such
     rights or preclude exercise of such rights at a later time.

17.  Choice of Law: Construction. This Agreement is deemed to have been executed
     in the State of Delaware and shall be construed and enforced in accordance
     with the laws of the State of Delaware, without regard to its conflict of
     laws principles. This Agreement shall not be construed against or in favor
     of any party by virtue of the fact that this Agreement was drafted
     primarily by any one party.

18.  Submission to Jurisdiction. The parties irrevocably submit to the
     jurisdiction of the federal and state courts of Wilmington, Delaware;
     provided, however, that nothing herein shall preclude -------- -------
     either party, if it thinks fit, from instituting proceedings against the
     other party or anyone acting by, through or under the other party in any
     place which may have jurisdiction for the purpose of protecting and
     enforcing such Party's rights either hereunder or pursuant to any other
     agreements, documents, instruments or otherwise. Each party hereby
     irrevocably waives any objection which it may now or hereafter have to the
     laying of venue of any suit, action or proceeding relating to this
     Agreement in Wilmington, Delaware, and further irrevocably waives any claim
     that Wilmington, Delaware is not a convenient forum for any such suit,
     action or proceeding.

19.  Remedies. Any remedy provided in this Agreement for a breach of a specific
     section of this Agreement shall be the sole and exclusive remedy for the
     breach to which it relates. Subject to the preceding sentence, the parties'
     respective rights and remedies under or with respect to breaches of this
     Agreement which are not specifically provided for in this Agreement are
     separate and cumulative, and no one of them, whether or not exercised,
     shall be deemed to be an exclusion of any of the others and shall not limit
     or prejudice any other legal or equitable right which any party to this
     Agreement may have.

20.  Entire Agreement; Amendment. This Agreement represents the complete and
     final expression of the parties' agreements and understandings with respect
     to its subject matter. This Agreement supersedes all other prior oral and
     written agreements between the parties with respect to the subject matter
     of this Agreement. Except to the extent expressly provided in this
     Agreement, this Agreement may not be amended or modified except pursuant to
     a written agreement executed by both parties.

<PAGE>   14

21.  Binding Effect. This Agreement shall be binding on an inure to the benefit
     of the parties and their respective successors and permitted assigns.

22.  Headings. The headings contained in this Agreement are for reference
     purposes only and shall not in any way affect the meaning or interpretation
     of this Agreement.

23.  No Third-Party Beneficiaries. This Agreement, and the respective
     obligations of PKI and GSI under this Agreement, are for the sole and
     exclusive benefit the parties to this Agreement. Any provision of this
     Agreement to the contrary notwithstanding, no party other than PKI, GSI and
     their respective successors and permitted assigns shall have the right to
     rely on or enforce the provisions of this Agreement as a third-party
     beneficiary or otherwise.

24.  Offset. Each party shall be entitled to offset any amounts due it by the
     other party against any amounts which it owes the other party.

25.  Pronouns. References to a party in the singular or plural, as him, her, it
     or other like preferences, shall also, where the context so requires, be
     deemed to include the singular or the plural, or masculine, feminine or
     neuter reference, as the case may be.

26.  Counterparts; Facsimile Signatures. This Agreement may be executed in
     counterparts, each of which shall be deemed an original and all of which
     together shall constitute one instrument. Facsimile or photostatic copies
     of signatures to this Agreement shall be deemed to be originals and may be
     relied on to the same extent as the originals.

27.  Severability. If any provision of this Agreement is declared invalid or
     unenforceable by a court having competent jurisdiction, it is mutually
     agreed that this Agreement shall endure except for the part declared
     invalid or unenforceable by order of such court. The parties shall consult
     and use their best efforts to agree upon a valid and enforceable provision
     which shall be a reasonable substitute for such invalid or unenforceable
     provision in light of the intent of this Agreement

     IN WITNESS WHEREOF, the undersigned have executed and delivered this Sales,
Marketing and Distribution Agreement as of December 14, 1999.

                             Genomic Solutions, Inc.

                             By: Jeffrey S. Williams
                                -----------------------------------
                             Its: President & CEO
                                 ----------------------------------
                             PerkinElmer, Inc.

                             By: Terrance Carlson
                                -----------------------------------
                             Its: SR V.P.
                                 ----------------------------------

<PAGE>   15

                                    EXHIBIT A

                                  GSI PRODUCTS

                          LIST PRICE AND TRANSFER PRICE

<TABLE>
<CAPTION>
------- ----------------------- ----------------------------------------------------------------
        CATEGORY                PRODUCT                                         GSI       PKI
                                                                                LIST   TRANSFER
                                                                               PRICE     PRICE
<S>     <C>                     <C>                                           <C>      <C>
------- ----------------------- ----------------------------------------------------------------

1       BioChip Systems         GeneTAC 2000                                  $ 80,000    [*]
------- ----------------------- ------------------------------------------------------
2       BioChip Systems         GeneTAC 3000                                  $ 99,000    [*]
------- ----------------------- ------------------------------------------------------
3       BioChip Systems         Flexys Gridding System                        $ 80,000    [*]
------- ----------------------- ------------------------------------------------------
4       BioChip Systems         Flexys Gridding with Autoloader               $150,000    [*]
------- ----------------------- ------------------------------------------------------
5       BioChip Systems         Flexys Picking System                         $ 90,000    [*]
------- ----------------------- ------------------------------------------------------
6       BioChip Systems         Flexys Picking with Autoloader                $160,000    [*]
------- ----------------------- ------------------------------------------------------
7       BioChip Systems         Flexys High Density Arraying                  $ 80,000    [*]
------- ----------------------- ------------------------------------------------------
8       BioChip Systems         Flexys High Density Arraying with Autoloader  $150,000    [*]
------- ----------------------- ------------------------------------------------------
9       BioChip Systems         Hybridization Station 12 Slide                $ 59,000    [*]
------- ----------------------- ------------------------------------------------------
10      Proteomic Systems       2-D Electrophoresis System                    $ 13,700    [*]
------- ----------------------- ------------------------------------------------------
11      Proteomic Systems       Gel Processor                                 $ 29,000    [*]
------- ----------------------- ------------------------------------------------------
12      Proteomic Systems       Proteomic Analyzer System (Darkroom)          $ 55,000    [*]
------- ----------------------- ------------------------------------------------------
13      Proteomic Systems       Proteomic Software only                       $ 25,000    [*]
------- ----------------------- ------------------------------------------------------
14      Proteomic Systems       Proteomic Analyzer System (Scanner)           $ 30,000    [*]
------- ----------------------- ------------------------------------------------------
15      Proteomic Systems       ProGest                                       $ 65,000    [*]
------- ----------------------- ------------------------------------------------------
16      Proteomic Systems       ProMS                                         $ 55,000    [*]
------- ----------------------- ------------------------------------------------------
17      Proteomic Systems       Flexys Proteomics system (Protein Picker)     $127,000    [*]
------- ----------------------- ------------------------------------------------------
18      Proteomic Systems       Maldi Mass Spec                               $265,000    [*]
------- ----------------------- ------------------------------------------------------
19      Gel Analysis            GelPrint 2000i                                $ 13,500    [*]
------- ----------------------- ------------------------------------------------------
</TABLE>

NOTE:    Destination shipping charges are not included.
         Shipping terms:  FOB GSI's U.S. or U.K. shipping dock.

[*]      Certain information on this page has been omitted and filed separately
         with the Commission. Confidential treatment has been requested with
         respect to the omitted portion.

                                      -16-

<PAGE>   16

                                    EXHIBIT B

                     GENOMIC SOLUTIONS' DISTRIBUTOR SCHEDULE

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
      DATE OF AGREEMENT            AGREEMENT WITH                    TERMINATION ASSUMING DEFINITIVE       COUNTRY
                                                                     AGREEMENT SIGNED DEC. 15, 1999
<S>                           <C>                                    <C>                              <C>
-----------------------------------------------------------------------------------------------------------------------------
          12/15/98            Science & Technology Ltd.              December 15, 2000*               New Zealand
-----------------------------------------------------------------------------------------------------------------------------
           2/15/99            Bio/Can Scientific                     January 14, 2000                 Canada
-----------------------------------------------------------------------------------------------------------------------------
           12/7/98            B&L                                    March 15, 2000                   Benelux
-----------------------------------------------------------------------------------------------------------------------------
           5/26/99            Proteigene SARL                        March 15, 2000                   France
-----------------------------------------------------------------------------------------------------------------------------
           3/16/99            Biogenet                               March 16, 2000                   Poland
-----------------------------------------------------------------------------------------------------------------------------
           3/31/99            Seoulin Scientific Co., Ltd.           March 31, 2000                   South Korea
-----------------------------------------------------------------------------------------------------------------------------
           3/26/99            AbiMed                                 June 15, 2000                    Germany
-----------------------------------------------------------------------------------------------------------------------------
           8/30/99            Sinc Do Brasil Inst.Cientifica         August 30, 2000                  Brazil
-----------------------------------------------------------------------------------------------------------------------------
           9/18/99            Labmate (Asia) PVT. LTD                September 22, 2000               India
-----------------------------------------------------------------------------------------------------------------------------
          11/16/98            Australian Laboratory Services         November 16, 2000                Australia
-----------------------------------------------------------------------------------------------------------------------------
           12/3/98            Feng Jih                               December 3, 2000                 Taiwan and China
-----------------------------------------------------------------------------------------------------------------------------
              ?               Bio Tech A.S.                          March 15, 2000**                 Czech Republic
-----------------------------------------------------------------------------------------------------------------------------
           12/3/98            Feng Jih                               December 3, 2000                 Taiwan and China
-----------------------------------------------------------------------------------------------------------------------------
</TABLE>

*CURRENT PKI DISTRIBUTOR
**NO CONTRACT CAN BE LOCATED.  GSI BELIEVES IT CAN CANCEL THIS AGREEMENT WITH
  90 DAYS NOTICE.

<PAGE>   17

                                    EXHIBIT C

                                PKI SALES TARGETS

<TABLE>
<CAPTION>

Calendar Quarter                     MINIMUM
----------------                     -------
<S>                                 <C>
Q1, 2000                               [*]
Q2, 2000                               [*]
Q3, 2000                               [*]
Q4, 2000                               [*]
</TABLE>

Note:  These minimums are dollar volume of sales based on orders received by GSI
from PKI and are at GSI's transfer price to PKI.

[*]    Certain information on this page has been omitted and filed separately
       with the Commission. Confidential treatment has been requested with
       respect to the omitted portion.

<PAGE>   18

                                    EXHIBIT D

                                PKI TECHNOLOGIES

                                      [*]

[*]     The information on this page has been omitted and filed separately with
        the Commission. Confidential treatment has been requested with
        respect to the omitted portion.<PAGE>   1
                                                                  Attachments to
                                                                  Exhibit 10.3

EX-10.3 Additional information to Business Loan Agreement among Genomic
        Solutions and certain of its warrantholders, dated April 23, 1999

<PAGE>   2
                                   EXHIBIT A

                                PROMISSORY NOTE

<PAGE>   3

THE RIGHTS OF THE HOLDER OF THIS NOTE TO RECEIVE PAYMENT ARE SUBJECT AND
SUBORDINATE TO THE PAYMENT OF ALL OBLIGATIONS OF MAKER OR OBLIGOR TO COMERICA
BANK, AND ITS SUCCESSORS AND ASSIGNS, UNDER THE TERMS OF THE SUBORDINATION
AGREEMENT DATED APRIL 23, 1999 EXECUTED BY GENOMIC SOLUTIONS, INC., THE PAYEE OF
THIS NOTE, ET AL.

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR OFFERED FOR SALE, PLEDGED,
HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT AND ANY APPLICABLE
STATE SECURITIES LAW OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED TO EFFECTUATE
SUCH TRANSACTION.

                         P R 0 M I S S 0 R Y   N 0 T E

$                                                            Ann Arbor, Michigan
                                                             April 23, 1999

     FOR VALUE RECEIVED, Genomic Solutions, Inc., a Delaware corporation, 4355
Varsity Drive, Suite E, Ann Arbor, Michigan 48108, Genomic Solutions, Ltd., a
United Kingdom corporation, Unit 3, Forge Close, Little End Road, Eaton Socon,
St. Neots, Cambridgeshire, England PE193TP and Genomic Solutions, K.K., a
Japanese corporation, Gotanda Chuo Bldg. 2F, 3-5, Higashigotanda 2-chome,
Shinagawa-ku, Tokyo 141-0022, Japan, jointly and severally, hereinafter
collectively referred to as "Borrower", promise to pay to the order of         ,
hereinafter called the "Lender", or holder the sum of   ($   ) dollars in lawful
money of the United States of America, with interest at the rate of twelve
percent (12.0%) per annum on all sums at any time unpaid, at         or at such
other place as the holder hereof may designate by written notice to the
Borrower, with interest from the date of the disbursement of the loan, until
paid.

     The principal and interest shall be payable over five (5) years ("Loan
Term") as follows: except as otherwise provided herein for early payment, the
principal shall be due and payable on the earliest of (i) April 23, 2004, (ii)
the settlement date following the effective date of a registration statement
filed by Genomic Solutions, Inc. (hereinafter sometimes referred to as "Parent")
with the Securities and Exchange Commission for a public offering and sale of
securities of Parent, (iii) the effective date, immediately after the effective
time, of any merger or consolidation of Parent, (iv) a transfer of more than 50%
of the issued and outstanding common stock of Parent (if

                                       1
<PAGE>   4

immediately after the transfer the transferee has control of Parent), or (v) a
sale of substantially all of the assets of Parent. Interest shall be payable
quarterly in arrears on each March 31, June 30, September 30 and December 31
commencing June 30, 1999. On each interest payment date, (i) 7/12ths of the
interest payable on such date shall be paid in cash, and (ii) 5/12ths of the
interest payable on such date shall be paid by the issuance to Lender of a
number of shares of common stock of Parent equal to the amount of such interest
divided by the Minimum Company Value, provided that on each scheduled interest
payment date, Lender may upon ten (10) days, prior written notice to Parent
elect not to receive such payment in shares of common stock of Parent and
instead elect to defer payment of 5/12ths of the interest due on such scheduled
interest payment date, which amount shall then be added to the outstanding
principal balance of this Note with effect as of such payment date. Except as
otherwise provided herein for early or accelerated payment, the entire unpaid
principal balance plus accrued interest and all other indebtedness shall be due
and payable on or before April 23, 2004. Interest shall be calculated on a 365
day basis on the unpaid principal balance for the actual days outstanding. For
purposes of the foregoing, "Minimum Company Value" shall be the same amount
determined as the Minimum Company Value in accordance with the provisions of the
Warrants attached to the Loan Agreement (defined below) as Exhibit B (initially
$5.00 per share).

     Parent has granted to Lender a security interest in or lien upon all assets
of Parent as described in the Security Agreement and Assignment and Pledge
Agreement of even date herewith, and Borrower may hereafter grant a security
interest in or lien upon other assets as may be described in any other security
agreement, mortgage, or other document executed at any time by the Borrower and
delivered to the Lender (herein collectively termed "Collateral") as security
for the payment of this Note, and for the payment of all other liabilities,
whether direct, indirect, absolute or contingent, now or hereafter existing, due
to become due, several or otherwise, of the Borrower to the Lender under the
Loan Documents (as defined in the Loan Agreement) (herein termed
"Indebtedness").

     Upon an event of default under any security agreement, the Business Loan
Agreement dated April 23, 1999 between Lender, Borrower and others (the "Loan
Agreement"), or any document given in connection with the Collateral, which
event of default is not cured within any applicable grace period, (i) this Note
and all Indebtedness shall, at the option of the Lender, become immediately due
and payable in full without notice, presentation or demand for payment, all such
being hereby waived by the Borrower and in such event, it is agreed that the
Lender may exercise all rights and remedies available to it under any security
agreement, hypothecation agreement, loan agreement, or other agreement relating
to or otherwise securing any of the Indebtedness or, which may be available to
Lender under the

                                       2
<PAGE>   5

Uniform Commercial Code as in effect in the State of Michigan or other
applicable law, and (ii) this note shall thereafter bear interest at the rate of
sixteen percent (16%) per annum until such default is cured. Delay or
forbearance by the Lender in the exercise of any right granted hereunder shall
not operate as a waiver thereof.

A late payment fee in the amount of five percent (5.0%) of the installment due
and owing will be assessed against the Borrower in the event the payment
required hereunder is received by the Lender more than ten (10) days after the
due date.

Provided that all interest payments on this Note shall then be current, Borrower
may prepay this Note in whole at any time or in part from time to time. Upon any
payment of the principal of this Note in whole or in part prior to April 23,
2004, including as a result of this Note becoming immediately due and payable at
the option of the Lender in accordance with the terms of this Note, Borrower
shall pay a premium equal to the following sums:

     (i) on amounts prepaid prior to April 24, 2000 - five percent (5%) of
amounts prepaid;

     (ii) on amounts prepaid after April 23, 2000 but prior to April 24, 2001,
four percent (4%) of amounts prepaid;

     (iii) on amounts prepaid after April 23, 2001 but prior to April 24, 2002,
three percent (3%) of amounts prepaid;

     (iv) on amounts prepaid after April 23, 2002 but prior to April 24, 2003,
two percent (2%) of amounts prepaid;

     (v) on amounts prepaid after April 23, 2003, one percent (1%) of amounts
prepaid,

provided however that (x) if such payment of this Note is a condition imposed by
parties purchasing not less than $10,000,000 of common stock or preferred stock
of Parent, the premium payable upon payment of this Note in whole or in part
prior to April 24, 2000 shall be 2-1/2% instead of 5%, and (y) no premium shall
be payable if the value of Borrower, implicit in the price at which shares of
common stock of Parent are sold in a public offering pursuant to a registration
statement, or the price applicable in any merger or consolidation of Parent or
the transfer of more than 50% of the issued and outstanding common stock of
Parent or the sale of substantially all of the assets of Parent, shall exceed
$50,000,000, and if the prepayment of this Note shall occur by reason of such
event. This Note is one of various promissory notes executed and delivered by
Borrower pursuant to the Loan Agreement. Borrower shall not prepay this Note in
whole or in part unless Borrower shall concurrently prepay in whole or a prorata
part of all other promissory notes originally executed and delivered by Borrower
on the same date as this Note.

                                       3
<PAGE>   6

     Notwithstanding any provision to the contrary, it is the intent of the
Lender and Borrower that neither the Lender nor any subsequent holder shall be
entitled to receive, collect, reserve or apply, as interest, any amount in
excess of the maximum lawful rate of interest permitted to be charged by
applicable law or regulations, as amended or enacted from time to time. In the
event the Note calls for an interest payment that exceeds the maximum lawful
rate of interest then applicable, such interest shall not be received,
collected, charged, or reserved until such time as that interest, together with
all other interest then payable, falls within the applicable maximum lawful rate
of interest. In the event the Lender, or any subsequent holder, receives any
such interest in excess of the then maximum lawful rate of interest, such amount
which would be excessive interest shall be deemed a partial prepayment of
principal and treated hereunder as such, or, if the principal indebtedness
evidenced hereby is paid in full, any remaining excess funds shall immediately
be paid to the Borrower.

     Borrower hereby waives presentment, demand, protest and notice of dishonor
and agrees that Borrower shall not be released or discharged by reason of any
release, sale or non-action with respect to the Collateral or other undertakings
securing this Note.

     The security rights of Lender and its assigns shall not be impaired by
Lender's sale, hypothecation, or rehypothecation of any Note of the Borrower or
any item of the Collateral, or by any indulgence, including but not limited to:
(i) Any renewal, extension, or modification which Lender may grant with respect
to the Indebtedness or any part thereof, (ii) Any surrender, compromise,
release, renewal, extension, exchange, or substitution which Lender may grant in
respect to the Collateral, or (iii) any indulgence granted in respect of any
endorser, comaker, guarantor or surety. The purchaser, assignee, transferee, or
pledgee of this Note, the Collateral, any guarantee, and any other document (or
any of them) , sold, assigned, transferred, pledged, or repledged, shall
forthwith become vested with and entitled to exercise all the powers and rights
given by this Note and all Loan Documents of the undersigned to Lender, as if
said purchaser, assignee, transferee, or pledgee were originally named as payee
in this Note and in the Loan Documents.

     This Note shall be construed, interpreted and enforced in accordance with
the laws of the State of Michigan without regard to its conflict of laws
principles. Borrower expressly submits to the jurisdiction and venue in the
Federal or state courts of the State of Michigan by process served by mail on
Borrower at the address set forth above.

     This Note has been negotiated between Borrower and Lender and shall be
deemed to be mutually drafted by them.

                                       4

<PAGE>   7

IN WITNESS WHEREOF, this Note has been executed by the duly authorized officers
of the Borrower.

                                   GENOMIC SOLUTIONS, INC.

                                   By:
                                      ------------------------------------------
                                      Jeffrey S. Williams, President

                                   GENOMIC SOLUTIONS, LTD

                                   By:
                                      ------------------------------------------
                                   GENOMIC SOLUTIONS, K.K.

                                   By:
                                      ------------------------------------------

                                       5

<PAGE>   8

                                   Exhibit B
                                    filed as
                          Exhibits 4.10, 4.11 and 4.12
<PAGE>   9
                                   EXHIBIT C

                               SECURITY AGREEMENT

<PAGE>   10

                              SECURITY AGREEMENT

     This Security Agreement is entered into this 23rd day of April, 1999, by
Genomic Solutions, Inc., a Delaware corporation, 4355 Varsity Drive, Suite E,
Ann Arbor, Michigan 48108 ("Borrower") in favor of White Pines Limited
Partnership I, a Michigan limited partnership, 2401 Plymouth Road, Suite B, Ann
Arbor, Michigan 48105 (hereinafter referred to as "WPLP"), Pacific Capital,
L.P., a Delaware limited partnership, 2401 Plymouth Road, Suite B, Ann Arbor,
Michigan 48105 (hereinafter referred to as "Pacific"), Chase Venture Capital
Associates, L.P., a California limited partnership, 380 Madison Avenue, 12th
Floor, New York, New York 10017 (hereinafter referred to as "Chase"), American
Healthcare Fund II, a Delaware limited partnership, 4430 Arapahoe Avenue, Suite
220, Boulder, Colorado 80303 (hereinafter referred to as "American"), Ian R. N.
Bund Smith Barney Prototype PS Plan Account #206-08291-12445, P.O. Box 2022,
Bloomfield Hills, Michigan 48303 (hereinafter referred to as "Bund"), Yocum
Consulting Associates, Inc., an Ohio corporation, 4622 Wyndwood Drive, Toledo,
Ohio 43623 (hereinafter referred to as "Yocum"), Volunteer Healthcare
Associates, L.L.C., a Tennessee limited liability company, 6 Cadillac Drive,
Suite 310, Brentwood, Tennessee 37027 (hereinafter referred to as "Volunteer"),
McDonald Investments Inc. Custodian FBO S. Sterling McMillan III IRA Rollover
Account #85362191, 2550 Som Center Road, Suite 300, Willoughby Hills, Ohio 44094
(hereinafter referred to as "McMillan"), J. Matthew Mackowski, 275 Post Street,
Suite 600, San Francisco, California 94108 (hereinafter referred to as
"Mackowski-CA"), Robert G. Shepler, 275 Post Street, Suite 600, San Francisco,
California 94108 (hereinafter referred to as "Shepler"), John J. Mackowski, 1506
Birkdale Lane, Ponte Verde Beach, Florida 32082 (hereinafter referred to as
"Mackowski-FL"), Grove Investment Partners, an Illinois partnership, 336 Essex
Road, Kenilworth, Illinois 60043 (hereinafter referred to as "Grove") Ronald G.
Kalish Living Trust u/a/d September 9, 1997, 445 Grand Bay Drive, #1009, Key
Biscayne, Florida 33149 (hereinafter referred to as "Kalish"), Lois F. Marler,
48951 Fox Drive South, Plymouth, Michigan 48170 (hereinafter referred to as
"Marler"), McDonald Investments Inc. Custodian FBO Daniel J. Boyle IRA Rollover
Account #85314893, 2550 Som Center Road, Suite 300, Willoughby Hills, Ohio 44094
(hereinafter referred to as "Boyle"), National City Bank of MI/IL, Custodian FBO
Herbert S. Amster IRA Rollover Account dated June 12, 1991 Account
#MI-1491-00-4, 101 National City Bank, 101 S. Main Street, Ann Arbor, Michigan
48104 (hereinafter referred to as "Amster"), Kantner and Associates Profit
Sharing Plan u/a/d January 1, 1991, 555 East William Street, Ann Arbor, Michigan
48104 (hereinafter referred to as "Kantner") and Michael G. Williams, 18000
Cavanaugh Lake Road, Chelsea, Michigan 48118 (hereinafter referred to as
"Williams") (WPLP, Pacific, Chase, American, Bund, Yocum, Volunteer, McMillan,
Mackowski-CA, Shepler, Mackowski-FL, Grove, Kalish, Marler, Boyle, Amster,
Kantner and Williams each being sometimes hereinafter referred to as "Lender", a
"Lender" or the "Lender" and collectively as "Lenders").

                                       1

<PAGE>   11

     For value received, the Borrower hereby grants to each Lender a security
interest in and to all of the Borrower's tangible and intangible real and
personal property and fixtures, whether now owned or hereafter acquired,
including, but not limited to, goods, documents, inventory, work in process,
instruments, equipment, furniture, machinery, fixtures, trade fixtures, contract
rights, chattel paper, accounts receivable, documents, patents, licenses and
motor vehicles, together with the proceeds from the sale or other disposition
thereof and the products thereof (the "Collateral"). The Collateral shall be
considered to be all of the assets of the Borrower. The Borrower hereby pledges,
assigns, transfers and grants to the Lender a security interest in the
Collateral to secure the payment of all loans, advances, and extensions of
credit from the Lender to the Borrower, including all renewals and extensions
thereof and any and all obligations of every kind whatsoever, whether now, or
hereafter existing or arising between the Lender and the Borrower and howsoever
incurred or evidenced, whether primary, secondary, contingent, or otherwise,
under or in connection with (1) the Borrower's Notes of even date herewith in
the aggregate amount of six million and no/100 ($6,000,000) dollars to the
Lenders, payable as to principal and interest as provided in the Notes; (2)
future advances by the Lender to the Borrower, if any; (3) all costs and
expenditures made or incurred by the Lender for taxes, insurance, and repairs to
and maintenance of the Collateral or made or incurred by Lender in the
disbursement, administration, collection or enforcement of the Notes; and (4)
all liabilities of Borrower to Lender now existing or incurred in the future,
matured or unmatured, direct or contingent, and any renewals, extensions, and
substitutions of those liabilities, and any other obligations of the Borrower,
under the Business Loan Agreement and Loan Documents (as defined therein) of
Borrower of even date herewith. The foregoing obligations shall be hereafter
collectively called the "liabilities" and shall also include all interest,
costs, expenses, and reasonable actual attorneys fees accruing to or incurred by
the Lender.

The Borrower hereby warrants, covenants and agrees as follows:

     1. Warranties. The Borrower warrants the following:

        (a) except as provided in the Business Loan Agreement, it has or will
acquire free and clear title to all of the Collateral and the security interest
granted to Lender shall be a first security interest, and the Borrower will
defend same to the Lender against the claims and demands of all persons;

        (b) the Borrower will fully cooperate in placing or maintaining Lender's
lien or security interest;

                                       2
<PAGE>   12

     (c) all of the collateral is located in the states of Michigan or
Massachusetts;

     (d) all accounts are genuine and collectible except to the extent of
reserves provided on the balance sheet;

     (e) the Borrower will not remove or change the location of any Collateral
without the Lender's prior written consent;

     (f) the Borrower will not use the Collateral or permit it to be used for
any unlawful purpose;

     (g) the Borrower will not conduct business under any name other than that
stated herein, nor change, nor reorganize the type of business entity as
described, except upon the prior written approval of the Lender, in which event
the Borrower agrees to execute any documentation of whatsoever character or
nature demanded by the Lender for filing or recording, at the Borrower's
expense, before such change occurs;

     (h) the Borrower will keep all records of account, documents, evidence of
title, and all other documentation regarding its business and the Collateral at
the address specified herein, unless notice thereof is given to the Lender at
least ten (10) days prior to the change of any address for the keeping of such
records; the Borrower will, at all times, maintain the Collateral in good
condition and repair, ordinary wear and tear excepted, and will not sell or
remove same except as to inventory in the ordinary course of business;

     (i) the Borrower is a legally created business entity, as described before,
and it has the power, and the person signing is duly authorized, to enter into
this Agreement; the execution of this Agreement will not create any breach of
any provision of any other agreement to which Borrower is a party; and

     (j) all Financial Statements delivered by the Borrower to the Lender to
obtain loans and extensions of credit taken as a whole (A) fairly present in all
material respects (subject, in the case of the interim financial statements, to
normal, recurring year-end adjustments which are not material individually or in
the aggregate) the financial position of the Borrower as of the dates indicated
and the results of operations of the Borrower for the periods indicated, (B) (x)
have been prepared in accordance with Generally Accepted Accounting Principles
("GAAP") consistently applied throughout the periods covered thereby (subject,
in the case of the interim financial statements, to normal, recurring year-end
adjustments which are not material individually or in the aggregate) or (Y) to
the extent not prepared in accordance with GAAP, then footnotes to the Financial
Statements will be provided describing in reasonable detail the differences, if
any, between the accounting

                                       3

<PAGE>   13

principles pursuant to which such Financial Statements were in fact prepared and
GAAP and (C) are in accordance with the books and records of the Borrower which
have been maintained in a manner consistent with historical practice.

     2. Insurance. Borrower shall maintain adequate fire and extended risk
coverage, business interruption, workers disability compensation, public
liability, environmental, flood, and such other insurance coverages as may be
required by law or as is customary and adequate among businesses in Borrowers'
industry engaged in the same or similar activities. All insurance policies shall
be in such amounts, upon such terms, in form, and carried with insurers with a
"best rating" of B or better or such insurers as are acceptable to Lender. Each
Borrower shall provide evidence satisfactory to Lender of all insurance
coverages and that the policies are in full force and effect, and for all
insurance coverages upon any property which is collateral, the insurance policy
shall be endorsed to provide Lender with a standard loss payable clause with not
less than thirty (30) days advance written notice to Lender by the insurer of
any cancellation or modification of coverage. Said proceeds may be utilized to
restore or replace the collateral with Lender's consent, which consent will not
be unreasonably withheld, provided Borrower is not in default other than a
default arising from the loss of or damage to collateral. In the event of
default or if said proceeds are not utilized to restore or replace the
collateral, Lender may apply such proceeds as it may receive toward the payment
of the liabilities in such order as the Lender may at its sole discretion
determine. If the Borrower at any time fails to obtain or to maintain any of the
insurance required above or pay any premium in whole or in part relating
thereto, the Lender, without waiving any default hereunder, may make such
payment or obtain such policies as the Lender, in its sole discretion, deems
advisable to protect the Borrower's property. All costs incurred by the Lender,
including reasonable attorney's fees, court costs, expenses, and other charges
thereby incurred, shall become a part of the liabilities and shall be payable on
demand.

     3. Taxes, Liens, etc. The Borrower agrees to pay all taxes, levies,
judgments, assessments, and charges of any nature whatsoever relating to the
Collateral or to the Borrower's business. Except to the extent that Borrower has
established a cash reserve and is actively pursuing a tax appeal, if the
Borrower fails to pay such taxes or other charges in accordance with the
foregoing, the Lender at its sole discretion, may pay such charges on behalf of
the Borrower; and all sums so dispensed by the Lender, including reasonable
actual attorney's fees, court costs, expenses, and other charges relating
thereto, shall become a part of the liabilities and shall be payable on demand.

     4. Information and Reporting. The Borrower agrees to supply to the Lender
such information concerning the status of any of its assets as the Lender, from
time to time, may

                                       4
<PAGE>   14

reasonably request. The Borrower further agrees to permit the Lender, its
employees, and agents to have access to the Collateral for the purpose of
inspecting it, together with all of the Borrower's other physical assets if any,
and to permit the Lender, from time to time, to verify accounts as well as to
inspect, copy, and to examine the books, records, and files of the Borrower.

     5. Accounts. The Borrower acknowledges that Lender has a security interest
in Accounts. It is understood that the Lender will initially permit the Borrower
to collect accounts from its debtors. The Borrower understands that this
privilege may be terminated by the Lender only after an event of default under
the Business Loan Agreement or the Notes, Warrants or this Agreement shall occur
and is not cured within any applicable grace period, and that, in such event:

        (a) the Lender shall be vested with all of the rights of the Borrower in
respect thereto, including the right of stoppage in transit, the ability to
notify any debtor or debtors of the assignment, and the ability to execute any
instrument on behalf of the Borrower in settlement or fulfillment of an account;

        (b) the Borrower agrees to execute such assignments as the Lender may
request to evidence the assignment and, in the event of an assignment to the
Lender, Borrower thereafter receives payment on any account as the agent of the
Lender, and the Borrower agrees to transmit such payment in the form in which it
was received to the Lender on the date of receipt thereof, appropriately
endorsed, if necessary, to permit negotiation by the Lender;

        (c) until such remittance, the Borrower agrees to keep all such receipts
on account separate and apart from the Borrower's own funds so that such
receipts are readily identifiable as the property of the Lender and to hold same
in trust for the Lender; and

        (d) in any event, the Lender is authorized to endorse or to sign, in the
name of the borrower, any instrument of whatsoever nature to effect the
collection of the accounts for application to the liabilities.

     6. Default. A default by the Borrower under the Business Loan Agreement,
the Notes, the Warrants or any other agreement entered into between the Borrower
and the Lender, which default is not cured within any applicable grace period,
shall constitute a default of this Security Agreement. The covenants,
conditions, events of default and other terms set forth or referred to in any
and all documents entered into between the Borrower and Lender are incorporated
into this Security Agreement with the same force and effect as if those such
covenants, conditions, and events of default were fully set forth herein.

                                       5

<PAGE>   15

     7. Remedy. The Borrower agrees that, whenever a default exists, Lender
shall have the remedies set forth in the Business Loan Agreement and Lender may
exercise, from time to time, any rights and remedies, including the right to
immediate possession of the Collateral, available to it under applicable law.
The lender shall have the right to hold any property then in or upon said
Collateral at the time of repossession not covered by the security agreement
until return is demanded in writing by the Borrower or other party entitled
thereto. The Borrower agrees, in the case of default, to assemble, at its own
expense, all Collateral at a convenient place acceptable to the Lender and to
pay all reasonable costs of the Lender in connection with the collecting of the
liabilities and enforcement of any rights hereunder, including reasonable
attorney's fees and legal expenses, and including participation in Bankruptcy
proceedings; and to pay all of the expense of locating the collateral, as well
as the expense of any repairs for any realty or other property to which any of
the Collateral may have been affixed or made a part. Any notification of
intended disposition of the Collateral by the Lender shall be deemed to be
reasonable and proper if sent postage prepaid, by regular mail, to the Borrower
at least seven (7) days before such disposition, and addressed to the Borrower
either at the address shown herein or at any other address. The Lender shall, in
the event of any default have the right to peacefully retake any of the goods.
In the event of a default, the Borrower expressly authorizes the Lender to
offset any debts of the Lender to the Borrower against the Liabilities.

     8. Termination. This Agreement and related financing statements shall be
terminated upon payment in full of the aforementioned Notes and all other sums
and expenses required to be paid pursuant to the terms of the Business Loan
Agreement, the Loan Documents other than the Warrants, and the Warrants but only
if prior to the time such termination would otherwise occur Borrower has been
notified of the exercise of Lenders' rights under subsection (K) of the
Warrants. If this Agreement and the related financing statements shall have been
terminated prior to the date on which Borrower is notified of the exercise of
Lenders' rights under subsection (K) of the Warrants, the effectiveness of this
Agreement shall automatically continue or be reinstated with respect to all
amounts payable in accordance with the terms of the Warrants upon notice to
Borrower of the exercise of Lenders, rights under subsection (K) of the
Warrants.

     9. Miscellaneous. Time is of the essence of this agreement. Except as
otherwise defined in this agreement, all terms herein shall have the meanings
provided by the Uniform Commercial Code as it has been adopted in the State of
Michigan. Any delay on the part of the Lender in exercising any power,
privilege, or right hereunder, or under any other document executed by the
Borrower to the Lender in connection herewith, shall not operate as a waiver
thereof, and no single or partial

                                       6

<PAGE>   16

exercise thereof or any other power, privilege, or right shall preclude other or
further exercise thereof. The waiver by the Lender of any default of the
Borrower shall not constitute a waiver of subsequent default. All rights,
remedies, and powers of the Lender hereunder are irrevocable and cumulative, and
not alternative or exclusive, and shall be in addition to all rights, remedies,
and powers given hereunder or in or by any other instruments or by the provision
of the Uniform Commercial Code as adopted in the State of Michigan, or any other
laws now existing or hereinafter enacted.

     This agreement has been delivered in the State of Michigan and shall be
construed in accordance with the laws of the State of Michigan. Whenever
possible, each provision of this agreement shall be interpreted in such manner
as to be effective and valid under applicable law; but, if any provision of this
agreement shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such provision or the invalidity without
invalidating the remainder of such provision or the remaining provisions of this
agreement. The rights and privileges of the Lender hereunder shall inure to the
benefits of its successors and assigns, and this agreement shall be binding on
all successors and assigns of the Borrower. The Borrower may not assign this
agreement or any benefits accruing to it hereunder without the express written
consent of the Lender.

     This agreement has been negotiated between Borrower and Lender and shall be
deemed to be mutually drafted by them.

     In witness whereof, the parties have executed this Agreement on the date
and year first above written.

LENDERS:                                     BORROWER:

                                             WHITE PINES LIMITED PARTNERSHIP I
                                             GENOMIC SOLUTIONS, INC.
By:   White Pines G.P., L.L.C.,
      its general partner

By:                                          By:
   ------------------------------------          -------------------------------
   Frederick L. Yocum, Chairman                  Jeffrey S. Williams
                                                                       President

PACIFIC CAPITAL, L.P.
By:   Pacific Capital Corporation,
      its general partner

By:
   ------------------------------------
   Frederick L. Yocum, Vice-Chairman

                                       7

<PAGE>   17

IAN R. N. BUND SMITH BARNEY
       PROTOTYPE PS PLAN ACCOUNT
       #206-08291-12445

YOCUM CONSULTING ASSOCIATES, INC.

VOLUNTEER HEALTHCARE ASSOCIATES, L.L.C
MCDONALD INVESTMENTS INC. CUSTODIAN
       FBO S. STERLING MCMILLAN III IRA
       ROLLOVER ACCOUNT #85362191
RONALD G. KALISH LIVING TRUST U/A/D
       SEPTEMBER 9, 1997
LOIS F. MARLER
MCDONALD INVESTMENTS INC. CUSTODIAN
       FBO DANIEL J. BOYLE IRA
       ROLLOVER ACCOUNT #85314893
NATIONAL CITY BANK OF MI/IL CUSTODIAN
       FBO HERBERT S. AMSTER IRA
       ROLLOVER ACCOUNT DATED JUNE 12, 1991
       #MI-1491-00-4
KANTNER AND ASSOCIATES PROFIT SHARING
       PLAN U/A/D JANUARY 1, 1991
MICHAEL G. WILLIAMS

By:    White Pines Management, L.L.C.,
       a Michigan limited liability
       company, attorney-in-fact

By:
   ----------------------------------------
   Frederick L. Yocum, Chairman

CHASE VENTURE CAPITAL ASSOCIATES, L.P.

By:
   ----------------------------------------
AMERICAN HEALTHCARE FUND II

By:
   ----------------------------------------
J. MATTHEW MACKOWSKI

-------------------------------------------
ROBERT G. SHEPLER

-------------------------------------------
JOHN J. MACKOWSKI

GROVE INVESTMENT PARTNERS

By:
   ----------------------------------------

                                        8

<PAGE>   18

                                   EXHIBIT D

                            SUBORDINATION AGREEMENT

<PAGE>   19
                            SUBORDINATION AGREEMENT
                          (All Indebtedness and Liens)

Genomic Solutions, Inc., Genomic Solutions, Ltd., and Genomic Solutions K.K.
(each, a "Borrower" and, together the "Borrowers') ("Borrower" is indebted to
the undersigned (each a "Creditor" and collectively "Creditors") in the
aggregate principal sum of Six Million Dollars ($6,000,000) evidenced by [ ] AN
OPEN ACCOUNT [X] PROMISSORY NOTES [ ] OTHER (DESCRIBE)________________
_____________________________________________which indebtedness is [ ] UNSECURED
[ ]SECURED by substantially all assets of the Borrowers, and Creditors are or
may become financially interested in Borrowers and desire to aid Borrowers in
obtaining or having continued financial accommodations, whether by way of loan,
commitment to loan, discounting of instruments, extensions of credit or the
obtaining of any other financial aid from Comerica Bank ("Bank").

In order to induce the Bank to extend or to continue to extend financial
accommodations to Borrowers from time to time, whether by way of a loan,
commitment to loan, discounting of instruments, extension of credit or otherwise
and in consideration of any of these financial accommodations, Bank, Borrowers
and Creditors agree as follows:

1.   Any and all obligations and liabilities of Borrowers to Creditors,
     including, without limit, principal and interest payments, whether direct
     or indirect, absolute or contingent, joint or several, secured or
     unsecured, due or to become due, now existing or later arising and whatever
     the amount and however evidenced (the "Subordinated indebtedness"), are
     subordinated in right of payment to any and all obligations and liabilities
     of Borrowers to the Bank, including, without limit, principal and interest
     payments, whether direct or indirect absolute or contingent, joint or
     several, secured or unsecured, due or to become due, now existing or later
     arising and however evidenced, together with all other sums due thereon and
     all costs of collecting the same (including without limit, reasonable
     attorney fees) for which Borrowers are liable (the "Senior Indebtedness")
     provided, however, that Senior Indebtedness does not include aggregate
     principal amounts at any one time outstanding in excess of $3,000,000
     during 1999, in excess of $6,000,000 during 2000, in excess of $7,000,000
     during 2001 or in excess of $8,000,000 during 2002 or thereafter.

2.   Except as otherwise provided in this agreement, Creditors will not ask for,
     demand, sue for, take or receive (by way of voluntary payment,
     acceleration, set-off or counterclaim, foreclosure or other realization on
     security, dividends in bankruptcy or otherwise), or offer to make any
     discharge or release of, any of the Subordinated Indebtedness, and
     Creditors waive any such rights with respect to the Subordinated
     Indebtedness nor shall Creditors exercise any rights of subrogation or
     other similar rights with respect to the Senior Indebtedness.

<PAGE>   20

3.   Subject to the provisions of Subsection 20(B) below, Creditors will not
     exercise any of Creditors' rights in any collateral now or later securing
     the Subordinated Indebtedness. All rights of Creditors in any collateral
     now or later securing the Subordinated Indebtedness are subordinated to all
     rights of the Bank now or later existing in any of the same collateral
     securing the Senior Indebtedness.

4.   The Bank, in its own name or in the name of Creditor, may collect and
     enforce the Subordinated Indebtedness and all claims and demands of
     Creditor in connection therewith, by proof of debt in bankruptcy, or in any
     other proceeding involving dissolution, insolvency, liquidation or an
     adjustment of the indebtedness of Borrower. Creditors make, constitute and
     appoint Bank their true and lawful attorney-in-fact with full power of
     substitution to take any action in furtherance of the foregoing in the
     event Creditors fail to do so promptly following request by Bank,
     including, but not limited to, the signing of proofs of claim, evidence of
     indebtedness, and the execution and delivery of all documents and
     agreements necessary to obtain or accomplish any protection for or
     collection or disposition of any part of the Subordinated Indebtedness or
     any collateral. Such appointment shall be deemed irrevocable and coupled
     with an interest.

5.   Should any payment, distribution or security or proceeds from these be
     received by Creditors upon or with respect to the Subordinated Indebtedness
     contrary to the terms of this Agreement, Creditors shall immediately
     deliver same to the Bank in the form received (except for endorsement or
     assignment by Creditors where required by the Bank), for application on the
     Senior Indebtedness (whether or not then due and in such order of maturity
     as Bank elects) and, until so delivered, the same shall be held in trust by
     Creditors as the property of the Bank.

6.   Each Creditor represents and warrants severally but not jointly that it has
     not made or permitted to be made any assignment, transfer, pledge, or
     disposition for collateral purposes or otherwise, of all or any part of the
     Subordinated Indebtedness or any collateral or other security for the
     Subordinated Indebtedness. The Creditors agree that any instrument or
     document evidencing the Subordinated Indebtedness shall at all times bear
     the following legend:

     The rights of the holder of this Note to receive payment are subject and
     subordinate to the payment of all obligations of maker or obligor to
     Comerica Bank, and its successors and assigns, under the terms of the
     Subordination Agreement dated _______________ executed by Genomic
     Solutions, Inc., the payee of this note, et al.

7.   This Agreement constitutes a continuing agreement of subordination, even
     though at times Borrowers are not indebted to the Bank. The Bank may
     continue, in reliance on this Agreement, without notice to Creditors, to
     lend monies, extend credit, modify, renew or make other financial
     accommodations, to or for the account of Borrowers until the fourteenth
     (14th) day ("effective date") following delivery by Creditors to Bank of
     revocation of this

                                       2
<PAGE>   21

     Agreement. Any such notice of revocation shall not be effective as to any
     Senior Indebtedness existing at the effective date of revocation or any
     Senior Indebtedness created after that pursuant to any commitment or
     agreement of the Bank or pursuant to any Borrower loan (whether advances or
     readvances by the Bank after the effective date of revocation are optional
     or obligatory) existing at the effective date of revocation or any
     modifications or renewals of any such Senior Indebtedness, whether in whole
     or in part. Possession by the Bank of any note or other evidence of
     indebtedness made, endorsed or guaranteed by Borrower shall be conclusive
     evidence (but not the only means of establishing) that Borrower is indebted
     to the Bank.

8.   [INTENTIONALLY OMITTED]

9.   Each Creditor delivers this Agreement based solely on its independent
     investigation of (or decision not to investigate) the financial condition
     of Borrowers and is not relying on any information furnished by the Bank.
     Each Creditor assumes full responsibility for obtaining any further
     information concerning Borrowers' financial condition, the status of the
     Senior Indebtedness or any other matter which it may deem necessary or
     appropriate now or later. Each Creditor waives any duty on the part of the
     Bank, and agrees that it is not relying upon nor expecting the Bank to
     disclose to it any fact now or later known by the Bank, whether relating to
     the operations or condition of Borrowers, the existence, liabilities or
     financial condition of any guarantor of the Senior Indebtedness, the
     occurrence of any default with respect to the Senior Indebtedness, or
     otherwise, notwithstanding any effect such fact may have upon Creditor's
     risk or Creditor's rights against any Borrower. Each Creditor knowingly
     accepts the full range of risk encompassed in this Agreement, which risk
     includes, without limit, the possibility that Borrowers may incur Senior
     Indebtedness to the Bank after the financial condition of Borrowers, or its
     ability to pay Borrowers' debts as they mature, has deteriorated. Each
     Creditor acknowledges and agrees that the Bank's rights under this
     Agreement are not conditioned upon pursuit by the Bank of any remedy the
     Bank may have against Borrowers or any other person or any other security.

10.  The Bank, in its sole discretion, without notice to Creditors, may release
     or exchange any security now or later held by the Bank for payment of the
     Senior Indebtedness or release any party now or later liable for payment of
     the Senior Indebtedness without affecting in any manner the Bank's rights
     under this Agreement. Each Creditor acknowledges and agrees that the Bank
     has no obligation to acquire or perfect any lien on or security interest in
     any asset(s), whether realty or personalty, to secure payment of the Senior
     Indebtedness, and that it is not relying upon assets in which the Bank has
     or may have a lien or security interest for payment of the Senior
     Indebtedness,

11.  Notwithstanding any prior revocation, termination, surrender, or discharge
     of this Agreement in whole or in part, the effectiveness of this Agreement
     shall automatically continue or be reinstated in the event that any payment
     received or credit given by the Bank in respect of the Senior Indebtedness
     is returned, disgorged, or rescinded under any applicable state or federal

                                       3

<PAGE>   22

     law, including, without limitation, laws pertaining to bankruptcy or
     insolvency, in which case this Agreement, shall be enforceable against each
     Creditor as if the returned, disgorged, or rescinded payment or credit had
     not been received or given by the Bank, and whether or not the Bank relied
     upon this payment or credit or changed its position as a consequence of it.
     In the event of continuation or reinstatement of this Agreement, each
     Creditor agrees upon demand by the Bank to execute and deliver to the Bank
     those documents which the Bank determines are appropriate to further
     evidence (in the public records or otherwise) this continuation or
     reinstatement, although the failure of the Creditor to do so shall not
     affect in any way the reinstatement or continuation.

12.  Each Creditor waives any right to require the Bank to: (a) proceed against
     any person or property; or (b) pursue any other remedy in the Bank's power.
     Each Creditor waives notice of acceptance of this Agreement and
     presentment, demand, protest, notice of protest, dishonor, notice of
     dishonor, notice of default, notice of intent to accelerate or demand
     payment of any Senior Indebtedness, and diligence in collecting any Senior
     Indebtedness, and agrees that the Bank may, once or any number of times,
     modify the terms of any Senior Indebtedness, compromise, extend, increase,
     accelerate, renew or forbear to enforce payment of any or all Senior
     Indebtedness, or permit any Borrower to incur additional Senior
     Indebtedness, all without notice to Creditors and without affecting in any
     manner the unconditional obligations of Creditors under this Agreement.

13.  Each Creditor acknowledges that the Bank has the right to sell, assign,
     transfer, negotiate or grant participations or any interest in, any or all
     of the Senior Indebtedness and any related obligations, including without
     limit this Agreement. In connection with the above, but without limiting
     its ability to make other disclosures to the full extent allowable, the
     Bank may disclose all documents and information which the Bank now or later
     has or acquires relating to Creditor and this Agreement, however obtained.
     Creditor further agrees that the Bank may disclose such documents and
     information to Borrowers. Each Creditor further agrees that the Bank may
     provide information relating to this Agreement or relating to Creditors to
     the Bank's parent, affiliates, subsidiaries and service providers.

14.  No waiver or modification of any rights under this Agreement shall be
     effective unless the waiver or modification shall be in writing and signed
     by an authorized officer of the applicable party. Each waiver or
     modification shall be a waiver or modification only with respect to the
     specific matter to which the waiver or modification relates and shall in no
     way impair the rights of the party or the obligations of the other parties
     in any other respect.

15.  This Agreement shall bind and be for the benefit of Creditors and the Bank
     and their respective successors and assigns, and shall be construed
     according to the laws of the State of Michigan, without regard to conflict
     of laws principles. If this Agreement is executed by two or more persons,
     it shall bind each of them individually as well as jointly.

                                       4
<PAGE>   23

16.  The term "Borrower", as used in this Agreement, includes any person,
     corporation, partnership or other entity which succeeds to the interests or
     business of a Borrower named above, and the terms "Senior Indebtedness" and
     "Subordinated Indebtedness" include indebtedness of any successor Borrower
     to the Bank and Creditors. Reference to the Borrowers' indebtedness in this
     Agreement refers to indebtedness of any one or more Borrowers.

17.  Creditors jointly and not severally agree to reimburse the Bank upon demand
     for any and all costs and expenses (including, without limit, court costs,
     legal fees, and reasonable attorney fees whether inside or outside counsel
     is used, whether or not suit is instituted and, if instituted, whether at
     the trial or appellate level, in a bankruptcy, probate or administrative
     proceeding, or otherwise) incurred in enforcing the duties and obligations
     of Creditors under Section 4 of this Agreement.

18.  Each Creditor waives any defense against the enforceability of this
     Agreement based upon or arising by reason of the application by any
     Borrower of the proceeds of any Indebtedness for purposes other than the
     purposes represented by any Borrower to the Bank or intended or understood
     by the Bank or Creditors. Each Creditor waives all rights to require the
     Bank to marshall the Collateral or any other property the Bank may at any
     time have as security for the Indebtedness and waives a right to require
     the Bank to first proceed against any guarantor or other person before
     proceeding against the Collateral.

19.  The relative priorities of the Bank and Creditors in the Collateral as set
     forth in this Agreement control irrespective of the time, method or order
     of attachment or perfection of the hens and security interests acquired by
     the parties in the Collateral and irrespective of the priorities as would
     otherwise be determined by reference to the Uniform Commercial Code or
     other applicable laws. Creditors shall not contest the validity, priority
     or perfection of the Bank's security interest in the Collateral (regardless
     of whether the Bank's security interest in the Collateral is valid or
     perfected). The priorities of any liens or security interests of the
     parties in any property of the Borrowers other than the Collateral are not
     affected by this Agreement and shall be determined by reference to
     applicable law. The Bank's rights under this agreement are in addition
     to, and not in substitution of, its rights under any other subordination
     agreement with any Creditor.

20.  Special Provisions

     A.   Notwithstanding anything to the contrary in this Agreement, Creditors
          may ask for, demand, sue for, take or receive from Borrowers the
          regularly scheduled quarterly payments which may come due under the
          above-described promissory notes ("Notes") and expense reimbursements
          permitted thereunder; provided, however, that Creditors may not ask
          for, demand, sue for, take or receive from Borrower any such payments
          after Creditors are given written notice by the Bank that a default or
          an event of default exists or has occurred under any note(s),
          guaranty(ies), and/or

                                       5
<PAGE>   24

agreement(s) between the Bank and Borrower or that any loan(s) between Borrower
and the Bank has (have) been called (a "Standstill Notice"). All such payments
due Creditors under the Notes must be suspended until such time (if ever) as
Creditor receives subsequent written notice from the Bank stating that the
default has been cured and/or the loan(s) has (have) been paid. The Bank agrees
to give Borrower copies of the notices, but the Bank's failure to do so shall
not affect its rights under this Agreement or any other agreement with Borrower.
The Notes may not be modified or prepaid without the prior written consent of
the Bank.

B.   Notwithstanding any of the other provisions of this Agreement, if within
     120 days after receipt by Creditors of a Standstill Notice the Bank has not
     accelerated the Senior Indebtedness and initiated legal action against
     Borrowers or the Collateral, and continued to diligently pursue such legal
     action and/or remedies, Creditors may accelerate the due date of the Notes,
     may demand and sue for the amounts due under the Notes and exercise any of
     Creditors' rights in any Collateral now or later securing the Subordinated
     Indebtedness regardless of the issuance of a subsequent Standstill Notice.
     Creditors shall give the Bank written notice of their intent to so exercise
     their remedies ten days prior to exercising such remedies. In exercising
     remedies against the collateral, the Creditors shall cooperate with the
     Bank and shall remit any proceeds of the sale or disposition of collateral
     to the Bank to be applied to the Senior Indebtedness until such time as the
     Senior Indebtedness is paid in full. In no event shall a Standstill Notice
     arising from default other than a payment default be in effect without the
     commencement of legal action by the Bank as provided in this paragraph for
     more than 120 days in any 12 month period.

C.   In the event of any distribution, division or application, whether partial
     or complete, voluntary or involuntary, by operation of law or otherwise, of
     all or any part of Borrowers' assets, or the proceeds of Borrowers' assets,
     in whatever form, to Creditors of Borrower or upon any indebtedness of
     Borrowers, whether by reason of the liquidation, dissolution or other
     winding-up of Borrowers, or by reason of any execution sale, receivership,
     insolvency, or bankruptcy proceeding, assignment for the benefit of
     Creditors, proceedings for reorganization, or readjustment of Borrowers or
     Borrowers' properties, then and in such event, (a) the Senior Indebtedness
     shall be paid in full before any payment is made upon the Subordinated
     Indebtedness, and (b) all payments and distributions, of any kind or
     character and whether in case, property, or securities, which shall be
     payable or deliverable upon or in respect of the Subordinated Indebtedness
     shall be paid or delivered directly to Bank for application in payment of
     the amounts then due on the Senior Indebtedness until the Senior
     Indebtedness shall have been paid in full.

D.   Upon payment in full of the Senior Indebtedness, Creditor shall be
     subrogated to any rights, liens and security interests of Bank pursuant to
     the Senior Indebtedness.

                                       6

<PAGE>   25

E.   This agreement may be executed in any number of counterparts, each of which
     shall constitute an original and all of which taken together shall
     constitute one and the same agreement.

F.   The parties acknowledge and agree that Bank is holding original stock
     certificates of Genomic Solutions, Ltd. and Genomic Solution, K.K. as
     security for the Senior Indebtedness and that Bank will not release those
     stock certificates without first giving Creditors the opportunity to take
     possession of those certificates to perfect their security interest in
     those stock certificates as security for the Subordinated Indebtedness.

THE UNDERSIGNED AND THE BANK ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A
CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED. EACH PARTY, AFTER CONSULTING (OR
HAVING HAD THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF THEIR CHOICE KNOWINGLY
AND VOLUNTARILY, AND FOR THEIR MUTUAL BENEFIT, WAIVES ANY RIGHT TO TRIAL BY JURY
IN THE EVENT OF LITIGATION REGARDING THE PERFORMANCE OR ENFORCEMENT OF, OR IN
ANY WAY RELATED TO, THIS AGREEMENT.

                                       7

<PAGE>   26
IN WITNESS WHEREOF, Creditors and Bank have caused this Agreement to be executed
as of April 23, 1999.

LENDERS:

WHITE PINES LIMITED PARTNERSHIP I

By:       White Pines G.P., L,L.C.,
          its general partner

By:
   -------------------------------------------
          Frederick L. Yocum, Chairman

PACIFIC CAPITAL, L.P.

By:       Pacific Capital Corporation,
          its general partner

By:
   --------------------------------------------
          Frederick L. Yocum, Vice chairman

IAN R. N. BUND SMITH BARNEY
          PROTOTYPE OS PLAN ACCOUNT
          #206-08291-12445

YOCUM CONSULTING ASSOCIATES, INC.

VOLUNTEER HEALTHCARE ASSOCIATES, L.L.C.

MCDONALD INVESTMENTS INC. CUSTODIAN
          FBO S. STERLING MCMILLAN III IRA
          ROLLOVER ACCOUNT #853162191

RONALD G. KALISH LIVING TRUST U/A/D
          SEPTEMBER 9, 1997

                                       8

<PAGE>   27
LOIS F. MARLER

MCDONALD INVESTMENTS INC. CUSTODIAN
         FBO DANIEL J. BOYLE IRA
         ROLLOVER ACCOUNT #85314893

NATIONAL CITY BANK OF MI/IL CUSTODIAN
          FBO HERBERT S. AMSTER IRA
          ROLLOVER ACCOUNT DATED JUNE 12, 1991
          #MI-1491-00-4

KANTNER AND ASSOCIATES PROFIT SHARING
          PLAN U/A/D JANUARY 1, 1991

MICHAEL G. Williams

By:      White Pines Management, L.L.C.,
         a Michigan limited liability company,
         attorney-in-fact

By:
   ----------------------------------------------
          Frederick L. Yocum, Chairman

CHASE VENTURE CAPITAL ASSOCIATES, L.P.

By: Chase Capital Partners, its General partner

By:
   ----------------------------------------------

AMERICAN HEALTHCARE FUND II

By:
    ---------------------------------------------

-------------------------------------------------
J. MATTHEW MACKOWSKI

-------------------------------------------------
ROBERT G. SHEPLER

-------------------------------------------------
JOHN J. MACKOWSKI

GROVE INVESTMENT PARTNERS

By:
   ----------------------------------------------

                                       9
<PAGE>   28

COMERICA BANK

By:                                              BANK'S ADDRESS:
   ----------------------------
Its:                                             500 Woodward Avenue
   ----------------------------                  Detroit, MI 48226

                            BORROWER'S ACKNOWLEDGMENT

The undersigned ("Borrowers") accept notice of subordination created by this
Agreement and agree that they will take no action inconsistent with this
Agreement. Borrowers agree that the Bank may, at its option, without notice and
without limiting Bank's other rights, upon any breach by Creditors holding at
least 10% of the aggregate outstanding principal amount of the Subordinated
Indebtedness ("Material Creditors") of, or purported termination by Material
Creditors of, this Agreement, declare all Senior Indebtedness to be immediately
due and payable and/or terminate any commitments of Bank to Borrowers.

GENOMIC SOLUTIONS, INC.

                                                        BORROWERS' ADDRESS

By:                                                     4355 Varsity Drive
   -----------------------------------                  Ann Arbor, MI 48108

Its:
    ----------------------------------
GENOMIC SOLUTIONS, LTD

By:
    ----------------------------------
Its:
    ----------------------------------
GENOMIC SOLUTIONS, K.K.

By:
    ----------------------------------
Its:
    ----------------------------------

                                       10

<PAGE>   29

                                    EXHIBIT E

                               BORROWER'S OPINION

<PAGE>   30

                    [JAFFE, RAITT, HEUER & WEISS LETTERHEAD]

                                 April 23, 1999

White Pines Limited Partnership I; Pacific Capital, L.P.;
Chase Venture Capital Associates, L.P.; American Health Care Fund II;
Ian R. N. Bund Smith Barney Prototype PS Plan Account #206-08291-12445;
Yocum Consulting Associates, Inc.; Volunteer Healthcare Associates, L.L.C.;
McDonald Investments Inc. Custodian f/b/o S. Sterling McMillan III IRA
Rollover Account #85362191; J. Matthew Mackowski; Robert G. Shepler;
John J. Mackowski; Grove Investment Partners; Ronald G. Kalish Living Trust
u/a/d September 9, 1997; Lois F. Marler; McDonald Investments Inc. Custodian
f/b/o Daniel J. Boyle IRA Rollover Account #85314893; National City Bank of
MI/IL
Custodian f/b/o Herbert S. Amster IRA Rollover Account Dated June 12, 1991
#MI-1491-00-4; Kantner and Associates Profit Sharing Plan u/a/d January 1, 1991;
and Michael G. Williams (collectively, the "Lenders")
c/o White Pines Management
2401 Plymouth Road, Suite B
Ann Arbor, Michigan 48105

     RE:  BUSINESS LOAN AGREEMENT, DATED APRIL 23, 1999 (THE "AGREEMENT") AMONG
          GENOMIC SOLUTIONS INC., A DELAWARE CORPORATION (THE "COMPANY"), ITS
          SUBSIDIARIES AND THE LENDERS

Gentlemen:

     We have acted as counsel to the Company in connection with the negotiation
and preparation of the Agreement and related documents and the consummation of
the transactions contemplated in the Agreement. We are delivering this opinion
to you at the request of the Company, pursuant to Section 6(e) of the Agreement.
Any capitalized terms used, but not defined, in this opinion have the same
meanings as in the Agreement.

     In rendering this opinion, we have examined and relied on the following
documents, all of which are dated the date hereof unless otherwise specified,
and nothing else:

<PAGE>   31

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 2

     A. The Agreement, including its Exhibits and Schedules;

     B. Promissory notes of the Company and its subsidiaries to each of the
Lenders, respectively (collectively, the "Notes");

     C. Warrants (noncancellable) to purchase shares of common stock of the
Company, issued to each of the Lenders, respectively, in the amounts set forth
in the Agreement (collectively, the "Noncancellable Warrants");

     D. Warrants (cancellable at $5.00 Liquidity Event) to purchase shares of
common stock of the Company, issued to each of the Lenders, respectively, in the
amounts set forth in the Agreement (collectively, the "Cancellable-at-$5.00
Warrants");

     E. Warrants (cancellable above $5.00 Liquidity Event) to purchase shares of
common stock of the Company, issued to each of the Lenders, respectively, in the
amounts set forth in the Agreement (collectively, the "Cancellable-above-$5.00
Warrants" and together with the Noncancellable Warrants and the
Cancellable-at-$5.00 Warrants, the "Warrants");

     F. Registration Rights Agreement between the Company and the Lenders (the
"Registration Rights Agreement");

     G. Security Agreement executed by the Company in favor of the Lenders (the
"Security Agreement").

     H. Assignment and Pledge Agreement between the Company and the Lenders;

     I. Subordination Agreement among Comerica Bank, the Company and each of the
Lenders (the "Subordination Agreement");

     J. Second Amendment to Shareholder Agreement of the Company (the
"Amendment"), executed by the Company, the Lenders and certain holders of Series
B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock of the
Company (collectively, "Preferred Stockholders") between April 16, 1999 and the
date hereof;

     K. Copies of Uniform Commercial Code financing statements on Michigan and
Massachusetts forms UCC-1 and on Michigan form UCC-lA, naming and executed by
the Company as debtor (collectively, the "Financing Statements"), to be filed in
the office of the Secretary of State of Michigan, the Secretary of State of
Massachusetts and the Washtenaw County, Michigan Register of Deeds,
respectively;

<PAGE>   32

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23,1999
Page 3

     L. Consent and Waiver of Shareholder forms, and Amended Consent and Waiver
of Shareholder forms, executed by certain Preferred Stockholders between April
16, 1999 and the date hereof;

     M. Certificate of Incorporation for the Company, as amended, as certified
by the Delaware Secretary of State on April 9, 1999;

     N. Certificate of Good Standing for the Company, as certified by the
Delaware Secretary of State on April 9, 1999;

     O. Certificate of Authority of the Company to transact business in
Michigan, as certified by the Michigan Department of Consumer and Industry
Services on April 12, 1999;

     P. A copy of the Bylaws of the Company, certified by the Secretary of the
Company on April 23, 1999;

     Q. A copy of the resolutions of the Board of Directors of the Company,
authorizing the execution and delivery of, and consummation of the transactions
contemplated in, the Agreement, certified by the Secretary of the Company on
April 23, 1999;

     R. Series B Preferred Stock Purchase Agreement between the B.I. Systems
Corporation (a predecessor to the Company by merger) ("B.I. Systems") and
certain purchasers of Series B Preferred Stock of the B.I. Systems Corporation,
dated May 1997;

     S. Series C Preferred Stock Purchase Agreement between the Company and
certain purchasers of Series C Preferred Stock of the Company, dated December
29, 1997

     T. Series D Preferred Stock Purchase Agreement between the Company and
certain purchasers of Series D Preferred Stock of the Company, dated May 27,
1998;

     U. Series M Preferred Stock Purchase Agreement between B.I. Systems and
Millipore Corporation, dated as of May 7, 1997 (the "Series M Agreement");

     V. Purchase Agreement among the Company, PBA Technology Limited ("PBA") and
certain shareholders of PBA, dated December 24, 1997;

     W. Current loan documentation between the Company and Comerica Bank;

     X. Minute Book of the Company, including stockholder records, from December
1997 to the present;

<PAGE>   33
JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 4

     Y. Shareholder Agreement of the Company, dated December 24, 1997, among
the Company and certain of its shareholders, as amended as of May 27, 1998 and
as of the date hereof (the "Shareholder Agreement"); and

     Z. A Certificate of Facts (the "Certificate of Facts"), dated as of the
same date as this opinion, executed by Jeffrey S. Williams, individually and as
an officer, director and shareholder of the Company, a copy of which is
attached.

     For the purposes of this opinion, the documents identified in paragraphs A
through K above, inclusive, are collectively referred to as the "Transaction
Documents," and the documents identified in paragraphs A through Z are
collectively referred to as the "Documents."

     In rendering this opinion, we have assumed, without independent
investigation: (i) the genuineness of all signatures of the persons signing the
Documents other than those officers of the Company signing on behalf of the
Company; (ii) the authority of the persons signing the Documents other than
those officers signing on behalf of the Company; (iii) the authenticity of all
documents submitted to us as originals; (iv) the conformity to authentic
original documents of all documents submitted to us as certified, conformed or
photostatic copies; (v) the accuracy and completeness of factual matters,
representations, warranties and recitals set forth in the Documents, (vi) the
parties to the Transaction Documents (other than the Company) have all necessary
power and authority to execute, deliver, accept and perform their respective
obligations under such Transaction Documents; (vii) all necessary action has
been taken by all parties to the Transaction Documents (other than the Company)
so as to cause each of them to be bound by the Transaction Documents to which
they are parties under the laws of their respective jurisdictions of residence;
(viii) each of the Lenders is an "Accredited Investor" as such term is defined
under the Securities Act of 1933 and the regulations promulgated thereunder; and
(ix) none of the collateral under the Security Agreement or the Financing
Statements consists of "instruments" or "chattel paper" as such terms are
defined in UCC Section 9-105, and none of such collateral consists of equipment
used in farming operations, farm products, accounts or general intangibles
arising from or relating to the sale of farm products, consumer goods, crops,
timber to be cut, minerals and the like (including oil and gas), or accounts
resulting from the sale thereof (as defined in UCC Section 9-103). All
references to "UCC" herein are references to the Uniform Commercial Code as
presently in effect in the State of Michigan, MCLA ss.440.1101 et seq.

     Our review has been limited to examining the Documents, applicable Michigan
and, where applicable, United States law and the General Corporation Law of the
State of Delaware, as amended. This opinion is qualified accordingly.

     To the extent that any opinion given in this letter is dependent on factual
information or is expressed in terms of our knowledge, we have relied
exclusively on the assumptions stated above, the Documents and the relevant
factual representations set forth in the Certificate of Facts.

<PAGE>   34

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 5

We have not undertaken to independently verify any such factual information,
assumptions or factual representations. In this opinion, "knowledge" means the
conscious awareness of facts or other information by (i) the attorney executing
this opinion on behalf of our firm; (ii) any attorney who has been actively
involved in (a) negotiating the terms and conditions of the Agreement, (b)
drafting the Documents, or (c) preparing this opinion; and (iii) the attorney
who is primarily responsible for providing the response for a particular issue
or confirmation addressed in this opinion.

     Based on the foregoing, and subject to the qualifications and limitations
set forth below, we are of the opinion that:

     1.   The Company is a corporation organized, validly existing and in good
          standing under the laws of the State of Delaware, and is qualified to
          do business as a foreign corporation in the State of Michigan. The
          Company has all required corporate power and authority to own its
          property, which to our knowledge it owns, and to carry on its
          business, which to our knowledge it carries on, and to execute and
          deliver the Transaction Documents and to perform all of the
          transactions contemplated thereunder.

     2.   The Company's execution and delivery of the Transaction Documents and
          the Company's performance of its obligations thereunder, have been
          duly authorized by all requisite corporate action.

     3.   The Company has duly executed and delivered the Transaction Documents,
          and the Transaction Documents constitute valid and binding obligations
          of the Company, enforceable against the Company in accordance with
          their respective terms. No consent, approval or authorization of, or
          designation, declaration or filing with, any governmental authority or
          any other person or entity is required of the Company, that has not
          already been obtained, in connection with the execution and delivery
          of the Transaction Documents or, except for compliance with applicable
          securities laws which are addressed in paragraph 8 below, the issuance
          and delivery of the Warrants in accordance with the terms of the
          Agreement or the consummation of any other transaction contemplated by
          the Agreement.

     4.   The Company's execution and delivery of the Transaction Documents, and
          the Company's performance and fulfillment of its obligations
          thereunder and compliance with the respective terms and provisions
          thereof, and the consummation of the transactions contemplated
          therein, does not and will not (a) violate any law, statute, rule or
          regulation to which the Company or its assets, properties or business
          is subject; (b) violate, result in the breach or violation of,
          constitute a default under, result in the creation of any lien,
          mortgage, security

<PAGE>   35

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 6

          interest, charge or other encumbrance on any assets or properties
          pursuant to, or give any third party the right to accelerate any
          obligation under, any mortgage, indenture, contract, agreement, lease,
          instrument, restriction, judgment, ruling, writ, injunction, decree or
          other obligation or court order which is known to us and to which the
          Company is a party or, to our knowledge, by which the Company or any
          of its assets, properties or business is bound or subject; or (c)
          violate, result in the breach or violation of or constitute a default
          under the terms, conditions or provisions of its Certificate of
          Incorporation or its Bylaws.

     5.   Immediately after the Closing as contemplated in the Agreement, the
          authorized capital stock of the Company shall consist of 40,000,000
          shares of common stock, par value $0.001 (the "Common Stock"), and
          10,000,000 shares of preferred stock, par value $0.001 (the "Preferred
          Stock"), of which 1,680,880 shares shall be designated as Series B
          Preferred Stock, 4,070,339 shares shall be designated as Series C
          Preferred Stock, 1,100,000 shares shall be designated as Series D
          Preferred Stock and 50,000 shares shall be designated as Series M
          Preferred Stock. Immediately after the Closing, to our knowledge,
          1,680,880 shares of Series B Preferred Stock, 4,070,339 shares of
          Series C Preferred Stock, 1,100,000 shares of Series D Preferred Stock
          and 50,000 shares of Series M Preferred Stock will be validly issued
          and outstanding and free of any preemptive rights which have not been
          waived. When issued against payment therefor in accordance with the
          terms of the Agreement and the Warrants, the common stock issuable
          upon exercise of the Warrants will be validly issued and outstanding
          and free of any preemptive rights existing as a matter of law or, to
          our knowledge, under the Certificate of Incorporation or Bylaws of the
          Company or any contractual agreement, which have not been waived.

     6.   The Company has reserved 1,100,000 shares of Common Stock for issuance
          upon conversion of the Series D Preferred Stock, 4,070,339 shares of
          Common Stock for issuance upon conversion of the Series C Preferred
          Stock, 5,093,576 shares of Common Stock for issuance upon conversion
          of the Series B Preferred Stock and 270,027 shares of Common Stock for
          issuance upon conversion of the Series M Preferred Stock. As of the
          date hereof, to our knowledge, options to acquire an aggregate of
          2,162,020 shares of Common Stock are outstanding. Except as aforesaid
          and as contemplated by the Agreement, to our knowledge: (i) no
          subscription, warrant, option, convertible security or other right
          (contingent or otherwise) to purchase or acquire from the Company any
          shares of capital stock of the Company is authorized or outstanding;
          (ii) there is not any commitment or offer of the Company to issue any
          subscription, warrant, option, convertible security or other such
          right or to issue or distribute to holders of any shares of its
          capital stock any evidences of indebtedness or assets of the Company;
          (iii) the Company has no obligation (contingent or otherwise) to
          purchase, redeem or

<PAGE>   36

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 7

          otherwise acquire any shares of its capital stock or any interest
          therein or to pay any dividend or make any other distribution in
          respect thereof; and (iv) there are no restrictions on the transfer of
          the Company's capital stock other than those arising from securities
          laws or the Documents or contemplated by the Agreement. To our
          knowledge, except as contemplated by the Agreement, Shareholder
          Agreement and the Series M Agreement, no person or entity is entitled
          to any preemptive or similar right with respect to the issuance of
          any capital stock of the Company. To our knowledge, except for the
          Shareholder Agreement and the Series M Agreement, there are no voting
          trusts, voting agreements, proxies or other agreements, instruments or
          understandings with respect to the voting of the capital stock of the
          Company and there are no agreements or understandings granting to any
          person or entity any rights with respect to the registration of any
          capital stock of the Company under the Securities Act of 1933, as
          amended (the "Securities Act").

     7.   We have no knowledge of any action, suit, proceeding or investigation
          before any court, public board or body pending to which the Company is
          the subject, and to our knowledge, no such proceedings are threatened
          by others in writing.

     8.   Based on a claim of exemption under Section 4(2) of the Securities
          Act, it is not necessary in connection with the offer, sale and
          delivery of the Warrants pursuant to the terms of the Agreement to
          register such Warrants under the Securities Act or under applicable
          state securities laws regulating the issuance or sale of securities.

     9.   The Company has granted to Lenders a valid security interest in all
          those assets of the Company in which a security interest may be
          granted by the execution of a security agreement under the UCC. All
          required filings necessary to perfect such security interest with
          respect to all collateral located in the State of Michigan and with
          respect to all receivables, contracts, contract rights and general
          intangibles to the extent the Company's chief executive office is
          located in the State of Michigan, but only to the extent such
          collateral consists of the type of property in which a security
          interest may be perfected by filing a financing statement in the State
          of Michigan under the UCC, have been made. In order to continue the
          effectiveness of the Financing Statements, continuation statements
          must be filed within the six-month period preceding the fifth
          anniversary of the date of the filing of such Financing Statements.
          The continuation statements extend the effectiveness of the original
          statements for an additional five years (running from the last date
          such filings would have been effective), and succeeding continuation
          statements must be filed in the same manner to further extend the
          effectiveness of the Financing Statements.

<PAGE>   37

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 8

     10.  The Warrants have been validly issued and are not subject to any
          preemptive rights or rights of first refusal existing as a matter of
          law or, to our knowledge, under the Certificate of Incorporation or
          Bylaws of the Company or any contractual agreement, which have not
          been effectively waived. The common stock of the Company issuable upon
          exercise of the Warrants (a) has been duly and validly reserved, and
          neither it nor its issuance will be subject to any preemptive rights
          or rights of first refusal existing as of the date hereof as a matter
          of law or, to our knowledge, existing as of the date hereof under the
          Certificate of Incorporation or Bylaws of the Company or any
          contractual agreement, which have not been effectively waived, and (b)
          upon issuance and payment therefor as provided in the Warrants, will
          be validly issued, fully paid and nonassessable.

     11.  The provisions of Article V(D)(4) of the Company's Certificate of
          Incorporation will not preclude or limit in any manner the exercise by
          the Lenders of their rights under Section 12(c) of the Agreement or
          subsection K of the Warrants.

     We express no opinion as to any of the following matters, and the foregoing
opinions are qualified accordingly:

     (a)  The effect on the Documents of: (i) bankruptcy, insolvency,
          reorganization, moratorium, fraudulent conveyance or similar laws
          relating to or affecting the enforcement of creditors' rights
          generally; or (ii) general principles of equity, whether at law or in
          equity;

     (b)  The interrelation with, or effect on the validity, enforceability or
          binding effect on the Documents or on anything in this opinion of any
          documents which we have not reviewed; although we have no reason to
          believe that there are any such documents which would effect the
          validity, enforceability or binding effect of the Documents;

     (c)  The validity, binding effect or enforceability of provisions of the
          Documents: (i) appointing any person as another person's
          attorney-in-fact; (ii) waiving rights or defenses to obligations where
          such waivers are against the statutes, laws or public policy of the
          State of Michigan, the State of Delaware or the United States of
          America; (iii) waiving any right of redemption, exemption, trial by
          jury, objection to personal jurisdiction or venue or other similar
          right; or (iv) providing that the rights and remedies of the parties
          to such Documents are not exclusive, that every right or remedy is
          cumulative and may be exercised in addition to or with any other right
          or remedy, or that the election of some remedy or remedies does not
          preclude recourse to one or more other remedies;

<PAGE>   38

JAFFE, RAITT, HEUER & WEISS

White Pines Management
April 23, 1999
Page 9

     (d)  Any subsidiary of the Company with its principal offices outside of
          the United States of America, including Genomic Solutions, K.K. and
          Genomic Solutions, Ltd., and all of our opinions are expressly
          limited to the Company and its assets, as distinguished from such
          subsidiaries and their respective assets;

     (e)  Any rights, powers or preferences of the holders of Series M Preferred
          Stock of the Company, including without limitation those rights,
          powers or preferences provided in the Series M Agreement; and

     (f)  Except as expressly provided in our opinion in paragraph eight, the
          compliance of the transactions contemplated herein with, or other
          effect of, the Securities Act or the securities laws of any
          jurisdiction.

     We are qualified to practice law in the State of Michigan only and do not
purport to be experts on or to express any opinion concerning any laws other
than the laws of the State of Michigan, the General Corporation Law of the State
of Delaware, as amended, and the laws of the United States of America. This
opinion is qualified accordingly.

     This opinion is for the sole benefit of the Lenders and may not be relied
on by any other party without our prior written consent. This opinion is given
on and as of the date hereof only, and it does not contemplate, and no opinion
is given or intended with respect to future events or subsequent changes in law
or fact, and the undersigned has no obligation to update this opinion with
respect thereto.

                                Very truly yours,

                          JAFFE, RAITT, HEUER & WEISS,
                            Professional Corporation

                                     Peter Sugar

<PAGE>   39

                              CERTIFICATE OF FACTS

                                 April 23, 1999

Jaffe, Raitt, Heuer & Weiss,
  Professional  Corporation
One Woodward Avenue, Suite 2400
Detroit, Michigan 48226

Gentlemen:

     The undersigned is executing this Certificate of Facts individually and as
an officer and director of Genomic Solutions Inc., a Delaware corporation
("Genomic"). I am aware that you will be relying on this Certificate as a basis
for formulating your opinion letter to various lenders (the "Lenders") with
respect to, among other things, Genomic's secured, subordinated loan of $6.0
million from, and the issuance of warrants to, the Lenders in accordance with
that Business Loan Agreement (the "Agreement") among Genomic, its subsidiaries
and the Lenders, dated as of the date hereof (the "Financing").

     I have been personally involved in the Financing and the statements herein
are made based on my personal actual knowledge. In furtherance thereof, I have
taken the utmost care and diligence to ascertain that each and every statement
herein is complete, true and accurate and I have undertaken to verify each and
every statement in order to determine not only the veracity of the statements
made, but also that all pertinent material, data and information have been
disclosed.

     Based upon the foregoing, I certify as follows to Jaffe, Raitt, Heuer &
Weiss, Professional Corporation ("JRHW").

     1.   I have delivered to JRHW true and complete copies of the Amended and
          Restated Certificate of Incorporation, Certificate of Good Standing,
          By-Laws, minute book and stockholder records of Genomic, as amended
          through the date hereof, all of which are in full force and effect.

     2.   I have delivered to JRHW a true and complete copies of the following:
          (a) the Agreement, including its Exhibits and Schedules; (b) the
          promissory notes of Genomic and its subsidiaries to each of the
          Lenders, respectively; (c) the Warrants issued to the Lenders
          (cancellable and noncancellable, as provided in the Agreement)
          (collectively, the "Warrants"); (d) the Registration Rights Agreement
          between Genomic and the Lenders; (e) the Security Agreement executed
          by Genomic in favor of the Lenders; (f) the Subordination Agreement
          among Comerica Bank, Genomic and each of the Lenders; (g) the Second
          Amendment to Shareholder Agreement of Genomic, executed by Genomic,
          the Lenders and certain holders of Series B, Series C and Series D
          Preferred Stock of Genomic; (h) UCC Financing Statements, to be filed
          with the Michigan Secretary of State, Secretary of State of
          Massachusetts and Washtenaw County Register of Deeds; and (i) Consent
          and Waiver of Shareholder forms, and Amended Consent and Waiver of
          Shareholder forms, executed by certain Preferred Stockholders of
          Genomic.

     3.   I have delivered to JRHW a true and complete copy of the resolution of
          the Board of Directors of Genomic, authorizing the execution and
          delivery of, and consummation of the transactions contemplated in, the
          Agreement.

     4.   I have delivered, or provided access, to JRHW of all other corporate
          documents, agreements and instruments to which Genomic is a party or
          by which it may be bound, which are pertinent or relate to the
          transactions contemplated in the Agreement.

<PAGE>   40

JAFFE, RAITT, HEUER & WEISS
MAY 27, 1998
Page 2

          bound, which are pertinent or relate to the transactions contemplated
          in the Agreement.

     5.   All of the directors of Genomic are aware that Genomic has entered
          into the Agreement and that Genomic is issuing the Warrants and
          granting the registration rights under the Registration Rights
          Agreement, and such directors have approved these transactions, as
          reflected in the resolutions referred to in Paragraph 3 above.

     6.   There are no litigation, suits, judgments, investigations or other
          proceedings before any court or administrative agency, pending or
          threatened, against Genomic.

     7.   No consent, approval, action, order or authorization of, or
          designation, registration, declaration, qualification or filing with,
          any governmental or regulatory authority is necessary or required,
          that has not already been obtained, as a prerequisite for Genomic to
          enter into the Agreement or to issue the Warrants or the common stock
          issuable upon the exercise thereof, or for Genomic to execute and
          deliver the other documents evidencing the transactions contemplated
          thereby.

     8.   I know of no reason why the documents executed by Genomic in
          connection with the above transactions would not constitute the valid
          and binding obligations of or be unenforceable against Genomic.

     9.   Neither entering into the Agreement, nor the execution and delivery of
          the documents executed in connection therewith, nor the issuance by
          Genomic of the Warrants or the common stock issuable upon the exercise
          thereof, will contravene, violate or cause a default under any
          agreement, mortgage, indenture, or lease or any license, permit,
          judgment, decree, order, statute, ordinance, rule or governmental
          regulation to which Genomic is a party or bound.

     10.  Documents and other information which I or other representatives of
          Genomic have given or made available to you during your review of
          Genomic and its affairs in connection with the negotiation and
          consummation of the Agreement (the "Documents") are complete and
          accurate in all material respects. Any copies of Documents which I or
          other representatives of Genomic have given to you are accurate
          reproductions of the originals.

     11.  I have reviewed the representations and warranties made in the
          Agreement and its exhibits and schedules, and I am not aware of any
          facts or circumstances that would render any of the representations or
          warranties in the Agreement and its exhibits and schedules untrue.

     You may make copies of this signed Certificate of Facts, and you may rely
on such copies, as well as facsimile copies of this Certificate of Facts, to the
same extent as the original.

                                 Very truly yours,

                                 _______________________________________________
                                 JEFFREY S. WILLIAMS, individually and as an
                                 officer and director of Genomic Solutions Inc.,
                                 a Delaware corporation

<PAGE>   41
                                   EXHIBIT F

                         REGISTRATION RIGHTS AGREEMENT

                              Filed as Exhibit 4.7
<PAGE>   42

                                   EXHIBIT G

                      AMENDMENT TO SHAREHOLDERS AGREEMENT

<PAGE>   43
                   SECOND AMENDMENT TO SHAREHOLDERS AGREEMENT

     THIS SECOND AMENDMENT TO SHAREHOLDERS AGREEMENT (the "Amendment") is made
and entered into by and between GENOMIC SOLUTIONS INC., a Delaware corporation
(the "Company"), and the undersigned persons (collectively, the "Shareholders")
as of April _, 1999. Capitalized terms not otherwise defined in this Amendment
shall have the meanings set forth in the Shareholders Agreement dated as of
December 24, 1997, as amended by the Amendment to Shareholders Agreement dated
May 27, 1998 (the "Agreement").

                                   RECITALS:

     A.   The Company and certain of its shareholders entered into the Agreement
which provides for certain rights, privileges and restrictions applicable to the
Company's Series B Preferred Stock, Series C Preferred Stock, Series D Preferred
Stock and Common Stock held by shareholders who executed and delivered the
Agreement.

     B.   The Company has authorized an additional borrowing of $6,000,000 from
certain lenders (the "Lenders") in exchange for the issuance by the Company to
the Lenders of subordinated promissory notes in the aggregate amount of
$6,000,000 providing for, among other things, quarterly interest payments at
12% per annum and a five-year maturity, together with warrants to acquire up to
1,400,000 shares of Common Stock with certain registration rights (the
"Warrants").

     C.   The Company and the Shareholders desire to amend the Agreement to
provide for and accommodate certain rights, privileges and certain restrictions
with respect to the Warrants.

     D.   Section 6.1 of the Agreement permits amendment with the approval of
not less than 66 2/3% of the shares of Series B Preferred Stock, Series C
Preferred Stock and Series D Preferred Stock, together with any shares issued
upon conversion of each respective class, each voting as a separate class on a
fully converted basis.

     E.   The holders of the Warrants are referred to individually as a
"Warrantholder" and collectively, as the "Warrantholders".

     NOW, THEREFORE, for and in consideration of the foregoing Recitals and
other good and valuable consideration, the receipt and adequacy of which is
acknowledged, the Company and the Shareholders agree as follows:

     SECTION 1.1 IS HEREBY DELETED IN ITS ENTIRETY AND REPLACED WITH THE
FOLLOWING SECTION 1.1:

<PAGE>   44
     1.1  Right of First Offer.

          (a) Subject to the terms and conditions specified in this Section 1.1,
     the Company hereby grants to each Preferred Shareholder and to each
     Warrantholder a right to participate in future sales by the Company of its
     Shares (as hereinafter defined). For purposes of this Section 1.1 and
     Section 1.4, Preferred Shareholder or Warrantholder includes any partners
     or retired partners, and designated affiliated purchasers ("Designees"),
     including spouses and ancestors, lineal descendants and siblings of such
     partners or spouses who acquire Series B Preferred Stock, Series C
     Preferred Stock, Series D Preferred Stock or Warrants (collectively, the
     "Senior Securities") or Common Stock issued upon conversion thereof, by
     gift, will or intestate succession, of a Preferred Shareholder or a
     Warrantholder. A Preferred Shareholder or Warrantholder shall be entitled
     to apportion the right of first offer hereby granted to it among itself and
     its partners and Designees in such proportions as it deems appropriate.

          (b) Each time the Company proposes to offer any shares of, or
     securities convertible into or exercisable for any shares of, any class of
     its capital stock ("Shares"), the Company shall first make an offering of a
     portion of such Shares (as determined in subsection (2) below) to each
     Preferred Shareholder and each Warrantholder in accordance with the
     following provisions:

              (1) The Company shall deliver a written notice ("Notice") to the
          Preferred Shareholders and Warrantholders stating (i) its bona fide
          intention to offer such Shares, (ii) the number of such Shares to be
          offered, and (iii) the price and terms, if any, upon which it proposes
          to offer such Shares.

               (2) Within 20 calendar days after the Notice is sent, any
          Preferred Shareholder and any Warrantholder may elect to purchase or
          obtain, at the price and on the terms specified in the Notice, up to
          that portion of such Shares which equals the proportion (such
          Preferred Shareholder's or Warrantholder's "Proportion") that the
          number of shares of Common Stock held by such Preferred Shareholder or
          Warrantholder (treating preferred stock and Warrants as if fully
          converted to Common Stock) bears to the total number of shares of
          Common Stock of the Company then outstanding (assuming for such
          calculation any shares issuable upon conversion of any capital stock
          convertible into Common Stock).

               (3) The Company may during the 10-day period following the
          expiration of the 20-day period provided in subsection (2) hereof,
          offer the remaining unsubscribed portion of such Shares which the
          Preferred Shareholders and Warrantholders have not elected to purchase
          to any person or persons at a price not less than, and upon terms no
          more favorable to the offeree than those specified in the Notice. If
          the Company does not enter into an agreement for the sale of the
          Shares within 90 days of the expiration of such 10-day period, or if
          such agreement is not consummated within 120 days following the
          expiration of such 10-day period, the right provided hereunder shall
          be deemed to be revived and

                                       2
<PAGE>   45
          such Shares shall not be offered unless first reoffered to the
          Preferred Shareholders and the Warrantholders in accordance herewith.

               (4) The right of first offer in this Section 1.1 shall not be
          applicable (i) to the issuance or sale of shares of Common Stock (as
          adjusted to reflect any stock splits, combinations or other events
          involving the Common Stock) to employees, consultants or members of
          the Board of Directors pursuant to employee or director stock plans
          which are approved in writing by the Company's Board of Directors,
          (ii) to the Public Offering (as defined in Section 2.15 hereof) or to
          any offering of Shares after consummation of the Public Offering,
          (iii) to the issuance of securities pursuant to the conversion or
          exercise of convertible or exercisable securities of the Company, (iv)
          to any Common Stock issued upon conversion of the Series B Preferred
          Stock, the Series C Preferred Stock, the Series D Preferred Stock, any
          other series of Preferred Stock issued pursuant to the Certificate of
          Incorporation or the Warrants, (v) to securities issued in connection
          with any acquisition or business combination transaction approved by
          the Board of Directors of the Company, or (vi) to securities issued in
          connection with equipment lease financings or other financings with
          commercial lenders or in strategic transactions involving the Company
          and other entities including joint ventures or marketing, distribution
          or development arrangements, in each case provided that any issuance
          pursuant to subsection (vi) has been approved by the Board of
          Directors of the Company.

     SECTION 1.3 IS HEREBY DELETED IN ITS ENTIRETY AND REPLACED WITH THE
FOLLOWING SECTION 1.3:

     1.3  Right of First Refusal.

          (a) If any Series B Holder, Series C Holder, Series D Holder or
     Warrantholder wishes to transfer any shares of Series B Preferred Stock,
     Series C Preferred Stock, Series D Preferred Stock or Common Stock issued
     upon conversion of such preferred stock or Warrants, and if Williams
     wishes to transfer any shares of Common Stock issued to him at any time, in
     any case except in a Permitted Transfer (each such person, a "Selling
     Shareholder"), the Selling Shareholder shall do so only for cash, unsecured
     promissory notes, cash equivalents, or a combination of the foregoing, and
     shall first give written notice (the "Offer Notice") to the Company,
     identifying the securities proposed to be transferred (the "Offered
     Securities"), identifying the proposed transferee, and stating the price at
     which, and other material terms on which, the Selling Shareholder wishes to
     transfer the Offered Securities, including the date of the proposed
     transfer. This Section 1.3 shall not apply in the case of a Public
     Offering, as defined in Section 2.15.

          (b) Delivery of an Offer Notice by any Series B Holder, Series C
     Holder, Series D Holder, Warrantholder or Williams to the Company shall
     constitute an offer to transfer the Offered Securities, in whole but not in
     part (the "Offer"), first to the Company, and then to the Preferred
     Shareholders and Warrantholders, pursuant to this Section 1.3, at the price
     and on the other material terms described in the Offer Notice.

                                       3
<PAGE>   46
          (c) Within seven calendar days after it receives an Offer Notice from
     a Series B Holder, Series C Holder, Series D Holder, Warrantholder or
     Williams, the Company will deliver a copy of the Offer Notice to each
     Preferred Shareholder and each Warrantholder.

          (d) The Company may elect, by written notice delivered to the Selling
     Stockholder not later than fourteen calendar days after the Company
     receives the Offer Notice from any Selling Stockholder, to accept the Offer
     with respect to all of the Offered Securities.

          (e) If the Company does not elect to accept an Offer, then within
     seven calendar days after the expiration of the period specified in Section
     1.3(d), the Company will notify each Preferred Shareholder and each
     Warrantholder of the Preferred Shareholder's and Warrantholder's rights
     under Section 1.4(f).

          (f) If the Company does not elect to accept an Offer made by the
     Series B Holders, Series C Holders, Series D Holders, Warrantholders or
     Williams within the period specified in Section 1.3(d), then each of the
     Preferred Shareholders and each of the Warrantholders may elect to accept
     the Offer with respect to all or any portion of the Offered Securities, but
     at least the Preferred Shareholder's or Warrantholder's Proportion of the
     Offered Securities, by written notice delivered to the Company not later
     than twenty-one calendar days after the Preferred Shareholder or the
     Warrantholder received the Offer Notice.

          (g) If pursuant to Section 1.3(f) Preferred Shareholders and
     Warrantholders who accept the Offer made by the Series B Holder, Series C
     Holder, Series D Holder, Warrantholder or Williams ("Participants") elect,
     in the aggregate, to accept all of an Offer, then the Participants shall
     participate in the purchase of the Offered Securities in the following
     proportions:

               (i)  first, each Participant shall purchase the Participant's
          Proportion of the Offered Securities; and

               (ii) then, if there are any Offered Securities remaining
          unpurchased, those Participants who elected to purchase more than
          their Proportion shall purchase the remaining Offered Securities in
          the relative proportions of the amounts by which each of them elected
          to purchase more than his, her or its Proportion, or in such other
          proportions on which the Participants shall agree.

          (h) If the Company or Participants elect to accept an Offer made by a
     Series B Holder, Series C Holder, Series D Holder, Warrantholder or
     Williams in its entirety, then the Selling Shareholder shall transfer the
     Offered Securities to the Company or the Participants, as the case may be,
     and the Company or the Participants, as the case may be, shall acquire the
     Offered Securities, at the price and on the other material terms described
     in the Offer Notice. The consummation of the transfer shall take place at
     the chief

                                        4
<PAGE>   47
     executive offices of the Company, on the date specified for the proposed
     transfer in the offer Notice (but not earlier than sixty-three calendar
     days after the Company shall have received the Offer Notice), or at such
     other location or date on which the participants in the transaction agree
     in writing.

          (i)  If neither the Company nor Participants accept an Offer made by a
     Series B Holder, Series C Holder, Series D Holder, Warrantholder or
     Williams in its entirety, then the Selling Stockholder may transfer the
     Offered Securities in accordance with Section 1.3(j) (subject to any other
     agreements binding on the Selling Shareholder) to the transferee named in
     the Offer Notice, at any time within the period of 120 calendar days
     beginning on the date the Company received the Offer Notice. The provisions
     of this Section 1.3 shall again apply to any transfer of Offered Securities
     not transferred within such period.

          (j)  A Selling Stockholder may not transfer the Offered Securities
     pursuant to Section 1.3(i), unless and until such transferee shall have
     executed this Agreement in counterpart or delivered a written
     acknowledgment to the Company that the securities to be received in the
     proposed transfer are subject to this Agreement, thereby agreeing to be
     bound hereby in all respects.

          (k)  A "Permitted Transfer" is a transfer of securities to a Permitted
     Transferee if, prior to the consummation of the transfer, the Permitted
     Transferee shall have agreed in writing to be bound as a party to this
     Agreement by all the terms of this Agreement applicable to the Selling
     Stockholder. A "Permitted Transferee" means any of:

               (i)   the spouse or a lineal ancestor or descendant (whether
          natural or adopted) of the transferor;

               (ii)  a trust all the beneficiaries (primary and contingent) of
          which are either the transferor or the spouse or a lineal ancestor or
          descendant (natural or adopted) of the transferor; or

               (iii) a partner in a transferor which is a partnership, or a
          stockholder of a transferor which is corporation or a member of a
          transferor which is a limited liability company, which person
          receives the transfer as part of a distribution among partners,
          stockholders or members, as the case may be, of the transferor.

     SECTION 1.4 IS HEREBY DELETED IN ITS ENTIRETY AND REPLACED WITH THE
FOLLOWING SECTION 1.4:

     Section 1.4    Tag-Along Rights. If a third-party ("Intended Transferee")
presents a bona fide written offer (the "Offer") to purchase fifty percent (50%)
or more of the Company's Subject Common Stock, as defined below, from any holder
or holders of the Company's common stock (the shares to be purchased are
referred to herein as the "Subject Shares"), and if the holder of the Subject
Shares (the "Intended Transferor") desires to accept the Offer and complies with
Section 1.3, it shall provide written notice of the Offer to the Company, which
immediately upon receipt

                                       5
<PAGE>   48

will send a written notice describing the Offer to the Preferred Shareholders
and the Warrantholders. The Preferred Shareholders and the Warrantholders shall
be entitled to participate in the transaction with the Intended Transferor, in
the same capacity as the Intended Transferor, such that each of the Preferred
Shareholders and each of the Warrantholders shall be entitled to transfer, on
the terms and conditions and in the manner set forth in the Offer, that
percentage of his or her Common Stock, including for these purposes, all Common
Stock that would be issued upon conversion, equal to the percentage of the
Subject Common Stock that the Subject Shares represent. "Subject Common Stock"
means all Common Stock including all stock that has been or may be converted
into Common Stock. To exercise his or her rights under this Section, a
Preferred Shareholder or Warrantholder shall so notify the Intended Transferor,
the Intended Transferee and the Board of Directors of the Company on or before
the twentieth (20th) business day after the Offer is received by the Preferred
Shareholders and the Warrantholders.

     SECTION 2.2 IS HEREBY DELETED IN ITS ENTIRETY AND REPLACED WITH THE
FOLLOWING SECTION 2.2:

     2.2  Company Registration.

          (a)  Subject to Section 2.2(b) below, if (but without any obligation
     to do so) the Company proposes to register any of its stock or other
     securities under the Act in connection with the public offering of such
     securities solely for cash (other than a registration relating solely to
     the sale of securities to participants in a Company stock plan, or a
     registration on any form which does not include substantially the same
     information as would be required to be included in a registration
     statement covering the sale of the Registrable Securities or a SEC Rule 145
     transaction), the Company shall, at such time, promptly give each Holder
     written notice of such registration. Upon the written request of each
     Holder given within fifteen (15) days after mailing of such notice by the
     Company in accordance with Section 6.6, the Company shall, subject to the
     provisions of Sections 2.4, 2.5, 2.6 and 2.7, cause to be registered under
     the Act all of the Registrable Securities that each such Holder has
     requested to be registered. Notwithstanding the foregoing, after the
     Company's initial public offering, the Company will not be required to give
     notice to the Holders of Registrable Securities if the underwriters
     managing the proposed offering have advised the Company in writing that in
     their judgment market conditions will not allow the inclusion of any
     secondary shares in such offering. If the managing underwriters and the
     Company subsequently determine to add any secondary shares in the offering,
     such notice shall be provided, and each Holder shall have the registration
     rights provided in this Section 2.

          (b)  The registration rights of the Holders pursuant to Section 2.2(a)
     above are subject to the demand registration rights of the Warrantholders,
     as more particularly described in the Registration Rights Agreement dated
     _______________, 1999, by and between the Company and the Warrantholders.
     The Company shall notify the Holders of any such registration unless the
     underwriters managing the proposed offering have advised the Company in
     writing that the inclusion of Registrable Securities in such registration
     will reduce the amount of shares of Common Stock requested by the
     Warrantholders to be

                                        6
<PAGE>   49

     included in such registration. The Company shall be required to include the
     Registrable Securities in any such demand registration only to the extent
     that such inclusion will not reduce the amount of shares of Common Stock
     requested by the Warrantholders to be included in the registration.
     Thereafter, to the extent that the total amount of Registrable Securities
     requested by the Holders to be included in such offering exceeds the amount
     of securities that the underwriters determine may be included in the
     offering, the Registrable Securities will be apportioned among the Holders
     according to the total amount of securities owned by each Holder or in such
     other proportions as shall mutually be agreed to by such Holders.

     SECTION 6.1 IS HEREBY DELETED IN ITS ENTIRETY AND REPLACED WITH THE
FOLLOWING SECTION 6.1:

     6.1  Waivers and Amendments. With the written consent of the holders of
more than 66 2/3% of the shares of Series B Preferred Stock, Series C Preferred
Stock and Series D Preferred Stock and of the Warrants, together with any shares
issued upon conversion of each, each voting as a separate class on a fully
converted basis, the obligations of the Company and the rights of the holders of
Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock,
the Warrants and shares issued upon conversion of each under this Agreement may
be waived (either generally or in a particular instance, either retroactively
or prospectively and either for a specified period of time or indefinitely), and
with the same consent the Company, when authorized by resolution of its board of
directors, may enter into a supplementary agreement for the purpose of adding
any provisions to or changing in any manner or eliminating any of the provisions
of this Agreement; provided, however, that no such waiver or supplemental
agreement shall reduce the aforesaid percentage which is required to consent to
any waiver or supplemental agreement, without the unanimous consent of the
record or beneficial holders of all of the then outstanding Series B Preferred
Stock, Series C Preferred Stock, Series D Preferred Stock, Warrants on a fully
converted basis, and shares issued upon the conversion of each. Upon the
effectuation of each such waiver, consent, agreement of amendment or
modification, the Company promptly shall give written notice thereof to the
record holders of the then outstanding Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock, Warrants and shares issued upon
conversion of each. This Agreement or any provision hereof may not be changed,
waived, discharged or terminated orally, but only by a statement in writing
signed by the party against which enforcement of the change, waiver, discharge
or termination is sought, except to the extent provided in this Section 6.1.

     Except as expressly set forth in this Amendment, the Agreement shall
remain in full force and effect as executed and is hereby ratified and
confirmed. In the event of any inconsistency or conflict between this Amendment
and the Agreement, the provisions of this Amendment shall govern and control.

     This Amendment may be executed in any number of counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument. Copies (facsimile, photostatic or otherwise) of signatures
to this Amendment shall be deemed to be originals and may be relied on to the
same extent as the originals.

                                       7
<PAGE>   50
     This Amendment shall be binding upon, and shall inure to the benefit of,
the parties hereto and their respective successors and assigns.

     IN WITNESS WHEREOF, the parties have caused this Amendment to be executed
by themselves or by their respective representatives thereunto duly authorized
as of the day and year first above written. The undersigned Shareholders execute
this Amendment with respect to all shares of capital stock of the Company
currently owned and hereafter acquired.

                                   GENOMIC SOLUTIONS INC.

                                   By: /s/ Jeffrey S. Williams
                                      ------------------------------------------
                                        Jeffrey   S. Williams

                                   Its: President and
                                        Chief Executive Officer

                                   ---------------------------------------------
                                   Jeffrey S. Williams

                                   ---------------------------------------------
                                   Murray G. Bodine

                                   ---------------------------------------------
                                   Donald Bronstein

                                   Corporate Capital Partners

                                   By:
                                      ------------------------------------------

                                   Its:
                                       -----------------------------------------

                                   ---------------------------------------------
                                   Brent Clapacs

                                       8
<PAGE>   51

                                    EXHIBIT H

                        ASSIGNMENT AND PLEDGE AGREEMENT

<PAGE>   52

                         ASSIGNMENT AND PLEDGE AGREEMENT

       1.  Genomic Solutions, Inc., a Delaware Corporation, 4355 Varsity Drive,
Suite E, Ann Arbor, Michigan 48108 (herein "Pledgor"), in consideration of
financial accommodations given, or to be given, or continued to Pledgor, Genomic
Solutions, Ltd., a United Kingdom corporation, Unit 3, Forge Close, Little End
Road, Eaton Socon, St. Neots, Cambridgshire, England PE193TP and/or Genomic
Solutions, K.K., a Japanese corporation, Gotanda Chuo Bldg. 2F, 3-5,
Higashigotanda 2-chome, Shinagawa-ku, Tokyo 141-0022, Japan (Genomic Solutions,
Ltd. and Genomic Solutions, K.K. each sometimes hereinafter being referred to as
a "Subsidiary" and sometimes hereinafter collectively referred to as the
"Subsidiaries" and each of Pledgor, Genomic Solutions, Ltd. and Genomic
Solutions, K.K. sometimes hereinafter referred to as "Borrower", a "Borrower" or
the "Borrower" and collectively sometimes referred to as the "Borrowers") by
White Pines Limited Partnership I, a Michigan limited partnership, 2401 Plymouth
Road, Suite B, Ann Arbor, Michigan 48105 (hereinafter referred to as "WPLP"),
Pacific Capital, L.P., a Delaware limited partnership, 2401 Plymouth Road, Suite
B, Ann Arbor, Michigan 48105 (hereinafter referred to as "Pacific"), Chase
Venture Capital Associates, L.P., a California limited partnership, 380 Madison
Avenue, 12th Floor, New York, New York 10017 (hereinafter referred to as
"Chase"), American Healthcare Fund II, a Delaware limited partnership, 4430
Arapahoe Avenue, Suite 220, Boulder, Colorado 80303 (hereinafter referred to as
"American"), Ian R. N. Bund Smith Barney Prototype PS Plan Account
#206-08291-12445, P.O. Box 2022, Bloomfield Hills, Michigan 48303(hereinafter
referred to as "Bund") , Yocum Consulting Associates, Inc., an Ohio corporation,
4622 Wyndwood Drive, Toledo, Ohio 43623 (hereinafter referred to as "Yocum"),
Volunteer Healthcare Associates, L.L.C., a Tennessee limited liability company,
6 Cadillac Drive, Suite 310, Brentwood, Tennessee 37027 (hereinafter referred to
as "Volunteer"), McDonald Investments Inc. Custodian FBO S. Sterling McMillan
III IRA Rollover Account #85362191, 2550 Som Center Road, Suite 300, Willoughby
Hills, Ohio 44094 (hereinafter referred to as "McMillan") , J. Matthew
Mackowski, 275 Post Street, Suite 600, San Francisco, California 94108
(hereinafter referred to as "Mackowski-CA") , Robert G. Shepler, 275 Post
Street, Suite 600, San Francisco, California 94108 (hereinafter referred to as
"Shepler"), John J. Mackowski, 1506 Birkdale Lane, Ponte Verde Beach, Florida
32082 (hereinafter referred to as "Mackowski-FL") , Grove Investment Partners,
an Illinois partnership, 336 Essex Road, Kenilworth, Illinois 60043 (hereinafter
referred to as "Grove") Ronald G. Kalish Living Trust u/a/d September 9, 1997,
445 Grand Bay Drive, #1009, Key Biscayne, Florida 33149 (hereinafter referred to
as "Kalish"), Lois F. Marler, 48951 Fox Drive South, Plymouth, Michigan 48170
(hereinafter referred to as "Marler"), McDonald Investments Inc. Custodian FBO
Daniel J. Boyle IRA Rollover Account #85314893, 2550 Som Center Road, Suite 300,
Willoughby Hills, Ohio 44094 (hereinafter referred to as "Boyle"), National City
Bank of MI/IL, Custodian FBO Herbert S. Amster IRA Rollover Account

<PAGE>   53

dated June 12, 1991 Account #MI-1491-00-4, 101 National City Bank, 101 S. Main
Street, Ann Arbor, Michigan 48104 (hereinafter referred to as "Amster"), Kantner
and Associates Profit Sharing Plan u/a/d January 1, 1991, 555 East William
Street, Ann Arbor, Michigan 48104 (hereinafter referred to as "Kantner") and
Michael G. Williams, 18000 Cavanaugh Lake Road, Chelsea, Michigan 48118
(hereinafter referred to as "Williams") (WPLP, Pacific, Chase, American, Bund,
Yocum, Volunteer, McMillan, Mackowski-CA, Shepler, Mackowski-FL, Grove, Kalish,
Marler, Boyle, Amster, Kantner and Williams each being sometimes hereinafter
referred to as "Lender", a "Lender" or the "Lender" and collectively as
"Lenders"), and as collateral security for the payment of all debts,
obligations or liabilities now or hereafter existing, absolute or contingent,
including any extensions or renewals thereof, present or future, direct or
indirect, due or to become due from the Borrowers to the Lenders under (i) the
Promissory Notes in the amount of six million and no/100 ($6,000,000) dollars,
(ii) the Business Loan Agreement of even date herewith between Borrowers and
Lenders, and (iii) all obligations due under any of the Loan Documents (as
defined in the Business Loan Agreement), (all of which shall be called
"Indebtedness"), hereby irrevocably assigns, orders, transfers, pledges and sets
over to Lenders, their successors and assigns:

              (a) All distributions, profit distributions, proceeds from sale of
stock included in the Collateral, and any and all other distributions due to
Pledgor from each Subsidiary and any successor in interest thereto.

              (b) All shares and other property delivered to and deposited with
the Lenders, all property which is hereafter delivered to or comes into the
possession or control of the Lenders in any manner and for any purpose during
the existence of this Agreement, together with the stock rights, rights to
subscribe, liquidating dividends, stock dividends, dividends paid in stock, new
securities or other property which the Pledgor is entitled to receive and grants
to Lenders a continuing security interest in certain instruments, stock, chattel
paper, notes, debentures or other securities, to wit:

All shares of and 100% of its ownership interest in each Subsidiary as well as
any and all other property now or hereafter in the Lenders' possession or
control (all of the above set forth in subparagraph 1(a) and 1(b) herein
collectively termed "Collateral").

       2.  Pledgor warrants:

           (a)  that it is the lawful owner of all the Collateral including one
hundred percent (100%) of the capital stocks of each Subsidiary, free of all
claims, liens, or encumbrances whatsoever other than as set forth in the
Business Loan Agreement and the security interest granted to Lenders pursuant
hereto;

<PAGE>   54

           (b)   all written information furnished by Pledgor to Lenders
hereafter, will be correct and true as of the date given; and

           (c)   that the pledge and security interest in the Collateral arising
out of this Agreement has been given and granted to induce the Lenders to
extend, or to continue to extend, credit accommodations to the Borrowers.

       3.  At any time, after an event of default under the Business Loan
Agreement or the Promissory Notes, Warrants or Security Agreement contemplated
therein shall occur and is not cured within any applicable grace period and
without notice, and at the expense of the Pledgor, Lenders may but are not
-obligated to:

           (a)  collect all dividends, interest, principal payments and other
sums payable upon or on account of the Collateral;

           (b)  Enter into an extension, reorganization, deposit, merger or
consolidation agreement, or other agreement related to or affecting the
Collateral, and in this connection may deposit or surrender control of the
Collateral, accept other property in exchange for the Collateral, and perform
such acts and things as it considers proper. Money or property received in
exchange for the Collateral shall be applied to the Indebtedness secured hereby;

           (c)  Compromise or settle claims or disputes as it deems desirable or
proper with reference to the Collateral;

           (d)  Insure, process and preserve the Collateral;

           (e)  Transfer the title to the Collateral to its name or the name of
the nominee;

           (f)  Exercise as to the Collateral, all the rights, powers and
remedies of an owner; and

           (g)  Perform any and all acts which Lenders in good faith deem
necessary for the protection and preservation of Collateral or its value or
Lenders' security interest therein, including, but not limited to, transferring
any Collateral to Lenders' own name and receiving the income thereon as
additional security hereunder.

       4.  If, during the term of this Agreement, any stock dividends,
reclassifications, adjustments or other changes are made in the capital
structure of the corporation or other entity issuing the Collateral or any
portion thereof, whether it is a reorganization, recapitalization, share
split-up, a combination of shares, merger, transfer, or consolidation, all new,
additional or substituted shares for securities of whatever

<PAGE>   55
class, issued with respect to the Collateral by reason of change, shall be
delivered to the Lenders immediately after issuance. The Lenders shall hold the
shares or security so issued as the Collateral under the terms of this
Agreement. If, during the term of this Agreement, warrants, options, or other
rights with respect to the Collateral are issued to the Pledgor, and if the
Pledgor exercises any such warrants, option, or right, all new stock or
securities received upon such exercise shall be delivered by the Pledgor to the
Lenders immediately after they are issued. Such new stock or securities shall be
held by the Lenders as Collateral under the terms of the Agreement.

       5.   (a)  At any time after a default shall occur in any of the
Indebtedness according to the terms thereof, which default is not cured within
any applicable grace period, including the Notes, Security Agreements, Business
Loan Agreement, Warrants, or any other Loan Document between Lenders and
Borrowers and/or the Pledgor (the terms of such being incorporated by reference
herein) ; including a material impairment in any way of the value of the
Collateral or Lender's rights therein, the Lender may at its option, without
notice or demand to Pledgor, declare all or part of the Indebtedness to be
immediately due and payable. The Lender shall have the remedies of a secured
party under the Uniform Commercial Code of the State of Michigan. The Lenders
may sell the Collateral in such manner and for such price as the Lenders deem
appropriate without any liability for any loss due to decrease in the market
value of the Collateral during the period held. The Lender shall have the right
to purchase all or part of the Collateral at public or private sale. If
notification of intended disposition of any of the Collateral is required by
law, such notification shall be deemed reasonable and properly given if mailed,
postage prepaid, at least seven (7) days before any such disposition to any
address of the Pledgor appearing on the records of the Lenders. Lenders shall
have the right, but shall not be obligated, to vote the Collateral.

            (b)  Upon the exercise of Lenders' rights to receive distributions
with respect to the Collateral as provided in Section 3 above, Lenders shall be
vested with all the rights of the Pledgor in respect thereto, the ability to
notify any obligor or payor of the assignment and the ability to execute any
instrument on behalf of the Pledgor in settlement or fulfillment thereof. In
such event, Pledgor agrees to execute such additional assignments, instruments
and documents as the Lenders may request to evidence the assignment. The Pledgor
agrees that if thereafter it receives any payment of any such sums it shall
receive same as the agent of the Lenders and the Pledgor agrees to transmit such
payment in the form in which it was received to the Lenders on the date of
receipt thereof, appropriately endorsed, if necessary, to permit negotiation by
the Lenders. In any event, the Lenders are authorized to endorse or to sign, in
the name of the Pledgor, any instrument of whatsoever nature to effect the
collection of said payments for application to all sums due the Lenders.

<PAGE>   56

       6.   The Collateral shall be evidenced by share certificates registered
in the name of Pledgor and accompanied by stock powers duly executed in blank.
Said share certificates and duly executed stock powers have been delivered to
Lenders concurrently with the execution of this Agreement

       7.   The proceeds of any sale shall be applied in the following order:

            (a)  to pay all costs and expenses of every kind for care,
safekeeping, collection, sale, foreclosure, delivery or otherwise respecting the
Collateral (including reasonable expenses incurred in the protection of the
Lenders' title or lien upon or right in any of the Collateral, reasonable actual
expenses for legal services of any kind in connection therewith or making of
such sale or sales, insurance, commission for sale, or guaranty).

            (b) to interest on all Indebtedness of the Borrowers to the Lenders;

            (c) to principal thereof, whether or not such Indebtedness is due or
accrued. After such application, Lenders will account to Pledgor for any
surplus and Borrowers shall remain liable to Lenders for any deficiency.

       Application of proceeds as between particular debts, obligations, or
liabilities of Borrowers, shall be in the absolute and sole discretion of the
Lenders. The Lenders shall have the right in their sole discretion to determine
which rights, security liens, security interests, or remedies, they shall at
any time pursue, relinquish, subordinate, modify, or take any action with
respect thereto, without in any way modifying or affecting any other security
for the Indebtedness or any of the Lenders' rights hereunder.

       8. Pledgor agrees that Lenders' security interest in the Collateral and
in any and all other property belonging to Pledgor, pledged or hypothecated, to
secure indebtedness shall be as valid as if Pledgor had duly assigned, released,
transferred and delivered said property to the Borrowers and the Borrowers, with
full ownership thereof, had pledged said property to secure all such
Indebtedness upon the terms herein stated.

       9. Any transferee of, or endorser, guarantor, or surety paying the
indebtedness secured hereby may take over all or any part of the Collateral
subject hereto, and shall succeed to all rights of the Lenders in respect
thereto and the Lenders shall be under no further responsibility therefore.

<PAGE>   57

       10.  The Pledgor authorizes Lenders, without notice or demand and
without affecting any liability on the Indebtedness to:

            (a) renew, extend, accelerate, or change the time for repayment or
other terms of the Indebtedness secured hereby, including increasing or
decreasing the rate of interest;

            (b) take and hold security other than the Collateral herein
described, for the payment of the Indebtedness and to exchange, substitute,
transfer, enforce, waive and release such security; and

            (c) release or substitute any Borrower, endorser, guarantor, or
other Pledgor of the Indebtedness.

       11.  The Pledgor waives presentment, demand for performance, notice of
non-performance, protest, notice of protest, or notice of dishonor in connection
with an obligation or evidence of indebtedness held by Lenders as Collateral, or
in connection with any obligation of or evidence of indebtedness which
represents the Indebtedness secured thereby. The Lenders shall not be required
to examine into the validity of or to exchange or to collect on any Collateral
subject to this Agreement or to take any action necessary to hold any
corporation, issuer, or other parties liable on the Collateral; and diligence in
looking after, preserving, or acting with respect to the Collateral or
collecting the same is hereby waived by the parties hereto.

       12.  No delay on the part of the Lenders in the exercise of any right or
remedy shall operate as a waiver thereof, and no single or partial exercise by
the Lenders of any right or remedy shall preclude other or further exercise
thereof or the exercise of any other right or remedy. All of the Lenders' rights
and remedies whether evidenced hereby or by any other writing, shall be
cumulative and may be exercised from time to time singularly or concurrently.

       13.  This is a continuing Agreement and the rights, powers and remedies
apply to all past, present and future Indebtedness of the Borrowers to the
Lenders including that arising under successive transactions which continue the
Indebtedness, increase or decrease it, or create new Indebtedness. No notice of
creation or existence of any Indebtedness or of any renewal, extension, or
modification thereof, need be given to Pledgor. This agreement and related
financing statements shall be terminated upon payment in full of the
Indebtedness and all other sums and expenses required to be paid thereby,
provided however that for purposes of the foregoing, no Indebtedness shall be
deemed to exist under the terms of the Warrants prior to such time as Borrower
has been notified of the exercise of Lenders' rights under subsection (K) of the
Warrants. If this Agreement and the related financing statements shall have been
terminated prior to the date on which Borrower is notified of the exercise

<PAGE>   58

of Lenders' rights under subsection (K) of the Warrants, the effectiveness of
this Agreement shall automatically continue or be reinstated with respect to all
amounts payable in accordance with the terms of the Warrants upon notice to
Borrower of the exercise of Lenders' rights under subsection (K) of the
Warrants. The breach of the terms of any Note, Warrant, Security Agreement,
Pledge or Business Loan Agreement of whatsoever nature between Borrowers and
Lenders, which is not cured within any applicable grace period, shall constitute
a default and breach of all such agreements including this agreement.

       14.  Lenders may deliver the Collateral or any part of it to the Pledgor
and the receipt by the Pledgor discharges the Lenders from any liability or
responsibility for said Collateral.

       15.  This Agreement shall be governed and interpreted according to the
laws of the State of Michigan without regard to its conflict of law principles.
Parties agree that all actions and proceedings arising in connection with this
Agreement shall be litigated in the State Courts or the Federal District Courts
in the State of Michigan. The parties hereby waive any right that they may have
to change the venue of any action against it by any other party in accordance
with this paragraph. The parties hereby consent and submit to the jurisdiction
and venue of the State Courts and Federal District Courts of the State of
Michigan. This Agreement shall inure to the benefit of and be binding upon the
Lenders, their successors and assigns, including the assignees of any
Indebtedness secured by this Agreement, and the Pledgor and its legal
representatives, successors and assigns. In the event any provision of this
Agreement shall be invalid or unenforceable, in full or in part, neither the
validity nor the enforceability of the remainder of this Agreement shall be
affected in any way.

       16.  Nothing herein contained shall be construed to bind Lenders to
perform any of the Pledgor's obligations under any of the Collateral as a
shareholder.

       17.  This Assignment and Pledge Agreement has been negotiated between the
parties and shall be deemed to have been mutually drafted by them.

       In Witness Whereof, the parties hereto have executed this Agreement this
23rd day of April, 1999.

LENDERS:                                       PLEDGOR:

WHITE PINES LIMITED PARTNERSHIP I              GENOMIC SOLUTIONS, INC.
By:  White Pines G.P., L.L.C.,
     its general partner

By:                                            By:
    --------------------------------              ------------------------------
    Frederick L. Yocum, Chairman                  Jeffrey S. Williams
                                                             President

<PAGE>   59

PACIFIC CAPITAL, L.P.
By:  Pacific Capital Corporation,
     its general partner

By:
   ---------------------------------
   Frederick L. Yocum, Vice-Chairman

IAN R. N. BUND SMITH BARNEY
      PROTOTYPE PS PLAN ACCOUNT
      #206-08291-12445
YOCUM CONSULTING ASSOCIATES, INC.
VOLUNTEER HEALTHCARE ASSOCIATES, L.L.C
MCDONALD INVESTMENTS INC. CUSTODIAN
      FBO S. STERLING MCMILLAN III IRA
      ROLLOVER ACCOUNT #85362191
RONALD G. KALISH LIVING TRUST U/A/D
      SEPTEMBER 9, 1997
LOIS F. MARLER
MCDONALD INVESTMENTS INC. CUSTODIAN
      FBO DANIEL J. BOYLE IRA
      ROLLOVER ACCOUNT #85314893
NATIONAL CITY BANK OF MI/IL CUSTODIAN
      FBO HERBERT S. AMSTER IRA
      ROLLOVER ACCOUNT DATED JUNE 12, 1991
      #MI-1491-00-4
KANTNER AND ASSOCIATES PROFIT SHARING
      PLAN U/A/D JANUARY 1, 1991
MICHAEL G. WILLIAMS
 By:    White Pines Management, L.L.C.,
        a Michigan limited liability
        company, attorney-in-fact

By:
   ---------------------------------
   Frederick L. Yocum, Chairman

CHASE VENTURE CAPITAL ASSOCIATES, L.P.

By:
   ---------------------------------

AMERICAN HEALTHCARE FUND II

By:
   ---------------------------------            -------------------------------
                                                JOHN J. MACKOWSKI

------------------------------------
J. MATTHEW MACKOWSKI                            GROVE INVESTMENT PARTNERS

                                                By:
                                                   ----------------------------
-----------------------------------
ROBERT G. SHEPLER

<PAGE>   60

                                  SCHEDULE 7.b

                             GENOMIC SOLUTIONS INC.

OUTSTANDING WARRANT:

           -  Warrant to Purchase Common Stock of Genomic Solutions Inc.

                  ESA, Inc., a Massachusetts corporation is entitled to purchase
                  from Genomic Solutions Inc., a Delaware corporation at the
                  exercise price of Six Dollars ($6.00) per share (the "Exercise
                  Price"), One hundred twenty-five thousand (125,000) shares of
                  Genomic Solutions Inc. common stock, par value $.001.

<PAGE>   61

                                   SCHEDULE 7.g

                             GENOMIC SOLUTIONS INC.

SEE ATTACHED LISTS:

<TABLE>
<CAPTION>

SCHEDULE         DESCRIPTION
--------         -----------

<S>             <C>
7.g.1            Series B Convertible Preferred Shareholders

7.g.2            Series C Convertible Preferred Shareholders

7.g.3            Series D Convertible Preferred Shareholders

7.g.4            Series M Convertible Preferred Shareholders

7.g.5            Common Stock Shareholders

7.g.6            Employee Stock Options

7.g.7            Non-Employee Stock Options

7.g.8            Warrant Holder (see Schedule 7.b)

7.g.9            Officers, Directors and Significant Employees

7.g.10           Officers, Directors and Significant Employees with indebtedness to the Borrower

7.g.11           Officers and Significant Employees who own directly/indirectly any interest in
                 any entity which is a Competitor, Customer or Supplier of Genomic Solutions

</TABLE>

<PAGE>   62

                                                                  SCHEDULE 7.g.1

                             GENOMIC SOLUTIONS INC.

                            SERIES B PREFERRED STOCK
                                SHAREHOLDERS LIST

<PAGE>   63

GENOMIC SOLUTIONS INC. (FORMERLY B. I. SYSTEMS CORP.) STOCK REGISTER
SERIES B PREFERRED STOCK
<TABLE>
<CAPTION>
                                                                                                                ON AN AS
                                                                                                             CONVERTED BASIS
CERT.                                                                            DATE OF        REISSUED     TO COMMON STOCK   % OF
 NO.      HOLDER              CONTACT                  ISSUE         SHARES   ORIGINAL ISSUANCE   AS GSI         3.03030       CLASS
----     -------          -------------------------   --------      --------  ----------------- ---------   ----------------   -----
<S>      <C>              <C>                         <C>           <C>       <C>               <C>         <C>                <C>
                          John J Cirigliano
                          Corporate Capital Partners
                          260 Sheridan Avenue, Ste.    Series B
         Corporate        416                         Preferred
 B1      Capital Partners Palo Alto, CA 94306-2011      Stock        24,007      10-Jun-97      24-Dec-97      72,748.48        1.4%
                          David Given                  Series B
                          19115 Shaker Boulevard      Preferred
 B2      David Given      Shaker Heights, OH 44122      Stock        24,007      10-Jun-97      24-Dec-97      72,748.48        1.4%
                          Mary Jane Hilker
                          Liberty BIDCO Investments
                          30833 N western Hwy, Ste
         Liberty BIDCO    211                          Series B
         Investment       Farmington Hills, MI 48334- Preferred
 B3      Corp.            2582                          Stock        52,016      10-Jun-97      24-Dec-97     157,624.24        3.1%
                          James B Hoover               Series B
         James B          Ivy Hill - Cleft Road       Preferred
 B4      Hoover           Mill Neck, NY 11765           Stock        20,000      10-Jun-97      24-Dec-97      60,606.06        1.2%
         Grove            John Kerr                    Series B
         Investment       336 Essex Road              Preferred
 B5      Partners         Kenilworth, IL 60043          Stock        24,007      10-Jun-97      24-Dec-97      72,748.48        1.4%
                          John J. Mackowski
                          1506 Birkdale Lane           Series B
         John J.          Porte Vedra Beach, FL      Preferred
 B6      Mackowski        32082                         Stock        24,007      10-Jun-97      24-Dec-97      72,748.48        1.4%
                          Dan Mitchell
                          Capital Health Venture
                          Partners
         American         20 N. Wacker Drive, Ste      Series B
         Healthcare       2200                        Preferred
 B7      Fund II          Chicago, IL 60606             Stock       400,353      10-Jun-97      24-Dec-97   1,213.190.91       23.8%
                          John Styles                  Series B
                          2200 Southwest Fwy          Preferred
 B8      John Styles      Houston, TX 77098             Stock        20,006      10-Jun-97      24-Dec-97      60,624.24        1.2%
                          Laverne Styles               Series B
                          2200 Southwest Fwy          Preferred
 B9      Laverne Styles   Houston, TX 77098             Stock        12,004      10-Jun-97      24-Dec-97      36,375.76        0.7%
</TABLE>

<PAGE>   64

GENOMIC SOLUTIONS INC. (FORMERLY B. I. SYSTEMS CORP.) STOCK REGISTER
SERIES B PREFERRED STOCK
<TABLE>
<CAPTION>
                                                                                                               ON AN AS
                                                                                DATE OF                    CONVERTED BASIS
                                                                                ORIGINAL     REISSUED      TO COMMON STOCK    % OF
CERT. NO. HOLDER                CONTACT                ISSUE        SHARES      ISSUANCE      AS GSI           3.03030        CLASS
--------- -------               -------                -----        ------      --------      ------     ------------------   ------
<S>      <C>              <C>                       <C>            <C>         <C>          <C>         <C>                   <C>
                          J Matthew Mackowski
                          343 Sansome Street, Ste    Series B
         J. Matthew       1215                      Preferred
 B10     Mackowski        San Francisco, CA 94104    Stock         526,336      1O-Jun-97   24-Dec-97      1,594,957.58        31.3%
                          Robert G. Shepler
                          343 Sansome Street, Ste    Series B
         Robert G         1215                      Preferred
 B11     Shepler          San Francisco, CA 94104     Stock        159,969      10-Jun-97   24-Dec-97        484,754.55         9.5%
                          Larry J. Kent
                          Kent & Kent
                          1265 Drummers Lane,         Series B
         Lawrence J.      Suite 208                  Preferred
 B12     Kent             Wayne PA 19087               Stock       300,000      10-Jun-97   24-Dec-97        909,090.91        17.8%
                          Robert G Shepler           Series B
         Robert G         343 Sansome Street 1215    Preferred
 B13     Shepler          San Francisco, CA 94104     Stock         20,161      25-Jun-97   24-Dec-97         61,093.94         1.2%
                          Ian R N Bund
                          White Pines Capital
                          2401 Plymouth Rd, Suite B   Series B
                          Ann Arbor, MI 48105        Preferred
 B14     Ian R. N. Bund   94104                        Stock        50,000      4-Aug-97    24-Dec-97        151,515.15         3.0%
                          Murray G. Bodine
                          Hoefer Arnet                 Series B
         Murray G.        353 Sacramento, 10th Fl.   Preferred
 B15     Bodine           San Franciso CA 94111        Stock        24,007      4-Aug-97    24-Dec-97          72,748.48        1.4%
                                                                   ---------                                -----------------------
 TOTAL SERIES B SHARES                                             1,680,880                                5,093,575.76      100.0%
                                                                   =========                                =======================

</TABLE>

<PAGE>   65

                                                                  SCHEDULE 7.g.2

                             GENOMIC SOLUTIONS INC.

                            SERIES C PREFERRED STOCK

                                SHAREHOLDERS LIST

<PAGE>   66

Genomic Solutions Inc. (formerly B. I. Systems Corp.) Stock Register
Series C Preferred Stock
<TABLE>
<CAPTION>
                                                                                                     On An As
                                                                                Date of          Converted Basis
                                                                               Original          to Common Stock      % of
Cert No. Holder                Contact                Issue        Shares       Issuance             1.00000          Class
-------- ---------             -------                -----        ------      --------        ------------------    ------
<S>      <C>              <C>                       <C>            <C>         <C>             <C>                   <C>
                          Chase Capital Partners
                          Damion Wicker
                          Dr. Risa Stack
                          380 Madison Avenue,
                          12th Floor                 Series C
         Chase Capital    New York, New York        Preferred
 C1      Partners         10017                      Stock         3,015,375    29-Dec-97          3,015,375          74.1%

                          Dan Mitchell
                          Capital Health Venture
                          Partners
         American         4430 Arapahoe Ave.         Series C
         Healthcare       Suite 220                 Preferred
 C2      Fund II          Boulder, CO 80303           Stock          342,857    29-Dec-97            342,857           8.4%

                          J. Matthew Mackowski
                          343 Sansome Street, Ste.
                          1215                        Series C
         J. Matthew       San Francisco, CA          Preferred
 C3      Mackowski        94104                        Stock         142,857    29-Dec-97            142,857           3.5%

                          Robert G. Shepler
                          343 Sansome Street, Ste.
                          1215                        Series C
         Robert G         San Francisco, CA          Preferred
 C4      Shepler          94104                       Stock           15,285    29-Dec-97             15,285           0.4%

                          2401 Plymouth Rd            Series C
                          Suite B                    Preferred
 C5      Ian R. N. Bund   Ann Arbor, MI 48105          Stock         104,924    29-Dec-97            104,924           2.6%

         Grove            John Kerr                   Series C
         Investment       336 Essex Road             Preferred
 C6      Partners         Kenilworth, IL 60043         Stock          50,378    29-Dec-97             50,378           1.2%

                          James B. Hoover             Series C
         James B.         Ivy Hill - Cleft Road      Preferred
 C7      Hoover           Mill Neck, NY 11765          Stock          17,143    29-Dec-97             17,143           0.4%

                          John J. Mackowski
                          1506 Birkdale Lane          Series C
         John J.          Ponte Vedra Beach, FL      Preferred
 C8      Mackowski        32082                       Stock           10,000    29-Dec-97             10,000           0.2%

                          Chase Capital Partners
                          Damion Wicker
                          Dr. Risa Stack
                          380 Madison Avenue,
                          12th Floor                  Series C
         Chase Capital    New York, New York         Preferred
 C9      Partners         10017                        Stock         358,053    6-Jan-98             356,053           8.7%

                          Murray G. Bodine
                          Hoefer Arnet                Series C
         Murray G.        353 Sacramento, 10th Fl.   Preferred
 C10     Bodine           San Franciso CA 94111        Stock          15,467    6-Jan-98              15,467           0.4%
                                                                   ---------                         ---------------------

 TOTAL SERIES C SHARES                                             4,070,339                         4,070,339       100.0%
                                                                   =========                         =====================

</TABLE>

<PAGE>   67

                                                                  SCHEDULE 7.G.3

                             GENOMIC SOLUTIONS INC.

                            SERIES D PREFERRED STOCK

                                SHAREHOLDERS LIST

<PAGE>   68
Series D.

Preferred Stock                    Schedule I

                                   INVESTORS

<TABLE>
<CAPTION>
                                                                                Shares of         Dollar
                                                                                Series D           Value
 Certificate                                                                    Preferred        Preferred
   Number                         Name and Address                                Stock            Stock
   ------                         ----------------                             ----------      -----------
<S>        <C>                                                                 <C>             <C>
D 1        Chase Venture Capital Associates, L.P.                                987,488       $ 5,924,928
           Chase Capital Partners
           380 Madison Avenue, 12th Floor
           New York, New York 10017

D 2        American Healthcare Fund II                                            25,000         $ 150,000
           Capital Health Venture Partners
           4430 Ararpahoe Ave., Suite 220
           Boulder, CO 80303

D 3        J. Matthew Mackowski                                                   10,000          $ 60,000
           343 Sansome Street, Suite 1215
           San Francisco, CA 94104

D 4        Robert G. Shepler                                                       4,000          $ 24,000
           343 Sansome Street, Suite 1215
           San Francisco, CA 94104

D 5        Liberty BIDCO Investment Corp.                                         18,379         $ 110,274
           30833 Northwestern Highway, Suite 211
           Farmington Hills, MI 48334-2582

D 6        James B. Hoover                                                        16,870         $ 101,220
           Ivy Hill - Cleft Road
           Mill Neck, NY 11765

D 7        Grove Investment Partners                                              16,667         $ 100,002
           336 Essex Road
           Kenilworth,  IL 60043

D 8        Murray G. Bodine                                                       10,286          $ 61,716
           C/o Van Kasper & Company
           600 California Street,  17th Floor
           San Francisco, CA 94108

D 9        John Styles                                                             7,069          $ 42,414
           2200 Southwest Fwy.
           Houston, TX 77098

D 10       Laverne Styles                                                          4,241          $ 25,446
           2200 Southwest Fwy.
           Houston, TX 77098
                                                                               ---------       -----------
           Total                                                               1,100,000       $ 6,600,000
                                                                               =========       ===========
</TABLE>

<PAGE>   69

                                                                  SCHEDULE 7.G.4

GENOMIC SOLUTIONS INC. (FORMERLY B. I. SYSTEMS CORP.) STOCK REGISTER
SERIES M PREFERRED STOCK
<TABLE>
<CAPTION>
                                                                                                       On An As Converted Basis
                                                                        Date of            Reissued         to Common Stock
Cert. No.       Holder         Contact      Issue      Shares     Original Issuance         as GSI               5.40054
---------       ------         -------    ---------    ------     -----------------        ---------   ------------------------
<S>             <C>            <C>        <C>          <C>        <C>                      <C>         <C>
                                           Series M
                Millipore                 Preferred
M 1             Corporation                 Stock      50,000        1O-Jun-97             24-Dec-97             270,027
                                                       ------                                                    -------
CAPITAL SERIES M SHARES                                50,000                                                    270,027
                                                       ======                                                    =======

</TABLE>

<PAGE>   70

                                                                  SCHEDULE 7.G.5

                             GENOMIC SOLUTIONS INC.

                                  COMMON STOCK

                                SHAREHOLDERS LIST

<PAGE>   71

                                                                  SCHEDULE 7.g.5

GENOMIC SOLUTIONS INC.
COMMON STOCK SHAREHOLDERS
AS OF: APRIL 23, 1999

<TABLE>
<CAPTION>
                                                             COMMON
INVESTOR                                                      STOCK
--------                                                   ---------
<S>                                                        <C>
 Matt Mackowski                                               98,796
 Bob Shepler                                                  87,154
 American Healthcare Fund II                                 172,870
 J. Williams                                                 675,000
 Liberty Bidco                                                25,535
 Corporate Capital Partners                                   11,785
 David Given                                                  11,785
 James Hoover                                                 19,642
 Grove investment Partners (J. Kerr)                          11,785
 John J. Mackowski                                            11,785
 John Styles                                                   9,821
 Laverne Styles                                                5,893
 Murray Bodine                                                11,785
 Don Bernstein                                                 4,911
 Brent Clapacs                                                 5,893
 Don Van Dyke                                                  7,333
 Jon Folan                                                     5,893
 E. Keegan                                                     5,893
 Inge Morrison                                                 4,911
 Charles Stewart                                              11,785
 T. Dahlberg                                                      21
 J. Hawthorne                                                     41
 Computational Biosciences                                    40,000
 Barb Kirkland                                                13,533
 Frank Becker                                                 16,666
 Rick Russell                                                  3,933
 George Brykit                                                 3,333
 Andy Jakimcius                                               13,333
 David Helmreich                                               3,333
 Shannon Richey                                                5,000
 Ed Burnham                                                    3,933
 Larry Siden                                                   3,733
 Chris Ethier                                                  1,866
 Arthur Weiss                                                 28,933
 Jeffrey Heuer                                                28,932
 Peter Sugar                                                  28,932
 David William Byatt                                         160,373
 Jacqueline Byatt                                            185,795
 Arthur John Pinkney                                         346,168
 Sam C. Whitbread                                            141,102
 Dr. Jane Stevens                                             14,110
 Simon Cooke                                                   9,407
 Martin Bloom                                                 47,033
 Malcolm Boston                                               14,110
 Anthony Gary Biddle                                         256,335
 Ian Boston                                                   47,033
 Suzanne C. Boston                                            47,033
 Paul Nicholas King                                           76,449
 Lois Margaret King                                           75,000
 Hansard Management Services Ltd.                            110,052
                                                           ---------
TOTAL SHARES OUTSTANDING                                   2,925,777
                                                           =========

</TABLE>

<PAGE>   72

SCHEDULE 7.g.6 -- 1 of 3

                                                            Stock Option Summary
                                      Stock Options summary as of April 23, 1999

GENOMIC SOLUTIONS INC.
SUMMARY OF EMPLOYEE
STOCK OPTIONS
As Of April 23, 1999

<TABLE>
<CAPTION>
                                Balance
                            Outstanding
---------------------------------------
<S>                         <C>
Jeff S. Williams                655,000
---------------------------------------
Andy Jakimcius                   76,667
---------------------------------------
Steve Richvalsky                117,250
---------------------------------------
Mike Kurek                       76,000
---------------------------------------
Kevin Auton                      75,000
---------------------------------------
Bill Skea                        40,000
---------------------------------------
John Pinkney                     40,000
---------------------------------------
David Byatt                      40,000
---------------------------------------
M. Akahori                       45,000
---------------------------------------
Frank Becker                     38,334
---------------------------------------
Greg Kinch                       42,000
---------------------------------------
Mary Lopez                       30,000
---------------------------------------
Chris Barker                     20,000
---------------------------------------
Mary Stanaway                    30,000
---------------------------------------
Paul Dunkley                     20,000
---------------------------------------
Rob Mount                        10,000
---------------------------------------
Irene Fox                         4,000
---------------------------------------
Jim Delhey                       15,000
---------------------------------------
Mike Ignatoski                   18,000
---------------------------------------
Mike Tincher                     18,000
---------------------------------------
Shannon Richey                   14,000
---------------------------------------
Robert Luton                     43,000
---------------------------------------
George Byrkit                    10,667
---------------------------------------
Chris Bliton                     13,000
---------------------------------------
Jeff Fosdick                     20,000
---------------------------------------
Robert Drazovich                 14,600
---------------------------------------
Claus Buchholz                   25,000
---------------------------------------
David Carter                     10,000
---------------------------------------
Bob Barker                        2,000
---------------------------------------
Mark Eddy                        10,000
---------------------------------------
Beverly Burk                      5,000
---------------------------------------
Bob Cole                          5,000
---------------------------------------
Ralph Seavolt                     5,000
---------------------------------------
Adriaan De Feitjer               10,000
---------------------------------------
N. Kato-san                      11,000
---------------------------------------
Barb Kirkland                    27,467
---------------------------------------
Scott Kralik                     11,000
---------------------------------------
John Hollingshead                10,000
---------------------------------------
Lotte Downey                     18,000
---------------------------------------
Van Vogel                        10,000
---------------------------------------
Jim Woynerowski                  10,000
---------------------------------------
Rick Russell                      7,167
---------------------------------------
Ed Burnham                        7,067
---------------------------------------
Andrew Loehr                     10,000
---------------------------------------
</TABLE>
<PAGE>   73

                                                            Stock Option Summary
SCHEDULE 7.g.6 -- 2 of 3              Stock Options summary as of April 23, 1999

GENOMIC SOLUTIONS INC.
SUMMARY OF EMPLOYEE
STOCK OPTIONS
As Of April 23, 1999

<TABLE>
<CAPTION>
                                                       Balance
                                                     Outstanding
                                                     -----------
<S>                                                  <C>
----------------------------------------------------------------
Clifton Brown                                           10,000
----------------------------------------------------------------
Larry Siden                                              8,267
----------------------------------------------------------------
Jeff Hoover                                              5,000
----------------------------------------------------------------
David O'Hagan                                            5,400
----------------------------------------------------------------
Askar Kuchumov                                           5,000
----------------------------------------------------------------
Dennis Snider                                            5,000
----------------------------------------------------------------
Sue Brown                                                1,000
----------------------------------------------------------------
William Kyle                                               250
----------------------------------------------------------------
Chris Smart                                              5,000
----------------------------------------------------------------
Steve Lanham                                             5,000
----------------------------------------------------------------
Dean Palmer                                              5,000
----------------------------------------------------------------
Hazel Jeffery                                              500
----------------------------------------------------------------
Aaron Custance                                           5,000
----------------------------------------------------------------
David Hockley                                            5,000
----------------------------------------------------------------
Ian Reed                                                 5,000
----------------------------------------------------------------
Robin Worley                                             5,000
----------------------------------------------------------------
James Pinkney                                            5,000
----------------------------------------------------------------
Graham Fordham                                           5,000
----------------------------------------------------------------
John Parker                                             10,000
----------------------------------------------------------------
David Thompson                                           5,000
----------------------------------------------------------------
Paul Noller                                              5,000
----------------------------------------------------------------
Clive Thomas                                             5,000
----------------------------------------------------------------
Chris Ethier                                             4,134
----------------------------------------------------------------
Ed Eckert                                                2,500
----------------------------------------------------------------
Leigh Ciesielski                                           250
----------------------------------------------------------------
Sally Jo Nelton                                          2,000
----------------------------------------------------------------
Mike Stanaway                                              250
----------------------------------------------------------------
Tammy Shelhart                                           6,000
----------------------------------------------------------------
Sam Profitt                                             11,000
----------------------------------------------------------------
Beth Bracey                                                500
----------------------------------------------------------------
Gale Hines                                               5,000
----------------------------------------------------------------
Doug Perry                                               3,500
----------------------------------------------------------------
Helen Thompson                                           6,000
----------------------------------------------------------------
Pat Becker                                               5,000
----------------------------------------------------------------
Jan Luton                                               10,000
----------------------------------------------------------------
Jeff Kent                                                2,500
----------------------------------------------------------------
Linda Mitchell                                           1,000
----------------------------------------------------------------
Ed Thompson                                              1,000
----------------------------------------------------------------
Elena Chemokalskaya                                      2,500
----------------------------------------------------------------
Phyllis Marshall                                           250
----------------------------------------------------------------
Ellen MacCallum                                            250
----------------------------------------------------------------
Myra Johnson                                               250
----------------------------------------------------------------
Nisha Sahay                                              2,500
----------------------------------------------------------------
Wayne Mellon                                               250

</TABLE>

<PAGE>   74

                                                            Stock Option Summary
SCHEDULE 7.g.6 -- 3 of 3              Stock Options summary as of April 23, 1999

GENOMIC SOLUTIONS INC.
SUMMARY OF EMPLOYEE STOCK OPTIONS
As Of April 23, 1999

<TABLE>
<CAPTION>
                                                       Balance
                                                     Outstanding
                                                     -----------
<S>                                                  <C>
----------------------------------------------------------------
Annette DeWind                                           2,500
----------------------------------------------------------------
Hina Thakkar                                               250
----------------------------------------------------------------
Richard Orrell                                           2,500
----------------------------------------------------------------
Andrea Jiggens                                             250
----------------------------------------------------------------
John Cox                                                   250
----------------------------------------------------------------
Ian Taylor                                              20,000
----------------------------------------------------------------

TOTAL                                                1,922,020
                                                    ============

</TABLE>

<PAGE>   75

                                 SCHEDULE 7.G.7

                             GENOMIC SOLUTIONS INC.

                           NON-EMPLOYEE STOCK OPTIONS

As of the date of closing the following persons have been granted and issued
stock options under the Genomic Solution's 1998 Non-Employee Director and
Consultant Stock Option Plan.

BOARD OF DIRECTORS OF GENOMIC SOLUTIONS INC.

<TABLE>
<S>                                                                                 <C>
             Robert G. Shepler ...............................................       20,000
             J. Matthew Mackowski .............................................      20,000
             American Healthcare Fund ........................................       20,000
             Chase Venture Capital Associates, L.P . .........................       20,000
             P. Nicholas King ................................................       20,000
                                                                                    -------
             TOTAL ...........................................................      100,000
</TABLE>

OTHER

-    Per the Subscription Agreement between Genomic Solutions Inc. and HD
     Technologies Ltd. stock options were granted and issued to:

<TABLE>
<S>                                                                                  <C>
      Steve Davis ...........................................................        30,000
      Andrew Hoffman ........................................................        30,000
                                                                                     ------
      TOTAL .................................................................        60,000
</TABLE>

-    Per the Collaboration Agreement between Genomic Solutions Inc. and HD
     Technologies Ltd., stock options were granted and issued to:

<TABLE>
<S>                                                                                  <C>
             Steve Davis .................................................           30,000
             Andrew Hoffman ..............................................           30,000
                                                                                     ------
             TOTAL .......................................................           60,000
</TABLE>

-    Scientific Advisory Board Members:

<TABLE>
<S>                                                                                  <C>
     Dr. Richard Wooster ............................... ..................          5,000
     Dr. Michael Liebman ..................................................          5,000
     Dr. Rolf Apweiler.....................................................          5,000
     Dr. James Sikela .....................................................          5,000
                                                                                   -------
     TOTAL ................................................................         20,000

 TOTAL NON-EMPLOYEE STOCK OPTIONS GRANTED & ISSUED ........................        240,000
                                                                                   =======
</TABLE>
<PAGE>   76

                                 SCHEDULE 7.g.9

LIST OF OFFICERS, DIRECTORS AND SIGNIFICANT EMPLOYEES:

1. GENOMIC SOLUTIONS INC. (GSI")

   1. The following persons are the duly elected and acting officers of the
   Genomic Solutions Inc., holding the office(s) set forth opposite their name
   below:

NAME                           OFFICE

Executive Officers:
Jeffrey S. Williams          President, Chief Executive Officer
Andrew A. Jakimcius          Executive Vice president of Operations
Michael P. Kurek             Executive Vice President, Marketing and Sales
Steven J. Richvalsky         Executive Vice President, Treasurer, Secretary and
                             Chief Financial Officer
William M. Skea              Vice President, Proteomic Business

General Officers:
Frank C. Becker              Vice President, Marketing
Gregory H. Kinch             Vice President, Sales (Americas)
Mary F. Lopez                Vice President, Proteomics Research & Development
Mary Stanaway                Vice President, Imaging Systems

2. The following persons are the duly elected and acting directors of Genomic
Solutions Inc.

Directors:
Jeffrey S. Williams
Robert G. Shepler, Chairman
P. Nicholas ("Nick") King
J. Matthew Mackowski
Dan Mitchell
Damion E. Wicker

3. The following persons have been identified as Significant Employees of
Genomic Solutions Inc.:

Significant Employees:
Chris Barker                 Vice President, Molecular Biology
Jeffrey Fosdick              Controller

<PAGE>   77

                           SCHEDULE 7.g.9 - CONTINUED

I.   GENOMIC SOLUTIONS LTD. (UNITED KINGDOM)

     The following persons are the acting directors and officers of the Genomic
     Solutions Ltd., holding the office(s) set forth opposite their name below:

     Directors:
     Jeffrey S. Williams                Chairman
     P. Nick King                       Vice Chairman
     Kevin A. Auton                     Managing Director
     David W. Byatt                     Director and Vice President, Development
     A. John Pinkney                    Director and Vice President, Operations
     A. Paul Dunkley                    Director and Controller

II.  GENOMIC SOLUTIONS K.K. (JAPAN)

  4. The following persons are the duly elected and acting officers and
     directors of Genomic Solutions K.K.:

     Directors:
     Jeffrey S. Williams                         Director
     Michael P. Kurek                            Director
     M. Akahori                                  Representative Director
     Steven J. Richvalsky                        Statutory Auditor

<PAGE>   78

                                 SCHEDULE 7.g.10

OFFICERS, DIRECTORS AND SIGNIFICANT EMPLOYEES
WITH INDEBTEDNES TO ANY GENOMIC SOLUTIONS COMPANY:

As defined and agreed to in the Employment Agreement by and between Genomic
Solutions Inc. and Jeffrey S. Williams, effective January 1, 1998, Genomic
Solutions provided to Mr. Williams a loan, evidenced by a five year promissory
note, the proceeds of which were used by Mr. Williams to exercise vested options
to purchase 675,000 shares of Genomic Solutions common stock. The principle
amount of the note was $47,250. Interest on the unpaid principal of the note is
accrued. The note is secured by 127,703 shares of Genomic's common stock, issued
in the name of Mr. Williams.

As of this date of closing, there are no other loans provided by Genomic
Solutions or any of its wholly owned subsidiaries to any of its officers,
director or significant employees (as listed on Schedule 7.g.9 of this
agreement).

<PAGE>   79

                                 SCHEDULE 7.g.11

    OFFICERS AND SIGNIFICANT EMPLOYEES OWNERSHIP INTEREST IN OUTSIDE PARTIES
       WHO ARE COMPETITORS, CUSTOMERS AND SUPPLIERS OF GENOMIC SOLUTIONS

Except for what ownership interest may be held within a mutual fund, the
following is a list of officers and  significant employees material ownership
interest in competitors, customers and suppliers of Genomic Solutions.

<TABLE>
<CAPTION>

    EMPLOYEE NAME            LOCATION                            COMPETITORS             CUSTOMERS                SUPPLIERS
    -------------            --------                            -----------             ---------                ---------
<S>                          <C>                                 <C>                     <C>                      <C>
  Jeffrey S. Williams          Inc.                                 None                    None                    None
  Andrew Jakimcius             Inc.                                 None                    None                    None
  Michael P. Kurek             Inc.                                 None                    None                    None
  Steven J. Richvalsky         Inc.                                 None                    None                    None
  William M. Skea              Inc.                                 None                    None                    None
  Frank C. Becker              Inc.                                 None                    None                    None
  Gregory H. Kinch             Inc.                            See (a.) below               None                    None
  Mary F. Lopez                Inc.                                 None                    None                    None
  Mary Stanaway                Inc.                                 None                    None                    None
  Chris Barker                 Inc.                                 None                    None                    None
  Jeffrey Fosdick              Inc.                                 None                    None                    None
  Kevin A. Auton               Ltd.                                 None                    None                    None
  P. Nick King                 Ltd.                                 None                    None                    None
  David W. Byatt               Ltd.                                 None                    None                    None
  A. John Pinkney              Ltd.                                 None                    None                    None
  A. Paul Dunkley              Ltd.                                 None                    None                    None
  M. Akahori                   K. K.                                None                    None                    None

</TABLE>

a.)  Greg Kinch owns common stock in the following companies as of the date of
     close;
                  Affymetrix                              500 shares
                  Incyte Pharmaceuticals                  250 shares
                  Gene Logic                            1,000 shares

<PAGE>   80

                                  SCHEDULE 7.h

                             GENOMIC SOLUTIONS INC.

 WHOLLY OWNED SUBSIDIARIES:
--------------------------------------------------------------------------------
     ITEM                              COMMENT
--------------------------------------------------------------------------------
       1.       Genomic Solutions Limited, a United Kingdom
                Corporation wholly owned by Genomic Solutions Inc.
                Office is located in Cambridgeshire, UK.
       2.       Genomic Solutions K.K., a Japanese Corporation wholly owned by
                Genomic Solutions Inc. office is located in Tokyo, Japan.

 FORMER SUBSIDIARIES:
--------------------------------------------------------------------------------
     ITEM                              COMMENT
--------------------------------------------------------------------------------
       3.       Nihon Bio Image, Ltd., a Michigan Corporation
                wholly owned by B.I. Systems Corporation, doing
                business as a branch office in Japan. Entity
                dissolved with formation of Genomic Solutions K.K.
                in June 1998.

       4.       Bio Image UK, Inc., a Michigan Corporation wholly
                owned by B.I. Systems Corporation. Operations
                ceased and office closed effective October 31,
                1997. Entity dissolved.

 OTHER:
--------------------------------------------------------------------------------
      ITEM                              COMMENT
--------------------------------------------------------------------------------
       5.        Genomic Solutions Limited subscribed Pound Sterling 91,000, for
                 Preference shares in the capital of, or
                 approximately 30% equity investment in, HD
                 Technologies, Ltd., of Manchester, England.

       6.        Genomic Solutions Inc holds (registered in the name of B.I.
                 Systems Corp.) 15,000 shares of the Series B Preferred Stock of
                 BioSeparations, Inc., a Delaware Corporation, as evidenced by
                 stock certificate           OB-81.

       7.        Genomic Solutions Inc. holds 3,000 shares of the Common Stock
                 of Gattac Corporation, a Michigan corporation, as evidenced by
                 stock certificate        16.

<PAGE>   81

                                  SCHEDULE 7.i

                             GENOMIC SOLUTIONS INC.

SEE ATTACHED FINANCIAL STATEMENTS:
<TABLE>
<CAPTION>

SCHEDULE          DESCRIPTION
--------          -----------

<S>               <C>
7.i.1             Audited Financial Statements as of December 31, 1998 and 1997.

7.i.2             Consolidating Balance Sheet as of December 31, 1998.

7.i.3             "Interim" Unaudited Consolidated Financial Statements as of February 28, 1999.

7.i.4             Consolidating Balance Sheet as of February 28, 1999.
</TABLE>

<PAGE>   82

                               ARTHUR ANDERSEN LLP               SCHEDULE 7.i.1

                             GENOMIC SOLUTIONS INC.

                       CONSOLIDATED FINANCIAL STATEMENTS

                        AS OF DECEMBER 31, 1998 AND 1997

           TOGETHER WITH THE REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

<PAGE>   83

                              ARTHUR ANDERSEN LLP

                    Report of Independent Public Accountants

To the Board of Directors and Stockholders of
   Genomic Solutions Inc.:

We have audited the accompanying consolidated balance sheets of GENOMIC
SOLUTIONS INC. AND SUBSIDIARIES (a Delaware corporation, see Note 1) as of
December 31, 1998 and 1997, and the related consolidated statements of
operations and comprehensive loss, stockholders' equity and cash flows for each
of the three years in the period ended December 31, 1998. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements.  An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Genomic Solutions Inc. and
subsidiaries as of December 31, 1998 and 1997, and the results of their
operations and their cash flows for each of the three years in the period ended
December 31, 1998, in conformity with generally accepted accounting principles.

/s/ Arthur Andersen LLP

Ann Arbor, Michigan,
    February 12, 1999, (except with respect
         to the matter discussed in Note 13
         as to which the date is April 23, 1999).

<PAGE>   84

                             GENOMIC SOLUTIONS INC.

          CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 1998 AND 1997

<TABLE>
<CAPTION>

                                   ASSETS                                                  1998                 1997
                                   ------                                              -----------          -----------
<S>                                                                                    <C>                  <C>
CURRENT ASSETS:
   Cash and cash equivalents                                                           $ 2,879,849           $5,088,799
   Accounts receivable                                                                   1,361,621            1,251,593
   Inventories                                                                           2,856,959              786,353
   Prepaid expenses and other                                                              663,842               97,684
                                                                                       -----------           ----------
              Total current assets                                                       7,762,271            7,224,429

PROPERTY AND EQUIPMENT, NET                                                              1,609,449              340,401

GOODWILL AND INTANGIBLE ASSETS, NET                                                      1,577,464              362,602

OTHER ASSETS                                                                               242,218               23,165
                                                                                       -----------           ----------
                                                                                       $11,191,402           $7,950,597
                                                                                       ===========           ==========
              LIABILITIES AND STOCKHOLDERS' EQUITY
              ------------------------------------

CURRENT LIABILITIES:
   Notes payable                                                                       $ 1,980,822           $  497,286
   Current portion of long-term debt                                                       300,941              136,891
   Accounts payable                                                                      1,962,065              495,448
   Accrued liabilities                                                                   1,209,839            1,113,028
   Deferred revenue                                                                        194,077              157,170
                                                                                       -----------           ----------
              Total current liabilities                                                  5,647,744            2,399,823
                                                                                       -----------           ----------

LONG-TERM DEBT, less current portion                                                       537,262              266,939
                                                                                       -----------           ----------
OTHER LONG-TERM LIABILITIES                                                                 23,540                -
                                                                                       -----------           ----------

COMMITMENTS (NOTE 11)

STOCKHOLDERS' EQUITY
   Convertible preferred stock, $0.001 par value,
     Series A, B, C, D and M                                                                 6,901                5,430
   Common stock, $0.001 par value                                                            2,919                2,126
   Additional paid-in capital                                                           16,525,232            9,225,877
   Note receivable                                                                         (47,250)                -
   Accumulated deficit                                                                 (11,609,784)          (3,949,598)
   Cumulative translation adjustment                                                       104,838                 -
                                                                                       -----------           ----------
              Total stockholders' equity                                                 4,982,856            5,283,835
                                                                                       -----------           ----------
                                                                                       $11,191,402           $7,950,597
                                                                                       ===========           ==========
</TABLE>

The accompanying notes are an integral part of these consolidated statements.

                                      -2-

<PAGE>   85

                             GENOMIC SOLUTIONS INC.

          CONSOLIDATED STATEMENTS OF OPERATI0NS AND COMPREHENSIVE LOSS

               FOR THE YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
<TABLE>
<CAPTION>

                                                                  1998            1997            1996
                                                              ------------    ------------   ------------
<S>                                                           <C>             <C>            <C>
REVENUE:
  Products                                                    $  4,930,727    $  1,992,385   $  2,834,833
  Services and other                                               576,634         171,156        421,872
                                                              ------------    ------------   ------------
      Total revenue                                              5,507,361       2,163,541      3,256,705

COST OF REVENUE                                                  3,266,189       1,062,771      1,311,482
                                                              ------------    ------------   ------------

      Gross profit                                               2,241,172       1,100,770      1,945,223
                                                              ------------    ------------   ------------
OPERATING EXPENSES:
  Selling, general, and administrative                           6,246,451       2,197,690      2,278,022
  Research and development                                       3,353,903         942,237        863,776
  Acquisition-related and other non-recurring chargers             340,000       2,205,786           -
                                                              ------------    ------------   ------------
      Total operating expenses                                   9,940,354       5,345,713      3,141,798
                                                              ------------    ------------   ------------

  Loss from operations                                          (7,699,182)      2,244,943     (1,196,575)
                                                              ------------    ------------   ------------

OTHER INCOME (EXPENSE):
  Interest income                                                  236,542            -              -
  Interest expense                                                (122,490)       (184,294)      (342,971)
  Other expense, net                                               (75,056)        (76,739)       (54,401)
                                                              ------------    ------------   ------------

      Total other income (expense)                                  38,996        (261,033)      (397,372)
                                                              ------------    ------------   ------------

      Loss before taxes and extraordinary gain                  (7,660,186)     (4,505,976)    (1,593,947)

PROVISION (CREDIT) FOR INCOME TAXES                                  -            (889,200)         5,685)
                                                              ------------    ------------   ------------

      Loss before extraordinary gain                            (7,660,186)     (3,616,776)    (1,599,632)

EXTRAORDINARY GAIN - Forgiveness of debt, net
  of tax expense of $ 899,200                                        -             997,491           -
                                                              ------------    ------------   ------------

NET LOSS                                                        (7,660,186)     (2,619,285)    (1,599,632)

OTHER COMPREHENSIVE INCOME - Foreign currency
  translation adjustment                                           104,838            -              -
                                                              ------------    ------------   ------------
COMPREHENSIVE LOSS                                            $ (7,555,348)   $ (2,619,285)  $ (1,599,632)
                                                              ============    ============   ============

</TABLE>

The accompanying notes are an integral part of these consolidated statements.

                                       -3-
<PAGE>   86
                             GENOMIC SOLUTIONS INC.

           CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
              FOR THE YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996

<TABLE>
<CAPTION>

                                                   Convertible
                                                 Preferred Stock         Common Stock       Additional
                                               ------------------    --------------------     Paid-In      Note
                                                Shares     Amount      Shares     Amount     Capital    Receivable
                                               ---------  -------    ---------   --------   ----------  ----------
<S>                                            <C>        <C>           <C>       <C>       <C>         <C>
BALANCE - DECEMBER 31, 1995                    1,250,00   $ 1,250       31,281    $    31   $  499,729  $    -

 Common stock issued upon exercise of
   stock options                                    -        -             447          1        3,428       -
 Net loss                                           -        -            -           -           -          -
                                               ---------   -------    ---------   --------  ----------  ----------

BALANCE - DECEMBER 31, 1996                    1,250,000     1,250       31,728         32     502,139       -

 Common stock issued upon conversion of
   Series A preferred stock                   (1,250,000)   (1,250)      45,821         46       1,204       -
 Series B preferred and common stock issued
   upon conversion of notes payable              413,169       413      200,986        201     426,624       -
 Series B preferred stock issued for cash      1,267,711     1,268         -          -      1,266,443       -
 Series M preferred stock issued upon
   conversion of notes payable                    50,000        50         -          -         49,950       -
 Common stock issued upon conversion of
   subordinated debt                                -         -         248,813        249      17,168       -
 Common stock issued upon settlement of
   accounts payable                                 -         -          13,100         13         904       -
 Common stock issued in connection with the
   acquisition of BioPhotonics, Inc.                -         -          85,000         85       5,866       -
 Series C preferred stock issued for cash      3,698,819     3,699         -          -      6,402,080       -
 Common stock issued in connection with the
   acquisition  of PBA Technology Limited           -         -       1,500,000      1,500     533,500       -
 Net loss                                           -         -            -          -           -          -
                                               ---------   -------    ---------   --------  ----------  ----------
BALANCE - DECEMBER 31, 1997                    5,429,699     5,430    2,125,448      2,126   9,225,877       -

 Series C preferred stock issued for cash        371,520       371         -          -        649,789       -
 Series D preferred stock issued for cash      1,100,000     1,100         -          -      6,681,539       -
 Common stock issued in exchange for software
   license                                          -         -          40,000         40      14,760       -
 Common stock issued in exchange for services       -         -             600       -          1,287       -
 Common stock issued upon exercise of
   stock options                                    -         -         753,330        753      61,980     47,250
 Foreign currency translation adjustment            -         -            -          -           -          -
 Net loss                                           -         -            -          -           -          -
                                               ---------   -------    ---------   --------  ----------  ----------
BALANCE - DECEMBER 31, 1998                    6,901,219   $ 6,901    2,919,378   $ 2,919  $16,525,232  $  47,250
                                               =========   =======    =========   ========  ==========  ==========

</TABLE>

<TABLE>
<CAPTION>
                                                               Cumulative
                                                 Accumulated   Translation
                                                  Deficit      Adjustment       Total
                                                ------------   -----------   ----------
<S>                                             <C>            <C>           <C>
BALANCE - DECEMBER 31, 1995                     $   (459,407)  $     -       $   40,593

 Common stock issued upon exercise of
   stock options                                        -            -            3,421
 Net loss                                         (1,599,632)        -       (1,599,632)
                                                ------------   -----------   ----------

BALANCE - DECEMBER 31, 1996                       (2,059,039)        -       (1,555,619)

 Common stock issued upon conversion of
   Series A preferred stock                             -            -             -
 Series B preferred and common stock issued
   upon conversion of notes payable                     -            -          427,238
 Series B preferred stock issued for cash               -            -        1,267,711
 Series M preferred stock issued upon
   conversion of notes payable                          -            -           50,000
 Common stock issued upon conversion of
   subordinated debt                                 644,643         -          662,060
 Common stock issued upon settlement of
   accounts payable                                   84,083         -           85,000
 Common stock issued in connection with the
   acquisition of BioPhotonics, Inc.                    -            -            5,950
 Series C preferred stock issued for cash               -            -        6,405,779
 Common stock issued in connection with the
   acquisition  of PBA Technology Limited               -            -          555,000
 Net loss                                         (2,619,285)        -       (2,619,285)
                                                ------------   -----------   ----------
BALANCE - DECEMBER 31, 1997                       (3,949,598)        -        5,283,835

 Series C preferred stock issued for cash               -            -          650,160
 Series D preferred stock issued for cash               -            -        6,582,639
 Common stock issued in exchange for software
   license                                              -            -           14,800
 Common stock issued in exchange for services           -            -            1,287
 Common stock issued upon exercise of
   stock options                                        -            -            5,483
 Foreign currency translation adjustment                -         104,838       104,838
 Net loss                                         (7,660,186)        -       (7,660,136)
                                                ------------   -----------   ----------
BALANCE - DECEMBER 31, 1998                     $(11,609,784)  $  104,838    $4,982,856
                                                ============   ===========   ==========
</TABLE>

The accompanying notes are an integral part of these consolidated statements.

                                      -4-

<PAGE>   87
                             GENOMIC SOLUTIONS INC.

                     CONSOLIDATED STATEMENTS OF CASH FLOWS

               FOR THE YEARS ENDED DECEMBER 31, 1998, 1997, 1996

<TABLE>
<CAPTION>
                                                                 1998           1997           1996
                                                             ------------   ------------   ------------
<S>                                                          <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss                                                   $(7,660,186)   $(2,619,285)   $(1,599,632)
  Adjustments to reconcile net loss to net cash
    used in operating activities-
    Depreciation and amortization                                622,108        216,405        340,160
    Acquisition-related and other non-recurring charges          340,000      2,205,756           -
    Extraordinary gain on forgiveness of debt                       -        (1,886,691)          -
    Common Stock issued in exchange for services                   1,287           -              -
    Increase (decrease) in cash resulting from
      changes in assets and liabilities, net of
      acquisitions-
        Accounts receivable                                     (36, 711)        114,497       474,523
        Inventories                                           (1,415,669)        133,868       (89,279)
        Prepaid expenses and other                              (534,237)        (25,437)       (9,215)
        Accounts payable                                       1,469,376        (130,053)       42,327
        Accrued liabilities                                       24,882         653,416       265,583
        Deferred revenue                                         (84,977)        (25,771)      (21,058)
                                                             -----------    ------------   -----------
           Net cash used in operating activities              (7,274,127)     (1,363,265)     (596,591)
                                                             -----------    ------------   -----------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Acquisitions of assets and stock of various companies       (2,607,092)       (659,066)         -
  Purchase of property and equipment                            (807,215)        (47,456)      (30,330)
  Increase in goodwill and intangible assets                     (73,248)           -             -
  Increase in other assets                                       (42,744)        (39,300)     (155,270)
                                                             -----------    ------------   -----------
           Net cash used in investing activities              (3,530,299)       (745,822)     (185,600)
                                                             -----------    ------------   -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from issuance of preferred stock                    7,232,799       7,673,490          -
  Net borrowings (repayments) under notes payable              7,482,454        (423,811)       43,811
  Proceeds from issuance of common stock                           5,483            -             -
  Repayment of long-term debt                                   (143,797)       (400,000)         -
  Proceeds from issuance of long-term debt                          -            130,000       670,000
                                                             -----------    ------------   -----------
           Net cash provided by financing activities           8,576,939       6,979,679       713,811
                                                             -----------    ------------   -----------

EFFECT OF EXCHANGE RATE CHANGES ON CASH                           18,537            -             -
                                                             -----------    ------------   -----------

NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS               (2,208,950)      4,870,592       (68,380)

CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR                  5,088,799         218,207       286,587
                                                             -----------    ------------   -----------

CASH AND CASH EQUIVALENTS - END OF YEAR                      $ 2,879,849    $  5,088,799   $   218,207
                                                             ===========    ============   ===========
</TABLE>

 The accompanying notes are an integral part of these consolidated statements.

                                      -5-
<PAGE>   88

                             GENOMIC SOLUTIONS INC.

                 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1) DESCRIPTION OF BUSINESS

    Genomic Solutions Inc. ("Genomic Solutions" or the "Company") designs,
         develops, manufactures and markets integrated, high-throughput biochip
         and proteomic systems and services for analyzing and quantifying
         biomolecules, such as DNA, RNA and proteins. The Company's biochip and
         proteomic systems include instrumentation, software, and consumables,
         which can be sold as integrated systems or as separate modular
         components. The Company's products are frequently used for building and
         maintaining DNA libraries, quantifying levels of gene expression, and
         characterizing proteins. Because the Company's products play a vital
         role in discovering genes and identifying drug targets, Genomic
         Solutions' customers are typically pharmaceutical, biotechnology and
         agriculture companies, universities, and government funded research
         institutions. In addition to selling products to customers, the Company
         also uses its equipment, software, consumables, and applications
         expertise to provide contract biochip and proteomic experimental
         services to researchers on a fee-for-service basis.

     The Company was incorporated in June 1994 under the name B.I. Systems
       Corporation. In July, 1994, the Company purchased certain assets,
       including software, inventory and fixed assets, from the Bio Image
       business unit ("Bio Image") of Millipore Corporation ("Millipore"). On
       December 5, 1997, the Company formed Genomic Solutions Inc. On December
       24, 1997, the Company merged with B.I. Systems Corporation, with Genomic
       Solutions being the surviving entity.

     As of December 31, 1998, the Company has operations in the United States,
       Japan and United Kingdom. Genomic Solutions K.K. is a wholly owned
       subsidiary of the Company located in Tokyo, Japan, and operates a sales
       and technical support office serving Japan. Effective December 31, 1997,
       the Company acquired all outstanding stock of PBA Technology Limited (a
       UK corporation, "PBA", see Note 12) which subsequently changed its name
       to Genomic Solutions Limited ("GSLtd").

     The Company is in the early phases of implementing its operating strategy
       and its future success is subject to several technical and business risks
       including customer acceptance, availability and retention of key
       employees, competition, technological changes and additional financing
       adequate to support operations.

(2) SIGNIFICANT ACCOUNTING POLICIES

      Principles of Consolidation

        The consolidated financial statements include the accounts of the
          Company and its subsidiaries, Genomic Solutions K.K. and Genomic
          Solutions Limited. All significant intercompany balances and
          transactions have been eliminated in consolidation.

                                      -6-
<PAGE>   89

                            GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

Revenue

     Revenue consists of product sales, consisting of instrumentation, hardware,
       consumables, software, and services which include revenue from software
       and service maintenance agreements. Revenue from product sales, including
       revenues generated through distributors, is recognized when a customer
       contract is fully executed and product is shipped. Revenue from software
       and service maintenance agreements is recognized on a straight-line basis
       over the period in which the services are provided.

Research and Development Expenses

     Research and development expenses include all employee payroll and related
       costs attributable to research and development activities.

Foreign Currency Translation

    The financial statements of foreign subsidiaries are translated using
       exchange rates in effect at period end for assets and liabilities and at
       average rates during the period for results of operations. The resulting
       foreign currency translation adjustments are reflected as a separate
       component of stockholders' equity. Foreign currency transaction losses
       resulting from sales in foreign denominated currencies totaled
       approximately $11,000, $40,000 and $96,300 in 1998, 1997, and 1996,
       respectively, and are included in other expense in the accompanying
       consolidated statements of operations.

Management Estimates

     The preparation of financial statements in conformity with generally
       accepted accounting principles requires management to make estimates and
       assumptions that affect the reported amounts of assets and liabilities
       and disclosure of contingent assets and liabilities at the date of the
       financial statements and the reported amounts of revenues and expenses
       during the reporting period. Actual results could differ from those
       estimates.

Cash and Cash Equivalents

     The Company considers all highly liquid investments with a maturity of
       three months or less to be cash equivalents.

Accounts Receivable

     As of December 31, 1998, accounts receivable are stated net of an
       allowance for doubtful accounts of approximately $73,000. there was no
       such allowance as of December 31, 1997.

                                       -7-

<PAGE>   90

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCING STATEMENTS
                                   (Continued)

Inventories

     Inventories consist primarily of purchased parts and components and are
       stated at the lower of cost, as determined on a first-in, first-out
       basis, or market.

Property and Equipment

     Property and equipment are recorded at cost. Depreciation is provided on a
       straight-line basis over the estimated useful lives of the related assets
       which generally range from three to five years. As of December 31,
       property and equipment consists of the following:

<TABLE>
<CAPTION>
                                                          1998              1997
                                                       ----------         --------
<S>                                                    <C>                <C>
        Furniture and office equipment                 $1,611,938         $555,182
        Computer equipment                                753,603          206,447
                                                       ----------         --------
                                                        2,365,541          761,629
        Less- Accumulated depreciation                    756,092          421,228
                                                       ----------         --------
                                                       $1,609,449         $340,401
                                                       ==========         ========
</TABLE>

Goodwill and Intangible Assets

     Certain goodwill and intangible assets arose from the acquisitions
       completed by the Company in 1998 and 1997 (see Note 12) and in prior
       years. These amounts are being amortized on a straight-line basis over
       periods ranging from five to ten years. As of December 31, 1998 and 1997,
       accumulated amortization totaled $340,000 and $13,000, respectively.
       Amortization expense totaled approximately $327,300, $56,000 and $118,000
       in 1998, 1997 and 1996, respectively, exclusive of the write-down
       discussed below.

     At each balance sheet date, the Company evaluates the carrying value of
       goodwill and other long-lived assets for impairment whenever events or
       changes in circumstances indicate that the carrying value may not be
       recoverable. In 1997, as a result of this evaluation, the Company
       wrote-down approximately $861,000 of goodwill and other intangible assets
       that originated from the acquisition of Bio Image from Millipore (see
       Note 1). These write-downs are included in acquisition-related and other
       non-recurring charges in the accompanying consolidated statements of
       operations.

                                      -8-

<PAGE>   91

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

Capitalized Software Development Costs

     The Company accounts for software development costs in accordance with
       Statement of Financial Accounting Standards ("SFAS") No. 86. Under SFAS
       No. 86, capitalization of software development costs begins upon the
       establishment of technological feasibility. The establishment of
       technological feasibility and the ongoing assessment of the
       recoverability of these costs require considerable judgment by management
       with respect to certain external factors, including, but not limited to,
       anticipated future gross product revenue, estimated economic product
       lives and changes in software and hardware technology. In 1998, amounts
       that would have been capitalized under this statement after consideration
       of the above factors were immaterial, and therefore no software
       development costs have been capitalized by the Company.

     In 1997, the Company wrote-off capitalized software development costs
       totaling approximately $328,000 as it was determined that certain
       products had no remaining economic life. This write-down is included in
       the acquisition-related and other non-recurring charges in the
       accompanying consolidated statement of operations. Amortization expense
       totaled $47,000 and $76,000 in 1997 and 1996, respectively, exclusive of
       the write-down.

Stock-Based Compensation

     The Company accounts for stock-based compensation using the intrinsic value
       method prescribed under Accounting Principles Board Opinion ("APB") No.
       25, "Accounting for Stock Issued to Employees." Accordingly, compensation
       cost for stock options is measured as the excess, if any, of the fair
       value of the Company's common stock at the date of the grant over the
       amount the employee must pay to acquire the stock. As supplemental
       information, the Company has provided pro forma disclosure of the fair
       value at the date of grant of stock options granted for each period
       presented in Note 9, in accordance with the requirements of SFAS No. 123,
       "Accounting for Stock-Based Compensation."

Fair Value of Financial Instruments

     In accordance with the requirements of SFAS No. 107, "Disclosures About
       Fair Value of Financial Instruments," the fair value of financial
       instruments is determined by reference to various market data for
       comparable financial instruments. Management's estimates of fair value
       require considerable judgment and are not necessarily indicative of the
       amounts that could be realized in a current market exchange. Unless
       otherwise disclosed, the fair value of financial instruments approximate
       their recorded values.

                                      -9-

<PAGE>   92

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

     Comprehensive Income

       Effective January 1, 1998, the Company adopted SFAS No. 130, "Reporting
         Comprehensive Income," which establishes standards for reporting and
         display of comprehensive income and its components in a full set of
         financial statements. Comprehensive income is the total of net income
         and all other non-owner changes in equity. The difference between net
         loss, as reported in the accompanying consolidated statements of
         operations, and comprehensive loss is the foreign currency translation
         adjustment for the respective periods. Accumulated other comprehensive
         income consists solely of the cumulative translation adjustment as
         presented in the accompanying consolidated balance sheets.

     New Accounting Pronouncements

       In June 1998, the Financial Accounting Standards Board issued SFAS No.
         133, "Accounting for Derivative Instruments and Hedging Activities,"
         which establishes accounting and reporting standards for derivative
         instruments. The Company does not currently engage in derivative
         activities.

(3) NOTES PAYABLE

       In August 1998, the Company entered into a new $2,000,000 line-of-credit
         agreement with a bank which provides for borrowings through July 1999.
         As of December 31, 1998, outstanding borrowings under this agreement
         totaled $1,750,000 and bear interest at the bank's prime interest rate
         (7.75% as of December 31, 1998). The agreement contains various
         covenants, including financial covenants which require the Company to
         maintain certain levels of working capital and tangible net worth.

       As of December 31, 1998, GSLtd. had line-of-credit agreements with a
         bank whereby GSLtd. may borrow up to $324,000. Outstanding borrowings
         bear interest at 10% and are collateralized by a letter of credit
         issued by the Company and eligible accounts receivable, as defined. As
         of December 31, 1998, outstanding borrowings totaled $230,822. The
         agreements expire at various dates through August 1999.

                                      -10-

<PAGE>   93

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (CONTINUED)

(4) LONG-TERM DEBT

     As of December 31, long-term debt consists of the following:

<TABLE>
<CAPTION>
                                                           1998               1997
                                                         --------           --------
<S>                                                      <C>                <C>
       Note payable by PBA, payable in monthly
         installments of approximately $6,900, plus
         interest at 10%, through November 2000          $159,341           $239,560
       Note payable by PBA, payable in monthly
         installments of approximately $4,600, plus
         interest at 10%, through January 2001            115,481            164,270
       Capital lease obligations, due in varying
         amounts with interest rates ranging from
         6.2% to 21%, through October 2002 (see
         Note 10)                                         563,381                  -
                                                         --------           --------
                                                          838,203            403,830
       Less- Current portion                              300,941            136,891
                                                         --------           --------
                                                         $537,262           $266,939
                                                         ========           ========
</TABLE>

     Scheduled future maturities of long-term debt, excluding capital lease
       obligations (see Note 10), as of December 31, 1998, are as follows:

<TABLE>
<S>                                                  <C>
                   1999                              $138,566
                   2000                               131,649
                   2001                                 4,607
                                                     --------
                                                     $274,822
                                                     ========
</TABLE>

(5) INCOME TAXES

      The components of the provision (credit) for income taxes are as follows:

<TABLE>
<CAPTION>
                                                 1998         1997          1996
                                             -----------   -----------   -----------
<S>                                          <C>           <C>           <C>
      Continuing operations:
        Currently payable (refundable)       $      -      $  (889,200)  $     5,685
        Deferred credit                       (2,432,000)     (241,800)     (492,400)
        Increase in valuation allowance        2,432,000       241,800       492,400
                                             -----------   -----------   -----------
                                                    -         (889,200)        5,685
      Extraordinary gain-
        Tax expense of gain on
          forgiveness of debt                       -          889,200          -
                                             -----------   -----------   -----------
                                             $      -      $      -      $     5,685
                                             ===========   ===========   ===========
</TABLE>

                                      -11-

<PAGE>   94
                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (CONTINUED)

The differences between the income tax provision calculated at the United
     States Federal statutory rate and the consolidated income tax provision
     from continuing operations are summarized as follows:

<TABLE>
<CAPTION>
                                              1998               1997            1996
                                              ----               ----            ----
<S>                                      <C>                <C>               <C>
     Federal statutory provision         $ (2,604,500)      $ (1,473,300)     $ (542,000)
     Nondeductible items                       34,000             16,000          49,600
     Increase in valuation allowance        2,432,000            321,900         492,400
     Write-off of acquired in-process
        research and development              115,600            285,600               -
     Other                                     22,900            (39,400)          5,685
                                         ------------       ------------      ----------
                                         $          -       $   (889,200)     $    5,685
                                         ============       ============      ==========
</TABLE>

The components of deferred income taxes as of December 31 are as follows:

<TABLE>
<CAPTION>
                                                1998                1997
                                                ----                ----
<S>                                         <C>                  <C>
     Net operating loss carryforwards       $ 2,939,700          $ 647,500
     Intangible assets                          210,800            242,000
     Goodwill                                   115,000             45,100
     Accruals and reserves                      101,100                  -
                                            -----------          ---------
                                              3,366,600            934,600
     Less-valuation allowance                (3,366,600)          (934,600)
                                            -----------          ---------
                                            $         -          $       -
                                            ===========          =========
</TABLE>

The Company has available net operating loss carryforwards of approximately
     $8,650,000 which can be utilized to offset future taxable income. These net
     operating loss carryforwards expire between 2010 and 2018. Additionally,
     utilization of net operating loss carryforwards are limited under Section
     382 of the Internal Revenue Code. These and other deferred income tax
     assets are fully reserved by a valuation allowance as realizability of
     these tax benefits is not assured.

                                      -12-
<PAGE>   95

                             GENOMIC SOLUTIONS INC.

                NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

(6)  RECAPITALIZATION

     In April 1997, the Company amended its Articles of Incorporation pursuant
          to which the majority of the Company's outstanding debt and all
          outstanding shares of Series A preferred stock were restructured (the
          "Recapitalization"). Significant components of the Recapitalization,
          together with the applicable accounting effects, were as follows:

          (1) The Company initiated a reverse stock split issuing one share of
               common stock for every 97.103 shares of outstanding common
               stock. All amounts and shares in the accompanying financial
               statements have been restated to reflect the reverse stock split.

          (2) Notes payable, bridge loan financing obtained during 1997 and
               accrued interest totaling $413,169 were converted to 413,169
               shares of Series B preferred stock at $1 per share. The Company
               also issued 200,986 shares of common stock to these creditors.

          (3) The Company issued 1,267,711 shares of Series B preferred stock
               at $1 per share for cash.

          (4) All outstanding shares of Series A preferred stock were converted
               to 45,821 shares of common stock.

          (5) Subordinated convertible debt of $1,200,000 and accrued interest
               of $429,027, payable to both stockholders (defined as
               stockholders with greater than 10% ownership interest) and
               non-stockholders, was converted to 248,813 shares of common stock
               at $0.07 per share. The difference between the carrying value of
               the debt and the fair value of the common stock issued to
               existing stockholders of $644,643 has been credited directly to
               retained earnings. The difference between the carrying value of
               the debt and the fair value of the common stock issued to
               non-stockholders of $966,967 is included in extraordinary gain in
               the accompanying consolidated statements of operations.

          (6) Accounts payable to stockholders for professional services
               rendered totaling $85,000 was converted to 13,100 shares of
               common stock at $0.07 per share. The difference, in the amount
               of $84,083, between the fair value of the common stock and
               amounts owed to these stockholders has been credited directly to
               retained earnings.

          (7) A note payable to Millipore and accrued interest totaling
               $983,764 was converted to 50,000 shares of Series M preferred
               stock at $1 per share. The difference, in the amount of $933,764,
               between the carrying value of the debt and the fair value of the
               common stock is included in extraordinary gain in the
               accompanying consolidated statements of operations.

                                      -13-
<PAGE>   96

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

(7)  PREFERRED STOCK

          Preferred stock consists of the following as of December 31:

<TABLE>
<CAPTION>
                                        1998                               1997
                           -----------------------------        -------------------------
                                              Issued and                       Issued and
                           Authorized        Outstanding        Authorized    Outstanding
                           ----------        -----------        ----------    -----------
<S>                        <C>               <C>                <C>           <C>
               Series A             -                  -                 -              -
               Series B     2,000,000          1,680,880         2,000,000      1,680,880
               Series C     4,070,339          4,070,339         4,070,339      3,698,819
               Series D     1,100,000          1,100,000                 -              -
               Series M        50,000             50,000            50,000         50,000
                            ---------          ---------         ---------      ---------
                            7,220,339          6,901,219         6,120,339      5,429,699
                            =========          =========         =========      =========
</TABLE>

          In May 1998, the Company authorized 1,100,000 shares of Series D
               convertible preferred stock for issuance. In December 1997, the
               Company authorized 4,070,339 shares of Series C convertible
               preferred stock for issuance.

          The various classes of preferred stock provide the following rights,
               preferences, privileges and restrictions:

          Dividends

          The holders of shares of Series B,C,D and M preferred stock are not
               entitled to receive any dividends.

          Conversion

          Each shares of Series B,C,D and M preferred stock shall be
               convertible, at the holder's option, into such number of common
               shares as is determined by dividing the original Series B,C,D
               and M issue prices by $0.33, $1.75, $6.00, and $1.111,
               respectively. These conversion factors are subject to adjustment
               upon any recapitalization of the Company's common stock, as
               defined, and to anti-dilution rights for certain issuances.

          Conversion of Series B,C,D and M preferred stock to the Company's
               common stock will occur automatically upon the consummation of
               the sale of common stock in a registration statement in
               connection with an initial public offering, as defined.

          Voting Rights

          The holders of Series B,C and D preferred stock have the right to one
               vote for each share of common stock into which such Series B,C
               and D preferred stock could then be converted. The holders of
               Series M preferred stock have no voting rights.

                                      -14-

<PAGE>   97

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

          Liquidation Preference

          In the event of any liquidation, dissolution or winding up of the
               affairs of the Company, either voluntarily or involuntarily, the
               holders of Series B,C,D and M preferred stock are entitled to
               receive, prior to and in preference to any distributions to the
               holders of common stock, an amount initially equal to $1, $1.75,
               $6, and $6, per share, respectively, subject to adjustment upon
               any recapitalization of the Company's common stock, as defined.
               The holders of Series B preferred stock are also entitled to
               receive, prior to and in preference to any distributions to the
               holders of common stock, an amount per share equal to 8% of the
               original issuance price of Series B preferred stock.

(8)  COMMON STOCK

          As of December 31, 1998 and 1997, the Company had authorized
               40,000,000 shares of common stock for issuance. The Company has
               reserved for issuance such number of shares of its authorized but
               unissued common stock necessary to effect conversion of all
               outstanding shares of preferred stock and exercise of all
               outstanding stock options.

(9)  STOCK OPTION PLANS

          The Company has three stock option plans: The 1994 Stock Option Plan
               ("the 1994 Plan"); the 1998 Employee Stock Option Plan ("the 1998
               Plan"); and the 1998 Non-Employee Director and Consultant Stock
               Option Plan (the "Non-Employee Plan"). Options granted under all
               plans are either incentive stock options, which are granted at
               the fair market value of the common stock on the date of grant,
               or nonqualified stock options, which are generally granted at the
               fair market value of the common stock on the date of grant.
               Options are granted at the discretion of the Board of Directors
               upon recommendation by the Compensation Committee and expire ten
               years after the date of grant.

          1994 Stock Option Plan

          The 1994 Plan provided for the grant of options to employees,
               consultants and directors. The maximum number of shares that may
               be granted under the 1994 Plan is 1,590,000. Options granted
               generally become exercisable at a rate of 33% per year over three
               years from the date of grant except that 540,000 options vested
               immediately upon issuance and 14,600 options vest over a
               five-year period.

          1998 Employee Stock Option Plan

           In January 1998, the Company established the 1998 Plan to increase
               its ability to attract and retain key employees. The maximum
               number of shares that may be granted under the Plan is 2,000,000.
               Options granted generally become exercisable at a rate of 20% per
               year over five years from the date of grant.

                                 -15-

<PAGE>   98

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

     1998 Non-Employee Director and Consultant Stock Option Plan

         In January 1998, the Company established the Non-Employee Plan to
               increase its abi1ity to retain consultants and directors. The
               maximum number of shares that may be granted under the Plan is
               300,000. Options granted generally become exercisable one year
               from date of grant except that 60,000 options vested immediately
               upon issuance.

     Summary of All Plans

         Stock option activity under all of the above plans is summarized below:
<TABLE>
<CAPTION>
                                                                        Weighted
                                                                         Average
                                                      Number of         Exercise
                                                       Shares             Price
                                                       ------             -----
<S>                                                 <C>                 <C>
      Outstanding at December 31, 1995                   7, 407          $0.072
         Options granted                                      -
         Options cancelled                                    -
         Options exercised                                 (447)         $0.072
                                                    -----------
      Outstanding at December 31, 1996                    6,960          $0.072
         Options granted                              1,582,100          $ 0.07
         Options cancelled                               (6,960)         $0.072
         Options exercised                                    -
                                                    -----------
      Outstanding at December 31, 1997                1,582,100          $ 0.07
         Options granted                             1, 224,000          $ 1.15
         Options cancelled                             (123,834)         $ 1.02
         Options exercised                             (753,330)         $ 0.07
                                                    -----------
      Outstanding at December 31, 1998                1,928,936          $ 0.69
                                                    ===========
      Exercisable at December 31, 1998                  721,245
                                                    ===========

</TABLE>

<TABLE>
<CAPTION>
                                          Weighted
                                           Average
                                         Contractual
              Number of      Price        Remaining
               Shares       Per Share        Life    Exercisable
               ------       ---------        ----    -----------
             <S>            <C>          <C>         <C>
               785,436        $0.07       8.4 Years     424,035
               618,500        $0.37       9.1 Years     154,963
               525,000        $2.00       9.4 Years     142,247
             ---------                                 --------
             1,928,936                                  721,245
             =========                                 ========
</TABLE>

                                      -16-
<PAGE>   99

                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

          Using the intrinsic value method under APB 25, no compensation expense
               has been recognized in the accompanying consolidated statements
               of operations for options granted at fair value. Had compensation
               expense been determined based on the fair value at the date of
               grant consistent with SFAS No. 123, the reported net loss would
               have been increased to the following pro forma amounts, which
               may not be representative of that to be expected in future years:

<TABLE>
<CAPTION>
                             1998            1997              1996
                             ----            ----              ----
<S>                      <C>             <C>               <C>
Net Loss-  As Recorded   $(7,660,186)    $ (2,619,285)     $ (1,599,632)
           Pro Forma      (7,724,855)      (2,621,134)       (1,599,979)
</TABLE>

          The fair value of these options was estimated at the date of grant
               using the minimum value option valuation method under SFAS 123
               with the following assumptions: weighted average risk free
               interest rate ranging from 5.82%; dividend yield of 0%; and
               expected life of options of 3 years. Option valuation models
               require the input of highly subjective assumption. Because
               changes in subjective input assumptions can materially affect the
               fair value estimate, in management's opinion, the existing model
               does not necessarily provide a reliable single measure of the
               fair value of the Company's stock options.

(10) EMPLOYEE BENEFIT PLAN

          The Company has a 4019k) plan covering all eligible employees.
               Participants may elect to defer a certain percentage of qualified
               compensation through voluntary contributions to the plan and the
               Company may make discretionary contributions to the plan based on
               the gross compensation of qualified participants. The Company
               made no contributions to the plan in the 1998, 1997 and 1996.

(11) LEASES

          The Company leases most of its office space, transportation, and
               laboratory and office equipment under various noncancelable
               capital and operating lease agreements. Initial leases vary in
               length and several of the leases contain renewal options. The
               Company leases certain equipment under long-term lease agreements
               that are classified as capital leases, and the leased assets are
               included in property and equipment in the accompanying
               consolidated balance sheets. These capital leases terminate at
               various dates through fiscal 2002. Other leases are classified as
               operating leases and are not capitalized.

<PAGE>   100
                             GENOMIC SOLUTIONS INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

       Future minimum payments required under all noncancelable capital and
         operating leases are as follows:

<TABLE>
<CAPTION>

                                                                          Operating           Capital
                                                         Total              Leases             Leases
                                                       ----------         ----------          --------
<S>                                                    <C>                <C>                 <C>
1999                                                   $  613,400         $  414,600          $198,800
2000                                                      541,600            349,300           192,300
2001                                                      455,800            285,400           170,400
2002                                                      373,700            293,600            80,100
2003                                                       70,300             70,300                 -
                                                       ----------         ----------          --------
                                                       $2,054,800         $1,413,200           641,600
                                                       ==========         ==========
Less- Amount representing
         interest                                                                               78,219
                                                                                               -------
                                                                                               563,381
Less-Current portion                                                                           162,375
                                                                                              --------
                                                                                              $401,006
                                                                                              ========
</TABLE>

       Total rental expense was approximately $425,000, $92,000 and $72,000 in
         1998, 1997 and 1996, respectively.

(12) ACQUISITIONS

       Electrophoresis Business from ESA, Inc.

         In October 1998, the Company acquired the gel electrophoresis and
           proteomic business of ESA, Inc. in exchange for approximately
           $1,750,000 in cash and a warrant to purchase 125,000 shares of common
           stock at an exercise price of $6.00 per share. The acquisition has
           been accounted for under the purchase method of accounting. In
           connection with the acquisition, the Company recorded a one-time
           charge to operations in 1998 of $340,000, associated with the
           write-off of in-process research and development acquired in the
           transaction that had not reached technological feasibility. The
           remaining excess of the aggregate purchase price over the fair value
           of the net assets acquired of approximately $906,000 has been
           recognized as goodwill and is being amortized over a seven-year
           period (See Note 2).

                                      -18-

<PAGE>   101

                               GENOMIC SOLUTIONS

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Continued)

       Insight Bio Medical, Inc.

         In April 1998, the Company acquired certain assets of Insight
           Biomedical Imaging Inc., in exchange for $650,000 in cash. The
           acquisition has been accounted for under the purchase method of
           accounting. The excess of the purchase price over the fair value of
           the net assets acquired of approximately $611,000 has been recognized
           as goodwill and is being amortized over a five-year period
           (see Note 2).

       PBA Technology Limited

         Effective December 31, 1997, the Company acquired 100% of the
           outstanding capital stock of PBA Technology Limited in exchange for
           $150,480 in cash and 1,500,000 shares of the Company's common stock
           valued at $555,000, for an aggregate purchase price of $705,480. The
           acquisition has been accounted for under the purchase method of
           accounting. In connection with the acquisition, the Company recorded
           a one-time charge to operations in 1997 of $1,017,000, associated
           with the write-off of in-process research and development acquired in
           the transaction that had not reached technological feasibility. The
           remaining excess of the aggregate purchase price over the fair value
           of the net assets acquired of approximately $230,000 has been
           recognized as goodwill and is being amortized over a five-year
           period (See Note 2).

       BioPhotonics, Inc.

         In June 1997, the Company acquired substantially all assets of
           BioPhotonics, Inc. in exchange for $302,300 in cash and 85,000 shares
           of common stock valued at $5,950. The acquisition has been accounted
           for under the purchase method of accounting. The excess of the
           purchase price over the fair value of the net assets acquired of
           approximately $126,000 has been recognized as goodwill as is being
           amortized over a five-year period (see Note 2).

(13) SUBSEQUENT EVENT

       On April 23, 1999, the Company issued subordinate debentures with
         warrants. The subordinated debentures are evidenced by promissory notes
         which in aggregate total $6,000,000, together with 1,400,000 warrants
         to purchase the Company's common stock. The notes are due April 2004
         and bear interest at an annual rate of 12% to be paid quarterly.

       While the Company is in the early stages of implementing its operating
         plan (see Note 1), management believes that this financing, along with
         other sources of credit, will provide adequate liquidity for its
         current year.

                                      -19-
<PAGE>   102

                                 SCHEDULE 7.i.2

                         1998 CONSOLIDATING FINANCIALS
                              As of December 1998

<TABLE>
<CAPTION>

                                                                                                         Post
                                            12/31/98       US GAAP         12/31/98       12/31/98       12/31/98       12/31/98
                                               PBA        Adjustment      GS Ltd (UK)        GSl         Adjust's     GS Inc. (USA)
                                           ----------------------------------------------------------------------------------------
<S>                                      <C>            <C>            <C>            <C>            <C>            <C>
BALANCE SHEET
ASSETS
Current Assets
   Cash and Cash Equivalents               $          -   $          -   $          -   $  2,659,122   $          -   $  2,659,122
   Accounts Receivable                          186,126              -        186,126        773,905              -        773,905
   Allowance for Doubtful Accounts                    -              -              -        (73,479)             -        (73,479)
                                           ----------------------------------------------------------------------------------------
   Accounts Receivable, net                     186,126              -        186,126        700,426              -        700,426
   Intercompany receivables                     357,183              -        357,183        160,173              -        160,173
   Inventory                                  1,063,234              -      1,063,234      1,780,904                     1,780,904
   Inventory reserve                                  -              -              -        (60,000)                      (60,000)
                                           ----------------------------------------------------------------------------------------
   Inventories, net                           1,063,234              -      1,063,234      1,720,904              -      1,720,904
   Prepaid expenses                             152,580                       152,580        112,967                       112,967
   Other                                         75,889        231,565        307,454         58,685              -         58,685
                                           ----------------------------------------------------------------------------------------
         Total current Assets                 1,835,011        231,565      2,066,576      5,412,277              -      5,412,277

Property and equipment, cost                    662,052                       682,052      1,775,832                     1,775,832
   Accumulated depreciation                    (247,707)                     (247,707)      (510,723)                     (510,723)
                                           ----------------------------------------------------------------------------------------
   Property & equipment, net                    414,345              -        414,345      1,265,109              -      1,265,109
Note Receivable - intercompany                                                      -      2,910,371                     2,910,371
Investment in HD Technologies                   152,152          5,040        157,192                                            -
Investment in KK                                                                    -         72,059                        72,059
Investment in PBA                                     -                             -        705,480                       705,480
PBA Acquisition Costs                                                               -        165,029                       165,029
Other intangibles (Goodwill)                    153,814       (153,814)             -      1,393,819                     1,393,819
Other long term assets                                -                             -         44,683                        44,683
                                           ----------------------------------------------------------------------------------------
Total Assets                               $  2,555,322   $     82,791   $  2,638,113   $ 11,968,827   $          -   $ 11,968,827
                                           ========================================================================================

LIABILITIES & STOCKHOLDERS EQUITY
Current Liabilities
    Notes Payable - Bank Overdraft         $    230,822   $              $    230,822   $  1,750,000   $          -   $  1,750,000
    Current Portion SFLG loan                   138,568         (4,299)       134,267
    Current Portion Finance Leases               23,406                        23,406                                            -
    Current Portion Transamerica                      -                             -        143,268                       143,268
    Accounts Payable                            921,002              -        921,002        990,439                       990,439
    Intercompany Payables                       346,988              -        346,998        348,997                       348,997
    Accrued Warranty                                                                -        202,000                       202,000
    Taxes Payable                                36,066                        36,066          6,063                         6,063
    VAT Liability                              (231,565)       231,565              0                                            -
    Accrued Liabilities                         105,839              -        105,839        751,024         (2,700)       748,324
    Directors Loan Accounts                           -                             -                                            -
    Deferred Revenue                                            67,856         67,856        126,221                       126,221
                                           ----------------------------------------------------------------------------------------
         Total Current Liabilities            1,571,123        295,122      1,866,245      4,318,012         (2,700)     4,315,312

Long Term Liabilities
    LTD - SFLG loan                             136,256          4,299        140,555                                            -
    LTD - Finance Leases                         12,689                        12,689                                            -
    LTD - Transamerica                                -                             -        384,018                       384,018
    LTD - Intercompany                        2,456,508                     2,456,508                                            -
    Other Long Term Liabilities                                                     -         23,540                        23,540
                                           ----------------------------------------------------------------------------------------
         Total Long Term Liabilities          2,605,453         4,299       2,609,752        407,558             -         407,558
                                           ----------------------------------------------------------------------------------------
    Total Liabilities                         4,176,576       299,421       4,475,997      4,725,570        (2,700)      4,722,870

Stockholders' equity
    Preferred Stock                                                                 -          6,901                         6,901
    Common Stock                                                                    -          2,919             -           2,919
    Add'l Paid in Capital                                                           -     16,525,232             -      16,525,232
    Share capital                             1,121,440                     1,121,440                                            -
    Beginning Retained Earnings              (1,197,068)    (259,152)      (1,456,220)    (3,182,956)                   (3,182,956)
    Current Year PA                          (1,532,574)      43,264       (1,489,310)    (6,060,225)            -      (6,060,225)
                                           ----------------------------------------------------------------------------------------
    Ending Retained earnings                 (2,729,643)    (215,888)      (2,945,531)    (9,243,181)            -      (9,243,181)
    Notes Receivable                                                                         (49,950)        2,700         (47,250)
    Cumulative Translation Adjustment           (13,051)        (742)         (13,793)         1,336                         1,336
                                           ----------------------------------------------------------------------------------------
    Total Stockholders Equity                (1,621,253)    (216,630)      (1,837,884)     7,243,257         2,700       7,245,957
                                           ----------------------------------------------------------------------------------------
Total Liabilities and Stockholders Equity  $  2,555,323   $   82,790     $  2,638,113   $ 11,968,827   $         -    $ 11,968,827
                                           ========================================================================================
      Assets = Liability + Equity          $         (0)  $        0     $         (0)  $          -   $         -    $          -
</TABLE>

<TABLE>
<CAPTION>

                                                                                         Investment
                                              12/31/98       12/31/98                    & Interco.        TOTAL
                                            Japan (K.K.)     Nihon BI       COMBINED     Elimination    CONSOLIDATED
                                           -------------------------------------------------------------------------
<S>                                      <C>            <C>            <C>            <C>            <C>
BALANCE SHEET
ASSETS
Current Assets
   Cash and Cash Equivalents               $     77,654   $  143,163     $  2,879,849   $          -  $  2,879,849
   Accounts Receivable                          475,069                     1,435,100                    1,435,100
   Allowance for Doubtful Accounts                    -                       (73,479)                     (73,479)
                                           -------------------------------------------------------------------------
   Accounts Receivable, net                     475,069            -        1,361,621              -     1,361,621
   Intercompany receivables                     105,440      262,852          885,648       (885,648)            -
   Inventory                                    178,761                     3,022,899       (105,940)    2,916,959
   Inventory reserve                                                          (60,000)                     (60,000)
                                           -------------------------------------------------------------------------
   Inventories, net                             178,761            -        2,962,899       (105,940)    2,856,959
   Prepaid expenses                                 846                       266,393                      266,393
   Other                                         31,311                       397,450                      397,450
                                           -------------------------------------------------------------------------
         Total current Assets                   868,991      406,015        8,753,859       (991,588)    7,762,271
                                                                                                                 -
Property and equipment, cost                      1,662                     2,439,546        (74,005)    2,365,541
   Accumulated depreciation                        (323)                     (758,753)         2,661      (756,092)
                                           -------------------------------------------------------------------------
   Property & equipment, net                      1,339            -        1,680,793        (71,344)    1,609,449
Note Receivable - intercompany                                              2,910,371     (2,910,371)            -
Investment in HD Technologies                                                 157,192                      157,192
Investment in KK                                                               72,059        (72,059)            -
Investment in PBA                                                             705,480       (705,480)            -
PBA Acquisition Costs                                                         165,029                      165,029
Other intangibles (Goodwill)                                                1,393,819         18,616     1,412,435
Other long term assets                           40,343                        85,026                       85,026
                                           -------------------------------------------------------------------------
Total Assets                               $    910,673   $  406,015     $ 15,923,628   $ (4,732,226) $ 11,191,402
                                           =========================================================================

LIABILITIES & STOCKHOLDERS EQUITY
Current Liabilities
    Notes Payable - Bank Overdraft                        $              $  1,980,822   $          -  $  1,980,822
    Current Portion SFLG loan                                                 134,267                      134,267
    Current Portion Finance Leases                                             23,406                       23,406
    Current Portion Transamerica                                              143,268                      143,268
    Accounts Payable                             50,624                     1,962,065                    1,962,065
    Intercompany Payables                       189,712                       885,697       (885,697)            -
    Accrued Warranty                             18,571                       220,571                      220,571
    Taxes Payable                                33,674            -           75,803                       75,803
    VAT Liability                                                                   0                            0
    Accrued Liabilities                           6,089       53,164          913,416             50       913,466
    Directors Loan Accounts                                                         -                            -
    Deferred Revenue                                                          194,077                      194,077
                                           -------------------------------------------------------------------------
         Total Current Liabilities              298,670       53,164        6,533,391       (885,647)    5,647,744

Long Term Liabilities
    LTD - SFLG loan                                                           140,555                      140,555
    LTD - Finance Leases                                                       12,689                       12,689
    LTD - Transamerica                                                        384,018                      384,018
    LTD - Intercompany                          453,864                     2,910,372     (2,910,372)            -
    Other Long Term Liabilities                                                23,540                       23,540
                                           -------------------------------------------------------------------------
         Total Long Term Liabilities            453,864            -        3,471,174     (2,910,372)      560,802
                                           -------------------------------------------------------------------------
    Total Liabilities                           752,534       53,164       10,004,565     (3,796,019)    6,208,546

Stockholders' equity
    Preferred Stock                                                             6,901                        6,901
    Common Stock                                     72                         2,991            (72)        2,919
    Add'l Paid in Capital                        71,987                    16,597,219        (71,987)   16,525,232
    Share capital                                                           1,121,440     (1,121,440)            -
    Beginning Retained Earnings                       -      250,358       (4,388,818)       439,220    (3,949,598)
    Current Year PA                             (31,215)     102,493       (7,478,257)      (181,929)   (7,660,186)
                                           -------------------------------------------------------------------------
    Ending Retained earnings                    (31,215)     352,851      (11,867,076)       257,291   (11,609,784)
    Notes Receivable                                                          (47,250)                     (47,250)
    Cumulative Translation Adjustment           117,295            -          104,838                      104,838
                                           -------------------------------------------------------------------------
    Total Stockholders Equity                   158,139      352,851        5,919,064       (936,208)    4,982,856
                                           -------------------------------------------------------------------------
Total Liabilities and Stockholders Equity  $    910,673   $  406,015     $ 15,923,628   $ (4,732,226) $ 11,191,402
                                           =========================================================================

Assets = Liability + Equity                $         (0)  $        -     $         (0)  $          0  $          0
</TABLE>

<PAGE>   103

                                 SCHEDULE 7.i.3

                             GENOMIC SOLUTIONS INC.

INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS:

SCHEDULE          DESCRIPTION
--------          -----------

7.i.3.a           Consolidated Statement Of Operations For The Two Months Ended
                  February 28, 1999.

7.i.3.b           Consolidated Statement Of Cash Flows For The Two Months Ended
                  February 28, 1999

7.i.3.c           Consolidated Balance Sheet As Of February 28, 1999.

<PAGE>   104

                                SCHEDULE 7.i.3.a

                             GENOMIC SOLUTIONS INC.

                      CONSOLIDATED STATEMENT OF OPERATIONS
                   FOR THE TWO MONTHS ENDED FEBRUARY 28, 1999
                            (Unaudited and in $000's)

<TABLE>
<S>                                                     <C>
Revenue                                                 $   1,580
Cost of revenue                                               833
                                                        ---------
        Gross profit                                          747

        Gross profit %                                       47.3%

Operating Expenses
        Sales and marketing                                   702
        Research and development                              736
        General and administrative                            472
                                                        ---------
                Total operating expenses                    1,910
                                                        ---------
Loss from operations                                       (1,163)

Other expense                                                  65
                                                        ---------
Loss before taxes                                          (1,228)

Benefit for income taxes                                        -
                                                        ---------
Net loss                                                $  (1,228)
                                                        =========
</TABLE>

<PAGE>   105

                                SCHEDULE 7.i.3.b

                             GENOMIC SOLUTIONS INC.

                      CONSOLIDATED STATEMENT OF CASH FLOWS

                   FOR THE TWO MONTHS ENDED FEBRUARY 28, 1999
                            (Unaudited and in $000's)

<TABLE>
<S>                                                                                <C>
OPERATING ACTIVITIES
     Net loss                                                                        $(1,228)
     Adjustments to reconcile net loss to net cash
      provided by (used in) operating activities:
       Depreciation and amortization                                                     131
       Provision for losses on accounts receivable                                         6
       Write-off of capitalized software                                                   -
       Non-cash interest expense                                                           -
       Changes in operating assets and liabilities:
               Accounts receivable                                                      (327)
               Inventories                                                              (145)
               Prepaid expenses and other assets                                         150
               Accounts payable                                                         (396)
               Accrued liabilities                                                       258
               Deferred revenue                                                          (41)
                                                                                     -------
                   Net cash provided by (used in) operating activities                (1,592)

INVESTING ACTIVITIES
     Capitalization of internal R&D                                                        -
     Purchase of Capitalized software                                                      -
     Purchase of property and equipment                                                 (196)
     Other                                                                                 1
                                                                                     -------
                                                                                        (195)
                   Net cash used in investing activities

FINANCING ACTIVITIES
     Net borrowings (repayments) under notes payable                                    (132)
     Repayment of long-term debt (SFLG Loan and Finance Lease)                             -
     Proceeds from issuance of LTD (SFLG Loan and Finance Lease)                          64
     Proceeds from Transamerica sale/leaseback                                           210
     Repayment of Transamerica sale/leaseback                                            (28)
     Issuance of common stock                                                              2
     Other                                                                                 -
                                                                                     -------
                   Net cash provided by financing activities                             116

EFFECT OF EXCHANGE RATE CHANGES                                                            9
                                                                                     -------

NET INCREASE (DECREASE) IN CASH                                                       (1,662)

BALANCE AT BEGINNING OF PERIOD                                                         2,880
                                                                                     -------

BALANCE AT END OF PERIOD                                                             $ 1,218
                                                                                     =======
</TABLE>

<PAGE>   106

                                SCHEDULE 7.i.3.c

                             GENOMIC SOLUTIONS INC.

                           CONSOLIDATED BALANCE SHEET
                             AS OF FEBRUARY 28, 1999
                                    ($000's)

<TABLE>
<S>                                                                          <C>
ASSETS                                                                        (UNAUDITED)
------
Cash and cash equivalents                                                        $   1,218
Accounts receivable, net                                                             1,641
Inventories, net                                                                     2,953
Prepaid & other current assets                                                         503
                                                                                 ---------
         Total current assets                                                        6,315

Property and equipment, net                                                          1,705

Other long-term assets:
         Intangibles, net                                                            1,870
         Other                                                                         244
                                                                                 ---------
            Total other long-term assets                                             2,114
                                                                                 ---------

                  TOTAL ASSETS                                                      10,134
                                                                                 =========

Liabilities & Stockholders' Equity
----------------------------------
Current liabilities:
          Short-term borrowings                                                      1,843
          Current portion of long-term debt                                            161
          Accounts payable                                                           1,534
          Accrued liabilities                                                        1,650
          Deferred revenue                                                             152
          Other                                                                          -
                                                                                 ---------
            Total current liabilities                                                5,340

Long-term debt, less current portion                                                   748

Stockholders' Equity
          Preferred convertible & common stock                                          10
          Additional paid-in-capital                                                16,527
          Accumulated deficit                                                      (12,498)
          Currency translation adjustments                                              57
                                                                                 ---------
          Total stockholders' equity                                                 4,096

Less: Notes receivable                                                                 (50)
                                                                                 ---------

                TOTAL LIABILITIES & STOCKHOLDERS EQUITY                          $  10,134
                                                                                 =========
</TABLE>

<PAGE>   107

                                                                 SCHEDULE 7.i.4

<TABLE>
<CAPTION>
                                                                     As of February 28, 1999
                                                                                                           Post
                                      2/28/99          US GAAP         2/28/99            2/28/99        2/28/99          2/28/99
                                        GSI          Adjustment          GSI                GSI          Adjust's           GSI
                                    -----------      ----------      -----------        -----------      --------       -----------
<S>                                <C>               <C>            <C>                <C>                <C>           <C>

BALANCE SHEET

ASSETS

Current Assets
 Cash and Cash Equivalents          $         -       $      -       $         -        $ 1,005,436        $   -        $ 1,085,436
 Accounts Receivable                    207,372              -           207,372            852,566            -            852,568
 Allowance for Doubtful Accounts              -                                -            (75,601)           -            (75,601)
                                    -----------       --------       -----------        -----------        -----        -----------
 Accounts Receivable, net               207,372              -           207,372            776,965            -            778,965
 Intercompany receivables               451,372              -           451,372            527,070            -            527,070
 Inventory                            1,061,130              -         1,061,130          1,883,167                       1,883,167
 Inventory reserve                            -                                -            (80,000)                        (80,000)
                                    -----------       --------       -----------        -----------        -----        -----------
 Inventories, net                     1,061,130              -         1,061,130          1,803,167            -          1,803,167
 Prepaid expenses                        57,030                           57,030            161,641                         161,641
 Other                                   47,155        169,054           216,209             60,698            -             60,698
                                    -----------       --------       -----------        -----------        -----        -----------
     Total current Assets             1,824,059        169,054         1,993,113          4,414,977            -          4,414,977

 Property and equipment, cost           735,344                          735,344          1,871,188                       1,871,188
 Accumulated depreciation              (275,240)                        (275,240)          (559,709)                       (559,709)
                                    -----------       --------       -----------        -----------        -----        -----------
 Property & equipment, net              460,105              -           460,105          1,311,479            -          1,311,479
 Receivable - Intercompany                                                     -          3,318,421                       3,318,421
 Amount in HD Technologies              152,152          4,005           156,157                  -                               -
 Amount in KK                                                                  -             72,059                          72,059
 Amount in PBA                                -                                -            705,480                         705,480
 Acquisition Costs                                                             -            158,153                         158,153
 Intangibles - (Goodwill)                     -                                -          1,693,044                       1,693,044
 Long term assets                             -                                -             49,823                          49,823
                                    -----------       --------       -----------        -----------        -----        -----------
     Assets                         $ 2,436,015       $173,050       $ 2,609,374        $11,723,436        $   -        $11,723,436
                                    ===========       ========       ===========        ===========        =====        ===========

LIABILITIES & STOCKHOLDERS EQUITY

Current liabilities

 Notes Payable - Bank Overdraft     $    93,184       $              $    93,184        $ 1,750,000        $   -        $ 1,750,000
 Accounts Payable                       793,655                          793,655            715,508         (426)           715,082
 Intercompany Payables                  412,772              -           412,772            414,293                         414,293
 Accrued Warranty                                                              -            224,000                         224,000
 Taxes Payable                           78,584                           78,584              5,964                           5,964
 VAT Liability                         (169,054)       169,054                (0)                                                 -
 Accrued Liabilities                     73,264              -            73,264          1,193,108            -          1,193,108
 Directors Loan Accounts                      -                                -                                                  -
 Deferred Revenue                                       59,175            59,175             92,584                          92,584
 Finance Leases                          27,748                           27,748                                                  -
 Debt - SFLG loan                       133,558                          133,558                                                  -
                                    -----------       --------       -----------        -----------        -----        -----------
     Total Current Liabilities        1,443,711        228,229         1,671,039          4,395,457         (426)         4,395,031

Long Term Liabilities
 Debt - SFLG loan                       126,881                          126,881                                                  -
 Deferred Taxation                            -                                -                                                  -
 Finance Leases                          73,258                           73,258                                                  -
 LTD - Intercompany                   2,864,557                        2,864,557                                                  -
 Other Long Term Liabilities                                                   -            547,925                         547,925
                                    -----------       --------       -----------        -----------        -----        -----------
     Total Long Liabilities           3,064,696              -         3,064,696            547,925            -            547,925
                                    -----------       --------       -----------        -----------        -----        -----------
 Total Liabilities                    4,508,406        228,229         4,736,635          4,943,382         (426)         4,942,956

Stockholders equity
 Preferred Stock                                                               -              6,901                           6,901
 Common Stock                                                                  -              2,926            -              2,926
 Add'l Paid in Capital                                                         -         16,526,907            -         16,526,907
 Share capital                        1,121,440                        1,121,440                                                  -
 Beginning Retained Earnings         (2,883,457)       (62,074)       (2,945,531)        (8,550,755)         426         (8,550,329)
 Current Year PA                       (378,964)         5,495          (373,469)        (1,053,360)           -         (1,053,360)
                                    -----------       --------       -----------        -----------        -----        -----------
 Ending Retained earnings            (3,262,421)       (56,579)       (3,319,000)        (9,604,115)         426         (9,603,689)
 Notes Receivable                                                                           (49,950)                        (49,950)
 Cumulative Translation Adjustment       68,890          1,409            70,299           (102,615)                       (102,615)
                                    -----------       --------       -----------        -----------        -----        -----------
 Total Stockholders Equity           (2,072,090)       (55,170)       (2,127,260)         6,780,054          426          6,780,480
                                    -----------       --------       -----------        -----------        -----        -----------
Total Liabilities and
 Stockholders Equity                $ 2,436,316       $173,059       $ 2,609,375        $11,723,436        $   -        $11,723,436
                                    ===========       ========       ===========        ===========        =====        ===========
 Assets = Liabilities + Equity      $        (1)      $      0       $        (0)       $         -        $   -        $         -
                                    ===========       ========       ===========        ===========        =====        ===========

<CAPTION>
                                                                     As of February 28, 1999
                                                        Post
                                      2/28/99          2/28/99        2/28/99                          Intercompany
                                       GSKK            Adjust's     Japan (K.K.)         COMBINED      Eliminations    CONSOLIDATED
                                    -----------      -----------    ------------       -----------     ------------    ------------
<S>                                 <C>               <C>           <C>               <C>              <C>            <C>

BALANCE SHEET

ASSETS

Current Assets
 Cash and Cash Equivalents          $  132,084          $  -        $  132,084        $  1,217,520     $         -    $  1,217,520
 Accounts Receivable                   657,089             -           657,089           1,717,027                       1,717,027
 Allowance for Doubtful Accounts             -             -                 -             (75,601)              -         (75,601)
                                    ----------          ----        ----------        ------------     -----------    ------------
 Accounts Receivable, net              657,089             -           657,089           1,641,426               -       1,641,426
 Intercompany receivables               (3,035)            -            (3,035)            975,407        (975,407)              -
 Inventory                             193,742             -           193,742           3,138,039        (104,870)      3,033,169
 Inventory reserve                                                           -             (80,000)                        (80,000)
                                    ----------          ----        ----------        ------------     -----------    ------------
 Inventories, net                      193,742             -           193,742           3,058,039        (104,870)      2,953,189
 Prepaid expenses                          309                             309             218,980                         218,980
 Other                                   7,468             -             7,468             284,375                         284,375
                                    ----------          ----        ----------        ------------     -----------    ------------
     Total current Assets              987,657             -         7,395,747           7,395,747      (1,080,277)      8,315,470

 Property and equipment, cost            1,583                           1,583           2,608,115         (74,005)      2,534,110
 Accumulated depreciation                 (308)                           (308)           (835,257)          5,744        (829,513)
                                    ----------          ----        ----------        ------------     -----------    ------------
 Property & equipment, net               1,275             -             1,275           1,772,859         (68,261)      1,704,598
 Receivable - Intercompany                                                               8,318,421      (3,318,421)              -
 Amount in xx Technologies                                                   -             156,157                         156,157
 Amount in xx                                                                -              72,059         (72,059)              -
 Amount in PBS                                                               -             705,480        (705,480)              -
 Acquisition Costs                                                           -             158,153                         158,153
 xxx Intangibles - (Goodwill)                                                -           1,693,044          17,842       1,710,666
 xxx long term assets                   38,433                          38,433              88,256                          88,256
                                    ----------          ----        ----------        ------------     -----------    ------------
                                    $1,027,365          $  -        $1,027,365        $ 15,360,175     $(5,228,656)   $ 10,133,520
                                    ==========          ====        ==========        ============     ===========    ============

LIABILITIES & STOCKHOLDERS EQUITY

Current liabilities

 Notes Payable - Bank Overdraft                         $  -        $        -        $  1,843,184     $         -    $  1,843,184
 Accounts Payable                       25,274             -            25,274           1,534,011                       1,534,011
 Intercompany Payables                 144,590                         144,590             971,655        (971,655)              -
 Accrued Warranty                       33,024                          33,024             257,024                         257,024
 Taxes Payable                          24,805                          24,805             109,353                         109,353
 VAT Liability                               -                               -                  (0)                             (0)
 Accrued Liabilities                    20,725                          20,725           1,287,097          (3,751)      1,283,346
 Directors Loan Accounts                                                     -                   -                               -
 Deferred Revenue                                                            -             151,759                         151,759
 Finance Leases                                                              -              27,748                          27,748
 Debt - SFLG loan                                                            -             133,558                         133,558
                                    ----------          ----        ----------        ------------     -----------    ------------
     Total Current Liabilities         248,418             -           248,418           6,315,388        (975,407)      5,339,982

Long Term Liabilities
 Debt - SFLG loan                                                            -             126,881                         126,881
 Deferred Taxation                                                           -                   -                               -
 Finance Leases                                                              -              73,258                          73,258
 LTD - Intercompany                    453,864                         453,864           3,318,421      (3,318,421)              -
 Other Long Term Liabilities                                                 -             547,925                         547,925
                                    ----------          ----        ----------        ------------     -----------    ------------
     Total Long Liabilities            453,864             -           453,864           4,066,485      (3,318,421)        748,064
                                    ----------          ----        ----------        ------------     -----------    ------------
 Total Liabilities                     702,282             -           702,282          10,381,873      (4,293,828)      6,088,046

Stockholders equity
 Preferred Stock                                                             -               6,901                           6,901
 Common Stock                               72                              72               2,926             (72)          2,926
 Add'l Paid in Capital                  71,987                          71,987          16,598,894         (71,987)     16,526,907
 Share capital                                                               -           1,121,440      (1,121,440)              -
 Beginning Retained Earnings           (31,215)            -           (31,215)        (11,527,075)        257,291     (11,269,784)
 Current Year PA                       195,384             -           195,364          (1,231,465)          3,380      (1,228,085)
                                    ----------          ----        ----------        ------------     -----------    ------------
 Ending Retained earnings              164,149             -           164,149         (12,758,540)        260,671     (12,497,869)
 Notes Receivable                                                            -             (49,950)                        (49,950)
 Cumulative Translation Adjustment      88,875             -            88,875              58,559                          58,559
                                    ----------          ----        ----------        ------------     -----------    ------------
 Total Stockholders Equity             325,083             -           325,083           4,978,303        (932,828)      4,045,474
                                    ----------          ----        ----------        ------------     -----------    ------------
Total Liabilities and
 Stockholders Equity                $1,027,365          $  -        $1,027,365        $ 15,360,176     $(5,226,656)   $ 10,133,520
                                    ==========          ====        ==========        ============     ===========    ============
 Assets = Liabilities + Equity      $        -          $  -        $        -        $         (0)    $         0    $         (0)
                                    ==========          ====        ==========        ============     ===========    ============

</TABLE>

<PAGE>   108
                                  SCHEDULE 7.k

                               GENOMIC SOLUTIONS

DEVELOPMENT SINCE "INTERIM" BALANCE SHEET DATE:

Since the "Interim" Balance Sheet Date as of February 28, 1999;

a.)  the consolidated cash balance of Genomic Solutions Inc. as of March 31,
     1999 was $1,270,726, which included approximately $440,000 received from
     certain Lenders, (American Healthcare Fund II, Robert Shepler, and Grove
     Investment Partners) and deposited into a separate Genomic Solutions Inc.
     bank account, and

b.)  the consolidated cash balance of Genomic Solutions Inc., as of April 19,
     1999 at 9 a.m., was approximately $1,404,413, which included approximately
     $691,505, received from certain Lenders, (American Healthcare Fund, Robert
     G. Shepler, Grove Investment Partners, John J. Mackowski, J. Matthew
     Mackowski) and deposited into a separate Genomic Solutions Inc. bank
     account.
<PAGE>   109

                                  SCHEDULE 7.1

                                  ENCUMBRANCES

(Unless previously provided, copies of these documents are available upon
request of the Secretary of the Corporation or the Company's legal counsel.)

Schedule 7.1.1   List of Secured Paries

<PAGE>   110

                                                                  SCHEDULE 7.l.1
                                                                   (page 1 of 3)

MICHIGAN DEPARTMENT OF STATE    DATE  APR 19, 1999   TIME  12:51  ACCOUNT NUMBER
  UNIFORM COMMERCIAL CODE
  LANSING, MICHIGAN 48918       DEBTOR INFORMATION   REQUESTOR INFORMATION

SEARCH RESULTS           B383383038                R28969
                         GENOMIC SOLUTIONS INC     JAFFE RAITT HEUER & WEISS
                         4355 VARSITY DR           ATTN KIM CASTEEL
                         ANN ARBOR  MI  48108      ONE WOODWARD AVE #2400
                                                   DETROIT  MI  48226
COPIES REQUESTED

<TABLE>
<CAPTION>

-------------------------------------------------------------------
FILING        DATE/TIME     DOCUMENT      SECURED       MICROFILM
NUMBER        OF HIRING       TYPE      PARTY CODFE     LOCATION
-------------------------------------------------------------------
<S>       <C>        <C>      <C>         <C>         <C>
D403758   02-28-98   09:00    ORIG        H44560      98049-377.03

D405624   08-04-98   09:00    ORIG        H44560      98051-1284.02

D432338   10-15-98   09:00    ORIG        H44560      98065-2447.03

D441949   11-09-98   09:00    ORIG        H44560      98070-2359.03

D464538   01-11-99   09:00    ORIG        J18739      99001-1549.03

D484565   03-01-99   09:00    ORIG        H44550      99012-536.03

D489019   06-10-99   09:00    ORIG        H44560      99014-1662.03

D489043   03-10-99   09:00    ORIG        H44560      99014-1691.03

D489058   03-10-99   09:00    ORIG        H44560      99014-1706.03

</TABLE>

SECURED PARTIES

H44560
TRANSAMERICA BUSINESS CREDIT CORP
76 BATTERSON PARK RD
FARMINGTON CT 06032

JIB239
TRANSAMERICA BUSINESS CREDIT CORP
76 BATTERSON PARK PD
FARMINGTON CT 06032

<PAGE>   111

                                                                  SCHEDULE 7.l.1
                                                                   (page 2 of 3)

MICHIGAN DEPARTMENT OF STATE    DATE  APR 19, 1999   TIME  12:51  ACCOUNT NUMBER
  UNIFORM COMMERCIAL CODE
  LANSING, MICHIGAN 48918       DEBTOR INFORMATION   REQUESTOR INFORMATION

SEARCH RESULTS           A383383038                    R28969
                         GENOMIC SOLUTIONS/BIO IMAGE   JAFFE RAITT HEUER & WEISS
                         4355 VARSITY DR               ATTN KIM CASTEEL
                         ANN ARBOR  MI  48108          ONE WOODWARD AVE #2400
                                                       DETROIT  MI  48226

COPIES REQUESTED

<TABLE>
<CAPTION>

-----------------------------------------------------------------------------
FILING        DATE/TIME   DOCUMENT      SECURED       MICROFILM
NUMBER        OF HIRING     TYPE      PARTY CODE      LOCATION
-----------------------------------------------------------------------------
<S>       <C>               <C>       <C>            <C>
D365088   04-22-98  09:00   ORIG        H38552       98024-2052.0

D403880   07-29-98  09:00   ORIG        J18739       98049-639.03
</TABLE>

SECURED PARTIES

H38552
IKON OFFICE SOLUTIONS
278012790 44TH ST SW
GRAND RAPIDS  MI 49509

J18739
TRANSAMERICA BUSINESS CREDIT CORP
76 BATTERSON PARK PD
FARMINGTON CT 06032

<PAGE>   112

                                                                  Schedule 7.x.1
                                                                   (Page 3 of 3)

MICHIGAN DEPARTMENT OF STATE    DATE  APR 19, 1999   TIME  12:51  ACCOUNT NUMBER
  UNIFORM COMMERCIAL CODE
  LANSING, MICHIGAN 48918       DEBTOR INFORMATION   REQUESTOR INFORMATION

SEARCH RESULTS           SEARCH RESULTS FOR:       R28969
                         GENOMIC SOLUTIONS INC.    JAFFE RAITT HEUER & WEISS
                                                   ATTN KIM CASTEEL
                                                   ONE WOODWARD AVE #2400
                                                   DETROIT  MI  48226
COPIES REQUESTED

<TABLE>
<CAPTION>

-------------------------------------------------------------------
FILING        DATE/TIME     DOCUMENT      SECURED       MICROFILM
NUMBER        OF HIRING       TYPE      PARTY CODE      LOCATION
-------------------------------------------------------------------
<S>       <C>                 <C>         <C>         <C>

                                                            FEES

                                                             1 Debtor(s) -- No TIN supplied:    $6.00
                                                            30 Print(s) @ $1.00/print:         $30.00

                                                               Expedited Search Fee:           $25.00
                                                             1 Total Debtor(s).
                                                                   TOTAL FEE                   $61.00

                                                            The Undersigned Filing Officer Certifies
                                                            that the above is a record of all
                                                            presently effective financing statements,
                                                            tax liens and assignments which name the
                                                            above debtor(s) and which are on file
                                                            as of APR 02 1999.

                                                            The attached photo copies are true copies
                                                            of the requested financing statements,
                                                            tax liens and assignments on file.

                                                            /s/ Jeffrey C. Nickerson
                                                            ---------------------------
                                                            Signature of Filing Officer

                                                            Retain this form for reconciliation to your
                                                            monthly stmt. Remit pmt based on statement only.

</TABLE>

<PAGE>   113
                                  SCHEDULE 7.o

LIST OF AGREEMENTS:
(Unless previously provided, copies of these agreements are available upon
request of the Secretary of the Corporation or its legal counsel.)

<TABLE>
<CAPTION>
           ENTITY                                       DESCRIPTION
<S>       <C>        <C>
            GSI      1994 Omnibus Equity Incentive Plan
            GSI      1998 Employee Stock Option Plan
            GSI      1998 Non-Employee Stock Option Plan
            GSI      401(k) Profit Sharing Plan and Trust
            GSI      Jeffrey S. Williams Employment Agreement effective January 1, 1998
           GSLtd.    Genomic Solutions Ltd. Employee Service Contracts with the following
                     managers; Kevin Auton, John Pinkney, David Byatt, and Paul Dunkley.
            GSI      All employees of Genomic Solutions Inc. sign prior to starting employment
                     with GSI an "Employment Agreement" of confidentiality and non-
                     disclosure.
           GSLtd.    All employees of Genomic Solutions Limited ("GSLtd.") sign
                     prior to starting employment with GSL a "Statement of Main
                     Terms and Conditions of Employment."
           GSLtd.    Consultancy Agreement between Genomic Solutions Ltd. and P. Nicholas
                     King, who also serves as a Director of Genomic Solutions Inc.
            GSI      Consultancy Agreement between Genomic Solutions Inc. and
                     Mackowski and Shepler, both Matt Mackowski (GSI)
            GSI      Punk, Ziegel & Company Services Agreement
Schedule   7.o.1     List of Distribution Agreements
Schedule   7.o.2     List of Genomic Solutions' Facilities
Schedule   7.o.3     List of Non-Disclosure Agreements
Schedule   7.o.4     List of Leases
Schedule   7.o.5     List of Other Contracts
            GSI      Shareholder Agreement and Amendments
            GSI      Series B Preferred Stock Purchase Agreements
            GSI      Series C Preferred Stock Purchase Agreements
            GSI      Series D Preferred Stock Purchase Agreements
            GSI      Series M Preferred Stock Purchase Agreement
Schedule   7.o.6     List of Borrowings
Schedule   7.o.7     List of Acquisitions and Strategic Alliance Agreements
</TABLE>

<PAGE>   114

                                 SCHEDULE 7.o.1

 LIST OF DISTRIBUTION AGREEMENTS:

 GENOMIC SOLUTIONS DISTRIBUTES THE PRODUCT OF:

<TABLE>
<CAPTION>
 DATE OF          AGREEMENT WITH               LENGTH OF AGREEMENT                COMMENTS
AGREEMENT
<S>          <C>                               <C>                    <C>
 05/28/98     General Scanning                      Terminated        Exclusive agent for General's Scan
                                                                      Array, 3000 Biochip scanner
 11/17/98     Spotfire, Inc                                           Distribute Spotfire Pro Software
 9/2/98       Biospace Mesures                 Terminates 12/31/99    Product Distribution Agreement
</TABLE>

     GENOMIC SOLUTION'S PRODUCTS ARE DISTRIBUTED BY THE FOLLOWING:

<TABLE>
<CAPTION>
 DATE OF          AGREEMENT WITH               LENGTH OF AGREEMENT                COMMENTS
AGREEMENT
<S>          <C>                               <C>                    <C>
 11/16/98    Australian Laboratory Services                           Australian Distribution Agreement
 12/15/98    Science & Technology Ltd.                                New Zealand Distribution Agreement
 2/15/99     Bio/Can Scientific                                       Canada Distribution Agreement
             B&L                                                      Holland Distribution Agreement with
                                                                      GSLtd.
             AbiMed                                                   German Distribution Agreement with
                                                                      GSLtd.
             Kebo Lab                            Letter of  Intent    Distributor for Nordic Region
                                                                      (Denmark, Norway, Sweden, Finland)
</TABLE>

<PAGE>   115
                                 SCHEDULE 7.o.2

LIST OF GENOMIC SOLUTIONS' FACILITIES:

1.)  Main Corporate offices which house - Sales(a), Marketing, Molecular
     Biology, Biochip production, Software development, Accounting and
     Administration.
       Address:          4355 Varsity Drive, Suite E
                         Ann Arbor, NE 48108

     Note (a): Corporate direct sales reps (5), manager (1), and a field service
     engineer (1) are located outside of Michigan and work out of their homes.

2.)  Imaging systems manufacturing and engineering operations are located in
     Lansing, Michigan.
       Address:          3120 Sovereign Drive, Suite A
                         Lansing, MI 48911

3.) Genomic Solutions' 2-D gel electrophoresis and proteomic services business
    is located in Chelmsford, Massachusetts. The company subleases approximately
    5,200 square feet from ESA, Inc.
       Address:          22 Alpha Road
                         Chelmsford, MA 01824

4.) Genomic Solutions Ltd. ("GSL") is located in Cambridgeshire, England,
    providing robot and fluidic handling systems development and manufacturing
    as well as European marketing, sales and service. The lease expires June 30,
    1999.
       Address:          Unit 3, Forge Close
                         Little End Road, St. Neots
                         Cambridgeshire, PE 19 3TP
                         United Kingdom

    4.a) Genomic Solutions Ltd. has entered into a facility lease agreement in
         April 1999 primarily to support increased demand for Genomic robotic
         and fluidic products and therefore increased production. The entire GSL
         operations will be moved to the following new facility sometime between
         May 1999 and August 1999.
           Address:      8 Blackstone Road
                         Huntingdon
                         Cambridgeshire, PE 19 6EF
                         United Kingdom

5.) Genomic Solutions K.K., located in Tokyo, Japan, provides domestic
    marketing, sales and technical support.
       Address:          Gotanda Chuo Bldg. 2F
                         3-5, Higashigotanda 2-chome
                         Shinagawa-Ku 141-0022
                         Tokyo, Japan
<PAGE>   116
                                 SCHEDULE 7.o.3

LIST OF NON-DISCLOSURE AGREEMENTS:

<TABLE>
<CAPTION>
    DATE OF AGREEMENT                      AGREEMENT WITH
<S>                               <C>
         3/17/99                  Affymetrix, Inc.
         2/12/99                  Amersham Pharmacia Biotech (UK) Limited
         10/8/98                  Amresco
         3/24/99                  Becton Dickinson & Co.
         2/1/99                   Bertrand Lemieux
         3/12/99                  Bio-Rad Laboratories, Inc.
         2/2/98                   BIOSEQ
        10/15/98                  BioWhittaker, Inc
         6/3/98                   Carl Zeiss Jena GmbH.
         3/2/99                   Chiroscience Group plc
         4/2/98                   Chromagen, Inc.
         12/9/98                  Corning, Inc.
         3/5/99                   Dow Chemical Company
         3/5/98                   Dr. Michel Schummer
         3/17/99                  EG&G Wallac
         3/15/99                  F. Hoffman-LaRoche Ltd.
         3/15/99                  GATTAC Corporation
         12/8/97                  Gene Logic Inc
         4/15/98                  Genosys Biotechnologies Inc
         2/8/99                   Isis Pharmaceuticals, Inc.
         10/5/98                  James Burk
         3/8/99                   Kebo Lab
         12/1/97                  Kloehn Company Ltd.
         3/15/99                  MDS Inc.
         2/26/99                  Micromass Inc.
         5/19/98                  Monsanto Corporation
         3/5/99                   Monsanto Corporation
         2/11/99                  Morgan Stanley Venture capital III, Inc.
        10/28/97                  Mosaic Technologies
         3/2/98                   MWG Biotech
        11/18/98                  Myogen, Inc
         3/l/99                   NEN Life Science Products, Inc.
        10/15/98                  Olli Kallioniemi
         3/12/99                  Packard BioScience Company
         2/24/98                  Photometrics Ltd
         8/12/98                  Polyfiltronics, Inc
         2/18/98                  Richard Fisher
         11/2/98                  Scanalytics, Inc.
         2/9/99                   Sigma-Aldrich Corp.
         9/3/98                   TeleChem International
        11/25/98                  The Perkin-Elmer Corporation
         2/l/99                   Timothy Zacharewski
         4/2/98                   University of Alberta
         7/1/98                   University of Michigan
         2/20/98                  WestElder Associates
         4/23/98                  Zeneca Limited
</TABLE>
<PAGE>   117
                                 SCHEDULE 7.o.4

LIST OF LEASES
1.                GENOMIC SOLUTIONS INC.

<TABLE>
<CAPTION>
 DATE OF               AGREEMENT WITH                  LENGTH OF     LOCATION   MONTHLY     COMMENTS
AGREEMENT                                             AGREEMENT-                PAYMENT
                                                        MONTHS
<S>          <C>                                        <C>                 <C>            <C>        <C>
   7/8/97    Highland Industrial Park                         60            Ann Arbor                 Effective 1/1/98
             Transamerica Business Credit Corporation    Master Lease
  7/16/98      Schedule # 1                                   48                           $2,009.57  $77,507.00 leased equipment -
  7/16/98      Schedule # 2                                   36                           $2,537.79  $78,444.83 leased equipment
 10/12/98      Schedule # 3                                   48                           $2,150.80  $82,954.22 lease equipment
 10/27/98      Schedule # 4                                   48                           $4,451.61  $171,693.63 leased equipment
  2/11/99      Schedule # 5                                   48                           $5,139.40  $200,109.00 leased equipment
 12/17/98      Schedule # 6                                   36                           $3,652.07  $112,888.04 leased equipment
   3/1/99      Schedule # 7                                   48                           $5,388.14  $205,886.53 leased equipment
   3/5/99      Schedule # 8                                   36                           $2,247.30  $69,465.61 leased equipment
   3/1/99      Schedule # 9                                   36                           $4,662.20  $152,758.70 leased equipment
   4/1/99      Schedule #10                                   48                           $5,956.00  $229,717.00 leased equipment
  7/22/98    Dart Container                                   60           Lansing                    Lansing Facility Lease
  6/23/98    GMAC                                             36                           $  424.81  98 Chevy Venture Van
  7/15/98    ADT Security Services                                                                    per year
                                                                                           $  622.00
  10/6/97    Dell Financial Services                          36           Ann Arbor       $  137.52  Dell Computer
  1/16/98    Dell Financial Services                          36           Ann Arbor       $  172.71  Dell Computer
  1/22/98    Green Tree Vendor Services                       36                           $  151.27  Gateway computer w/ printer
 12/18/98    Chrysler Financial                               24           Ann Arbor       $  334.35  1999 Grand Caravan
 12/18/98    Chrysler Financial                               24           Lansing         $  334.35  1999 Grand Caravan
   1/5/98    01d Kent Leasing                                 36           Ann Arbor       $   84.75  Fax Machine
  2/26/98    IKON                                             60           Ann Arbor       $  397.00  Ricoh Copier
 10/21/98    Off Tech                                         36           Chelmsford      $  494.00  Ricoh Copier
  1/11/99    Accutemp Engineering Inc                         12           Chelmsford      $   36.25  Preventive Maintenance
                                                                                                              - Lab Equipment
  12/2/98    EZ Mini Storage                                               Chelmsford      $  195.00  Off site storage
   3/2/98    EZ Mini Storage                                               Chelmsford      $  195.00  Off site storage
 12/30/98    Infotrac                                         12           Chelmsford      $   30.85
   3/9/99    GMAC                                             36           Ann Arbor       $  743.20  1999 Escalade - Auto Lease
</TABLE>

<PAGE>   118
                           SCHEDULE 7.O.4 - CONTINUED

 II.                GENOMIC SOLUTIONS LTD LEASES

<TABLE>
<CAPTION>
 DATE OF            AGREEMENT WITH                LENGTH OF        MONTHLY            COMMENTS
AGREEMENT                                        AGREEMENT-        PAYMENT
                                                   MONTHS
<S>          <C>                                <C>             <C>                          <C>
   2/6/97    Peugeot Finance                         48         Pound Sterling 338.62        Auto Lease - Van
   2/2/96    Woodchester Finance Ltd                 36         Pound Sterling 298.09        Auto Lease Rover
  4/30/98    Caryle Finance                          36         Pound Sterling 395.84        Auto Lease Ford Scarpio
  1/20/99    Guarantee Finance                       36         Pound Sterling 425.50        Auto Lease - Peugeot
 11/27/96    Lombard North Central PLC               36         Pound Sterling 208.39        Auto Lease
   Mar-97    Caryle Finance                          36         Pound Sterling 283.81        Auto Lease - Mondeo
   3/5/99    Guarantee Finance                       48         Pound Sterling 443.20        Auto Lease - BMW
 11/27/98    Caryle Finance                          36         Pound Sterling 358.24        Auto Lease -Rover
  9/11/98    Schroders Leasing Ltd.                  36         Pound Sterling 592.46        NEC MT1020 LCD Projector
  2/13/98    Apple Commercial Credit                 36         Pound Sterling 688.07        Epic Pentium II Computer
  5/29/98    Dell Financial Services                 36         Pound Sterling 363.02        Computer Equipment
  4/29/97    Danwood Financial Services              60         Pound Sterling 420.06        Sharp Photocopier
  4/15/99    Winter thru Life UK Limited             120        Scaled                       Facility Lease - 8 Blackstone Road
                                                                                             Huntingdon, Cambridgeshire, UK
     1996    Turrett Construction and Property  June 30, 1999                                Facility Lease - Unit 3
             Company Ltd                                                                     St. Neots, Cambridgeshire, UK
    12/98    Turrett Construction and Property  May 3, 1999                                  Facility Lease - Unit 2
             Company Ltd                                                                     St. Neots, Cambridgeshire, UK
</TABLE>

III.                GENOMIC SOLUTIONS K.K. LEASES

<TABLE>
<CAPTION>
 DATE OF         AGREEMENT WITH                 LENGTH OF         MONTHLY       COMMENTS
AGREEMENT                                       AGREEMENT-         PAYMENT
                                                  MONTHS
<S>          <C>                                <C>             <C>             <C>
  4/21/98    Chuo Tochi K.K.                         24          Yen 639,000    Facility lease in Tokyo, Japan
                                                                                May 1, 98 - April 30, 2000
             Various                                                            General office equipment, fax and copier
</TABLE>

<PAGE>   119
                                 SCHEDULE 7.o.5

                            LIST OF OTHER CONTRACTS

<TABLE>
<CAPTION>
 DATE OF          AGREEMENT WITH            LENGTH OF    ENTITY OR    MONTHLY        COMMENTS
AGREEMENT                                   AGREEMENT     LOCATION    PAYMENT
                                             -MONTHS
<S>         <C>                            <C>           <C>          <C>       <C>
  6/24/98   AbiMed                                       UK                     Development of DigestPro and MALDI
                                                                                Robot
     1997   BioSeparations                               Ann Arbor
  1/29/98   Computational Biosciences Inc   Terminated   Ann Arbor              Software License Agreement
   7/1/98   Dr. Liang Li                                 Chelmsford
            (University of Alberta)
  2/23/99   GATTAC                                       Ann Arbor              PCR Machines - agency relationship -worid
                                                                                wide exclusive right to market
  2/23/99   GATTAC                                       Ann Arbor              Supply PCR products.
  3/17/99   White Pines Management                       Ann Arbor              Letter of Intent - Financing agreement
            L.L.C.
            Frontier Communications                      Inc.                   Long distance telephone carrier.
 11/20/98   Granger Container                            Lansing        40.00   Recycling and refuse service
  2/10/99   Bergstrom's Inc                      12      Ann Arbor     113.67   Preventive Maintenance - Heating & Air
                                                                                conditioning Equipment
  12/3/98   Pitney Bowes                         16      Ann Arbor     195.00   Postage meter
     4/99   Myogen                                       Inc.                   Genomic & Proteomic Analysis Contract
                                                                                Services Agreement
  2/26/98   HD Technologies Ltd.                         UK                     Co-operate on exclusive basis - Mass
                                                                                Spectrometry Instrumentation (see
                                                                                Schedule 7.o.7)
   5/5/98   WestElder Associates                                        75/hr   Consulting Contract
 12/31/97   MRC License Agreement                        UK                     License of robot from Sanger Centre.
  9/1 /98   University of Alberta             9/1/99     UK                     Global Research Agreement in Proteomics

 Pending
 April 99   Molecular Probes                             Chelmsford             Term sheet signed progressing to License
                                                                                Agreement
</TABLE>

<PAGE>   120
                                 SCHEDULE 7.o.6

LIST OF BORROWINGS:

a.) Genomic Solutions Inc. has a $2,000,000 bank borrowing facility evidenced by
    a line of credit agreement with Comerica Bank. Outstanding borrowings bear
    interest at the Bank's prime interest rate. This facility is subject to
    various covenants including the maintaining certain levels of tangible net
    worth and working capital.

b.) Genomic Solutions Inc. has a fixed asset master lease agreement whereby it
    may finance up to $1,500,000 in various laboratory, office and computer
    equipment. Current funding is available through May 15, 1999, but may be
    extended by the Lessor.

c.) Genomic Solutions Ltd. has an overdraft facility with a bank whereby Genomic
    Solutions Ltd. may borrow up to approximately 120,000 pound sterling
    ($200,000). Outstanding borrowings bear interest at the bank's prime rate
    plus 3.75% and are collateralized primarily by a stand-by letter of credit
    issued by the parent company's (Genomic Solutions Inc.) bank.

d.) Genomic Solutions Ltd. has a line of credit agreement with a bank whereby
    Genomic Solutions Ltd. may borrow up to 75,000 pound sterling (approximately
    $120,000). Outstanding borrowings bear interest at 10.5% and are
    collateralized by eligible accounts receivable.

e.) Note payable by Genomic Solutions Ltd. payable in monthly installments of
    $4,167 plus interest at 10.5% through November 2000.

f.) Note payable by Genomic Solutions Ltd. payable in monthly installments of
    $2,778, plus interest at 10.5% through January 2001.

<PAGE>   121
                                 SCHEDULE 7.o.7

LIST OF ACQUISITIONS AND STRATEGIC ALLIANCE AGREEMENTS:

BIOPHOTONICS, INC.:
ACQUISITION OF THE ELECTROPHORESIS RELATED ASSETS OF BIOPHOTONICS CORPORATION
BY B.I. SYSTEMS CORPORATION, D/B/A BIO IMAGE INCLUDING ASSET PURCHASE AGREEMENT
AND ALL OTHER DOCUMENTS ASSOCIATED WITH ACQUISITION.

In June 1997, Genomic Solutions Inc. acquired substantially all assets of
BioPhotonics, Inc. in exchange for $302,300 in cash and 85,000 shares of common
stock at $0.07 per share. The acquisition has been accounted for under the
purchase method of accounting. The excess of the purchase price over the fair
value of the net assets acquired has been recognized as goodwill and is being
amortized over a five-year period.

PBA TECHNOLOGY LTD.:
AGREEMENT FOR THE SALE AND PURCHASE OF THE ENTIRE ISSUED SHARE CAPITAL OF PBA
TECHNOLOGY LIMITED AND ASSOCIATED DOCUMENTS IN CONNECTION WITH THIS TRANSACTION.

Effective December 31, 1997, Genomic Solutions Inc. acquired 100% of the
outstanding capital stock of PBA Technology Limited. The aggregate purchase
price of approximately $705,480 consisted of $150,480 in cash and 1,500,000
shares of the Company's common stock valued at $555,000. The acquisition has
been accounted for under the purchase method of accounting. In connection with
the acquisition, the Company recorded a one-time charge to operations in 1997 of
$1,017,000, associated with the write-off of in-process research and development
acquired in the transaction that had not reached technological feasibility. The
remaining excess of the aggregate purchase price over the fair value of the net
assets acquired of approximately $230,000, including acquisition costs of
approximately $206,000, has been recognized as goodwill and will be amortized
over a five-year period.

HD TECHNOLOGIES, LTD.:
SUBSCRIPTION AND COLLABORATION AGREEMENT BETWEEN GENOMIC SOLUTIONS INC. AND HD
TECHNOLOGIES, LTD. AND ALL OTHER DOCUMENTS ASSOCIATED WITH THIS TRANSACTION.

On April 15, 1998, HD Technologies, Ltd., of Manchester, England, and Genomic
Solutions Limited entered into a Subscription Agreement whereby Genomic acquired
for 91,000 pound sterling Preference Shares of HD Technologies. In addition the
companies entered into a Collaboration Agreement to design, construct and
develop a MALDI-TOF mass spectrometer (and related computer software) for use in
the field of proteomics and genomics.

INSIGHT BIOMEDICAL IMAGING SYSTEMS:
ACQUISITION OF THE MERIDIAN ASSETS OF INSIGHT BIOMEDICAL IMAGING, INC. BY
GENOMIC SOLUTIONS INC. INCLUDING ASSET PURCHASE AGREEMENT, SHARING AGREEMENT,
AND ALL OTHER DOCUMENTS ASSOCIATED WITH ACQUISITION.

On April 22, 1998, Genomic Solutions Inc. acquired certain assets of Insight
Biomedical Imaging Systems, Inc. for $65,000 cash. Genomic acquired from Insight
the laser scanning confocal imaging business unit located in Lansing, Michigan.
Assets acquired by Genomic were inventory and fixed assets, and assumed the
existing service contracts.

<PAGE>   122
                           SCHEDULE 7.o.7 - CONTINUED

LIST OF ACQUISITIONS AND STRATEGIC ALLIANCE AGREEMENTS:

ESA, INC.:
ACQUISITION OF THE ELECTROPHORESIS ASSETS OF ESA, INC. BY GENOMIC SOLUTIONS INC.
INCLUDING ASSET PURCHASE AGREEMENT, WARRANT, MANUFACTURING AGREEMENT, ROYALTY
AGREEMENT AND CONSENT FROM MILLIPORE, SUBLEASE AND ALL OTHER DOCUMENTS
ASSOCIATED WITH ACQUISITION

In October 1998, Genomic Solutions Inc. acquired the gel electrophoresis and
proteomic business of ESA, Inc. located in Chelmsford, Massachusetts. The
aggregate purchase price of approximately $1,750,000 in cash and a warrant to
purchase 125,000 shares of the Company's common stock at an exercise price of
$6.00 per share. The acquisition has accounted for under the purchase method of
accounting.

B. I. SYSTEMS CORPORATION:
AGREEMENT AND PLAN OF MERGER BETWEEN B.I. SYSTEMS CORPORATION, A DELAWARE
CORPORATION WITH AND INTO GENOMIC SOLUTIONS INC., A DELAWARE CORPORATION, AND
ALL RELATED DOCUMENTS.

On December 24, 1997, Genomic Solutions Inc. merged with B.I. Systems,
Corporation, with Genomic Solutions Inc., being the surviving entity.
<PAGE>   123
                                  SCHEDULE 7.p

                             GENOMIC SOLUTIONS INC.

INTELLECTUAL PROPERTY

PATENTS AND KNOW-HOW

The Company owns or has rights to certain proprietary information relating to
the products, systems and databases that it develops and markets. The Company
intends to actively seek, when appropriate, protection for its products and
proprietary information by means of United States and international patents,
trademarks and contractual arrangements. In addition, the Company plans to rely
upon trade secrets and contractual arrangements to protect certain of its
proprietary information and products.

The Company owns three issued patents and approximately five pending patent
applications worldwide relating to its biochip and proteomic products. There can
be no assurance that patents will issue from such applications, or, with respect
to issued or allowed patents, that they will provide the Company with
significant protection. In addition, the patent law relating to the areas of the
Company's research efforts is still developing which adds further uncertainty to
the protection afforded by existing patents and any additional patents the
Company may obtain.

Much of the know-how of importance to the Company's technology and many of its
processes are dependent upon the knowledge, experience and skills, which are not
patentable, of key scientific and technical personnel- To protect its rights to
its proprietary know-how and technology, the Company requires all employees,
consultants and advisors to enter 'into confidentiality agreements, which
prohibit the disclosure of confidential information to anyone outside the
Company. There can be no assurance that these agreements will effectively
prevent disclosure of the Company's confidential information or will provide
meaningful protection for the Company's confidential information if there is
unauthorized use or disclosure. In the absence of patent or other protection of
intellectual property, the Company's business may be adversely affected by
competitors who develop substantially equivalent or superior technology or
know-how.

I.        PATENTS GRANTED

          U.S. Patent 4,592,089: ELECTROPHORETOGRAM ANALYTICAL IMAGE PROCESSING
          SYSTEM
          Date of Patent: May 27, 1986
          Describes an analytical image processing system for analyzing spots on
          color electrophoretograms.

          U.S. Patent 4,966,667: GEL TRANSFER PROCESS AND COMPOSITE
          Date of Patent: Oct. 30, 1990
          Describes an apparatus and process for transferring a gel shaped as a
          cylinder from a first to a second electrophoresis step for the purpose
          of creating 2-D electrophoresis gels.

          US. Patent 5,281,322: ELECTROPHORESIS CASSETTE
          Date of Patent: Jan. 25, 1994
          Describes a cassette used to conduct gel electrophoresis separation of
          samples.
<PAGE>   124
                            SCHEDULE 7.p - CONTINUED

II.       PATENTS APPLIED FOR (USPO EARLY DISCLOSURE)

          LINE SCANNING IMAGER (11/11/97)
          Describes an imaging system used for the collection of images from
          high-density arrays of fluorescently tagged polynucleotides or protein
          spots.

          A THERMAL/FLUIDIC CYCLING DEVICE FOR THE PURPOSE OF NUCLEIC ACID
          HYBRIDIZATION (8/10/98)
          Describes an instrument designed to precisely control the
          thermodynamics of nucleic acid hybridization reactions, thereby
          significantly improving hybridization yields over manual methods.

          LID LIFT SYSTEM (2/20/99)
          Describes a system for the automated lifting of lids from microtitre
          plates to gain access to material deposited in the plates.

          AN AUTOMATED SYSTEM FOR EXCISING PROTEINS FROM TWO-DIMENSIONAL
          ELECTROPHORESIS GELS (2/17/99)
          Describes a novel laboratory robot-based solution for extracting
          protein molecules from electrophoresis gels for further study.

          A Laser Scanning Instrument for the Purpose of Acquiring Images of
          Fluorescent Samples (4/22/99)

          Describes a laser-based imaging system optimized for acquiring images
          of fluorescent samples, especially fluorescently labeled cDNA.

III.      PATENTS APPLIED FOR (UNITED KINGDOM)

          UK PATENT APPLICATI0N NO. 9815457.8:IMPROVED MASS SPECTROMETER
          Describes the design of an instrument used to measure the mass of
          large biological molecules.

IV.       PATENT APPLICATIONS IN PROGRESS (TO BE SUBMITTED TO THE USPO,
          EARLY DISCLOSURE)

          1.  Hybridization Station (Autohybridizer) - several claims.
          2.  Flexys Laboratory Robot - several claims:
              - Pneumatic Picking Tool
              - Microarray Gridding Tool(s)
              - Optical Fiber Gridding Tool
              - A novel approach to cooling biological storage compartments
          3.  GeneTAC 1000 CCD-based biochip Imaging System - several claims
          4.  Biochip Production/Analysis - several claims, including:
              - The novel application of specific genetic material onto biochips
                for the purposes of quality assurance and landmark detection
              - A technique for cleaning biochips to minimize background and
                cross-channel contamination.
              - A technique for detecting landmark spots on biochips
<PAGE>   125
                            SCHEDULE 7.p - CONTINUED

LICENSED TECHNOLOGY

The technology used to create the Flexys(R) Robotic System was originally
developed in the United Kingdom in collaboration with the Sanger Centre. Genomic
Solutions holds an exclusive license, granted by the Medical Research Council,
London, United Kingdom ("MRC"), which represents the Sanger Centre in matters of
technology transfer, granting Genomic Solutions a worldwide exclusive right to
use technology created by the Sanger Centre for the Flexys(R) Robot. These
rights include any and all knowledge, experience, design data, construction
data, operating data, or other information or know how possessed by the Sanger
Centre which relates to the Flexys(R) Robot. In addition, improvements to the
underlying technology are covered by the license agreement. In consideration for
these rights, Genomic Solutions pays the MRC a royalty of 0.5% of the sale price
of instrumentation utilizing the licensed technology. The license agreement will
remain in-place so long as Genomic Solutions continues to use the licensed
technology.

COPYRIGHTS

The Company copyrights all of its software, software source code, applications
protocols, and operator and service manuals. Also, the Company copyrights
various other documents that Genomic Solutions believes may benefit from
copyright protection.

TRADEMARKS

The Company is the owner of the registered trademarks "Bio Image(R)" and
"Flexys(R)". Genomic Solutions has applied for registration of the trademarks
"GeneTAC", "GelPrint", and "Genomic Solutions". The Company also uses the common
law trademarks Investigator(TM), ProGest(TM), Genomic Integrator(TM), Scout(TM),
Advanced Quantifier(TM), and Intelligent Quantifier(TM)".

<PAGE>   126
                                 SCHEDULE 7.p.1

                             GENOMIC SOLUTIONS INC.

                       OFFICERS, AND SIGNIFICANT EMPLOYEES
       WITH ARRANGEMENTS OR AGREEMENTS WITH FORMER EMPLOYERS RELATING TO
                            CONFIDENTIAL INFORMATION

Jeffrey S. Williams had an employment agreement covering, among other things,
non-disclosure of confidential information and non-recruiting of key employees
with both IRIS Corporation and Boehringer Mannheim Company. Both IRIS and
Boehringer principal business operates within the clinical diagnostics market.

Michael P. Kurek has a non-disclosure agreement with Gene Codes Corporation, an
Ann Arbor based bioinformatics company.

As of this date of closing and to the best of our knowledge, no other officer or
significant employees (as listed on Schedule 7.g.9 of this agreement) of Genomic
Solutions and its subsidiaries has any agreements or arrangements with former
employers relating to confidential information.

<PAGE>   127
                                  SCHEDULE 7.x

INFORMATION SUPPLIED TO LENDERS:
(Unless previously provided, copies of these documents are available upon
request of the Secretary of the Corporation.)

<TABLE>
<CAPTION>
SCHEDULE          DESCRIPTION
<S>       <C>
7.x.1     Confidential Descriptive Memorandum ("CDM"), dated February 1999.

7.x.2     Consolidated Financial Projection (the "Update") updated to
          incorporate this $6,000,000 subordinated debt financing, dated
          April 14,1999.
</TABLE>
<PAGE>   128
                                  SCHEDULE 7.z

COMPANY HISTORY OF NAMES AND LOCATIONS:

1.       GENOMIC SOLUTIONS INC. (UNITED STATES)

         The Company history during the most recent five years is as follows:
<TABLE>
<S><C>
         -  Genomic Solutions Inc ........................December 5, 1997 to present
                Address:  4355 Varsity Drive, Suite E
                          Ann Arbor, MI 48108
         -  Genomic Solutions Inc. merges with B.I. Systems Corporation with
            Genomic Solutions the surviving entity .......December 24, 1997
         -  B.I. Systems Corporation
            (Doing Business as Bio Image) ................August 1994 to December 23, 1997
         -  B.I. Systems Corporation......................July 1996 to December 1997
                Address:  525 Avis Drive, Suite 10
                          Ann Arbor, MI 48108
         -  B.I. Systems Corporation .....................July 1994 to July 96
                Address:  777 Eisenhower Parkway, Suite 900
                          Ann Arbor, MI 48108

         B.I. Systems Corporation operated several offices outside the United
         States, operating as Michigan Corporations which were wholly owned by
         B.I. Systems and operated as branch offices. Each of these branches
         have been closed and subsequently dissolved as follows:

         -  Bio Image UK, Inc ............................operations from February 1995 to October,
            1997, liquidation in process.
                Address:  Business & Technology Centre
                          Radway Green,
                          Crewe, Cheshire CW2 5PR
         -  Bio Image France .............................operations from February 1995 to May 1996,
            liquidation completed.
                Address:  ZI Paris Nord 11
                          385 rue de la Belle Etoile BP 40053
                          Parc des Nations
                          95913 Roissy CDG Cedex
                          France
         -  Bio Image Systems Deutschland Inc. (Germany)..operations from January 1996 to
            May 1996, liquidation completed.
                Address:  Eschenriederstr. 24
                          82194 Greobenzell
                          Germany
</TABLE>

<PAGE>   129
                            SCHEDULE 7.z - CONTINUED

         -  Nihon Bio Image Ltd .....operations from February 1995 to June 1998,
            liquidation in process.
               Address:  Wistaria Higashigotanda, Bldg 5F
                         21-9 Higashigotanda 1-Chrome
                         Shinagawa-Ku
                         Tokyo, Japan

II.      GENOMIC SOLUTIONS LTD (UNITED KINGDOM)

         Located in Cambridgeshire, England the history of PBA Technologies,
         during the most recent five years is as follows:

         - Genomic Solutions Ltd ......................March 9, 1998 to present

         - PBA Technology Ltd ................December 1, 1995 to March 8, 1998

         - Pinkney Byatt Ltd ................November 1998 to November 30, 1995

III.     GENOMIC SOLUTIONS K.K. (JAPAN)

         The Company history during the most recent five years is as follows:

         -  Genomic Solutions K.K ......................June 1, 1998 to present

         Prior to Genomic Solutions K.K., the sales and marketing activities in
         Japan were previously conducted under the name of Nihon Bio Image Ltd.,
         a Michigan corporation wholly owned by B.I. Systems Corporation for the
         period February 1995 to June 1998.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]